Lactam derivatives for inhibiting NLRP3 and their use
Lactam derivatives are developed to inhibit NLRP3 activity, addressing the need for modulating NLRP3 to treat inflammatory and degenerative diseases by reducing excessive inflammation.
Patent Information
- Application Number
- JP2026529599
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-15
- Filing Date
- 2024-11-15
- Publication Date
- 2026-11-19
AI Technical Summary
There is an unmet need to develop small molecules that can modulate NLRP3 activity to treat various inflammatory and degenerative diseases, as NLRP3 overreaction is associated with conditions such as NASH, atherosclerosis, Alzheimer's disease, Parkinson's disease, diabetes, and autoinflammatory diseases.
Development of NLRP3 inhibitors in the form of lactam derivatives, which can be used to inhibit NLRP3 activity and modulate the inflammatory response, thereby treating associated diseases.
The lactam derivatives effectively inhibit NLRP3 activity, providing therapeutic benefits for a range of inflammatory and degenerative diseases by reducing excessive inflammatory responses.
Smart Images

Figure 2026539114000001_ABST
Abstract
Description
[Background technology]
[0001] Related applications This application claims priority and benefit of U.S. Provisional Patent Application No. 63 / 599,319, filed on 15 November 2023, the entirety of which is incorporated herein by reference.
[0002] The innate immune response is mediated by different types of receptors called pattern recognition receptors (PRRs). PRRs recognize the presence of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). When these receptors bind, they trigger the activation of downstream inflammatory pathways that help repair damage. However, in many cases, this activation can be uncontrolled, leading to disease.
[0003] Inflammasomes represent a class of PRRs, which are crucial components of the innate immune response. Activation of inflammasomes triggers a cascade of events that promote an inflammatory form of cell death called pyroptosis, which is induced by gasdermin activation by releasing IL-1β and IL-18. Pyroptosis is an inherent form of inflammatory cell death that leads to the release of not only cytokines but also other intracellular components that promote a broader immune response in both the innate and adaptive immune systems. Therefore, inflammasome activation is a major control of the inflammatory cascade.
[0004] NLRP3 is the most distinctive inflammasome and is known to be essential for innate immune and inflammatory responses. While some other NLR complexes, such as NLRC4, are activated under very specific circumstances, NLRP3 can be activated by a wide range of stimuli and should therefore be viewed as a sensor of intracellular homeostatic imbalance. Thus, its precise function is essential. In addition to playing a role in host immune defense, NLRP3 dysregulation is associated with the pathogenesis of many inflammatory diseases. These include genetic disorders such as cryopyrin-associated periodic syndromes (CAPS) caused by gain-of-function mutations in the NLRP3 gene, as well as many prevalent neurological and systemic diseases. Importantly, NLRP3 overreaction has been demonstrated in the preclinical stage to play a significant role in numerous inflammatory and degenerative diseases, including NASH, atherosclerosis, and other cardiovascular diseases, Alzheimer's disease, Parkinson's disease, diabetes, gout, and many other autoinflammatory diseases. For example, see Li et al., European Journal of Pharmacology (2022) 928:175091, Nguyen et al., Journal of Parkinson's Disease (2022) 12:2117-2133, Su et al., Current Medicinal Chemistry (2021) 28:569-582, and Zahid et al., Frontiers in Immunology (2019) 10:2538. Therefore, there is an unmet need in the art to develop small molecules to modulate NLRP3 activity in order to treat various diseases and disorders. [Overview of the Initiative]
[0005] This specification refers to NLRP3 inhibitors of the following formula (I): [ka] and a pharmaceutically acceptable salt thereof, in which R 1 , R 3 , R 4, R 5 , R 6 , R 6’ , R 6’’ , and Z are as described herein, and R 7 and R 2 are joined to form a 5-10 membered monocyclic or bicyclic heterocyclyl or a 5-10 membered monocyclic or bicyclic heteroaryl, there are provided NLRP3 inhibitors and pharmaceutically acceptable salts thereof.
[0006] Further provided are preparation methods, therapeutic and prophylactic methods, and pharmaceutical compositions comprising the same.
[0007] Definitions Definitions of specific functional groups and chemical terms are described in greater detail below. Chemical elements are identified according to the Periodic Table of the Elements, CAS version, inside cover of the 75th Edition of the Handbook of Chemistry and Physics, 75 th Ed., and specific functional groups are generally defined as described therein. Furthermore, general principles of organic chemistry as well as specific functional moieties and reactivity are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999, Smith and March March’s Advanced Organic Chemistry, 5 th Edition, John Wiley & Sons, Inc., New York, 2001, Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989, and Carruthers, Some Modern Methods of Organic Synthesis, 3 rd Edition, Cambridge University Press, Cambridge, 1987.
[0008] The compounds described herein may contain one or more chiral centers and therefore may exist in various stereoisomers, such as enantiomers and / or diastereomers. For example, the compounds described herein may be in the form of individual enantiomers, diastereomers, or geometric isomers, separable atropisomers (resulting from rotational obstruction resulting in axial chirality), or in the form of a mixture of stereoisomers, including a racemic mixture and a mixture of one or more stereoisomer-enriched mixtures. The isomers can be isolated from the mixture by methods known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC), as well as the formation and crystallization of chiral salts, or preferred isomers can be prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981), Wilen et al., Tetrahedron 33:2725 (1977), Eliel, ELStereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962), and Wilen, SHTables of Resolving Agents and Optical Resolutions p.268 (ELEliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The compounds described herein may additionally include individual isomers that substantially do not contain other isomers, or alternatively, they may be included as mixtures of various isomers.
[0009] Unless otherwise stated, the compounds described herein are also intended to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having this structure may undergo hydrogen substitution with deuterium or tritium. 19 F 18 Substitution with F, or carbon 13 C- or 14Except for carbon substitution with 1C-enriched carbon, the compounds are within the scope of this disclosure. Such compounds are useful, for example, as analytical tools or probes in biological assays.
[0010] When a range of values is listed, it is intended to include each value within that range and its sub-ranges. For example, "C 1-6 "Alkyl" refers to C1, C2, C3, C4, C5, C6, C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 , and C 5-6 It is intended to include alkyl groups.
[0011] "Alkyl" refers to a radical of a straight-chain or branched saturated hydrocarbon group having 1 to 6 carbon atoms ("C 1-6 (alkyl). In some embodiments, the alkyl group has 1 to 5 carbon atoms ("C"). 1-5 (alkyl). In some embodiments, the alkyl group has 1 to 4 carbon atoms ("C"). 1-4 (alkyl). In some embodiments, the alkyl group has 1 to 3 carbon atoms ("C"). 1-3 Alkyl). In some embodiments, the alkyl group has 1 to 2 carbon atoms ("C"). 1-2 In some embodiments, the alkyl group has one carbon atom ("C1 alkyl"). In some embodiments, the alkyl group has two to six carbon atoms ("C1 alkyl"). 2-6 Alkyl). C 1-6Examples of alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), and n-hexyl (C6).
[0012] "Haloalkyl" refers to a substituted alkyl group as defined herein, in which one or more hydrogen atoms are independently substituted with a halogen, such as fluoro, bromo, chloro, or iodine. In some embodiments, the haloalkyl group has 1 to 6 carbon atoms ("C"). 1-6 Haloalkyl)). In some embodiments, the haloalkyl has 1 to 5 carbon atoms ("C"). 1-5 ("Haloalkyl"). In some embodiments, the haloalkyl has 1 to 4 carbon atoms ("C"). 1-4 Haloalkyl)). In some embodiments, the haloalkyl has 1 to 3 carbon atoms ("C"). 1-3 Haloalkyl)). In some embodiments, the haloalkyl has 1 to 2 carbon atoms ("C"). 1-2 (Haloalkyl). In some embodiments, all hydrogen atoms of the haloalkyl group are substituted with fluoro atoms to provide a perfluoroalkyl group. In some embodiments, all hydrogen atoms of the haloalkyl group are substituted with chloro atoms to provide a "perchloroalkyl" group. Examples of haloalkyl groups include -CF3, -CF2CF3, -CF2CF2CF3, -CCl3, -CFCl2, and -CF2Cl.
[0013] "Cycloalkyl" refers to a non-aromatic ring with 3 to 6 ring carbon atoms ("C"). 3-6A cycloalkyl group refers to a radical of a non-aromatic, fully saturated or partially saturated cyclic hydrocarbon group having zero heteroatoms. In some embodiments, the cycloalkyl group has three carbon atoms ("C3 cycloalkyl"). In some embodiments, the cycloalkyl group has four carbon atoms ("C4 cycloalkyl"). In some embodiments, the cycloalkyl group has five carbon atoms ("C5 cycloalkyl"). In some embodiments, the cycloalkyl group has six carbon atoms ("C6 cycloalkyl"). Exemplary C 3-6 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), and cyclohexadienyl (C6).
[0014] A "heterocyclyl" refers to a radical that is a 3- to 10-membered non-aromatic fully saturated or partially saturated monocyclic or bicyclic ring system having a ring carbon atom and one or more ring heteroatoms (e.g., 1, 2, 3, or 4 ring heteroatoms), each of which is independently selected from nitrogen, oxygen, and sulfur. In heterocyclyl groups containing a nitrogen atom, the bond site may be on the carbon or nitrogen ring atom, if the valency allows. Examples of 3-membered heterocyclyl groups containing one ring heteroatom include, but are not limited to, azilidinyl, oxyranil, and thiranil. Examples of 4-membered heterocyclyl groups containing one ring heteroatom include, but are not limited to, azetidinyl, oxetanil, and thietanil. Examples of five-membered heterocyclyl groups containing one ring heteroatom include, but are not limited to, tetrahydrofuranil, dihydrofuranil, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinil, dihydropyrrolyl, and pyrrolyl-2,5-dione. Examples of five-membered heterocyclyl groups containing two ring heteroatoms include, but are not limited to, dioxolanil, oxathiolanil, and dithiolanil. Examples of five-membered heterocyclyl groups containing three ring heteroatoms include, but are not limited to, triazolinil, oxadiazolinil, and thiadiazolinil. Examples of six-membered heterocyclyl groups containing one ring heteroatom include, but are not limited to, piperidinil, tetrahydropyranil, dihydropyridinil, and thianil. Examples of six-membered heterocyclyl groups containing two ring heteroatoms include, but are not limited to, piperazinil, morpholinil, dithianil, and dioxanil. Examples of six-membered heterocyclyl groups containing three ring heteroatoms include, but are not limited to, triazinanyl. Examples of seven-membered heterocyclyl groups containing one ring heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Examples of eight-membered heterocyclyl groups containing one ring heteroatom include, but are not limited to, azocanyl, oxecanyl, and thiocanyl.Examples of bicyclic heterocyclyl groups include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydroclomenyl, octahydroisoclomenyl, decahydronaphthilidinyl, decahydro-1,8-naphthilidinyl, octahydropyrrolo[3,2-b]pyrrole, indolinyl, phthaliumidyl, and naphthaliumidyl. For clarity, substituted or unsubstituted pyrrolidine-2-one moieties, such as the divalent moieties shown below, are considered heterocyclyl groups. [ka]
[0015] As used herein, “aryl” refers to a radical of a monocyclic aromatic ring system having six ring carbon atoms and zero ring heteroatoms provided to the aromatic ring system (“C6 aryl”, i.e., phenyl).
[0016] As used herein, the term “heteroaryl” refers to a 5-, 6-, or 7-membered monocyclic or 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic aromatic ring, comprising a ring carbon atom and one or more ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, for example, one or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 ring heteroatoms, or for example, one, two, three, four, five, or six ring heteroatoms. In heteroaryl groups containing one or more ring nitrogen atoms, the bond sites may be carbon or nitrogen atoms, if the valency is permissible. The ring nitrogen atoms may be substituted or unsubstituted, as long as the valency and aromaticity are permissible. Examples of 5-membered heteroaryl groups containing one ring heteroatom include, but are not limited to, pyrrolyl, furanyl, and thiophenyl. Examples of five-membered heteroaryl groups containing two ring heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Examples of five-membered heteroaryl groups containing three ring heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Examples of five-membered heteroaryl groups containing four ring heteroatoms include, but are not limited to, tetrazolyl. Examples of six-membered heteroaryl groups containing one ring heteroatom include, but are not limited to, pyridinyl. Examples of six-membered heteroaryl groups containing two ring heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Examples of six-membered heteroaryl groups containing three or four ring heteroatoms include, but are not limited to, triazinyl and tetradinyl, respectively. Examples of seven-membered heteroaryl groups containing one ring heteroatom include, but are not limited to, azepinyl, oxepinyl, and thiepinyl.Examples of 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranil, benzoisofuranil, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolidinyl, and prinyl. Examples of 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthylidinyl, pteridinyl, quinolinyl, isoquinolinyl, sinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. For clarity, substituted or unsubstituted pyridine-2(1H)-one, pyrazine-2(1H)-one, pyrimidine-4(3H)-one, and pyridazine-3(2H)-one moieties, such as the divalent moieties shown below, are considered heteroaryl groups. [ka]
[0017] "Halo" or "halogen" refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iod, -I) radicals.
[0018] Adding the suffix "-ene" to a group indicates that the group is a divalent moiety; for example, C1-C6 alkylene is the divalent moiety of a branched or linear C1-C6 alkyl group. As an example, C1-C6 alkyl can be linear or branched. 1-3 Alkylenes include, but are not limited to, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH2CH(CH3)-, -CH2C(CH3)2-, and -CH2CH2CH2-.
[0019] The terms "alkoxy" or "alkoxyl" refer to alkyl groups covalently bonded to an oxygen atom by a direct bond, where the radical (bonding site) is located on this oxygen atom. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups.
[0020] The term "haloalkoxy" or "haloalkoxyl" refers to a haloalkyl group covalently bonded by a direct bond to an oxygen atom, where the radical (bonding site) is located on this oxygen atom. Examples of alkoxy groups include, but are not limited to, halomethoxy, haloethoxy, haloisopropyloxy, halopropoxy, halobutoxy, and halopentoxy groups.
[0021] Compounds of formula (I) and salts of their intermediates, pharmaceutically acceptable salts, and non-ionized compounds (e.g., non-ionized acids (also called free acids) and / or free bases) are intended herein.
[0022] "Salt" refers to any salt and all salts.
[0023] "Non-ionized" compounds refer to the neutral form of compounds that are not salts or pharmaceutically acceptable salts.
[0024] A "pharmaceutically acceptable salt" is defined as a salt that, within the bounds of sound medical judgment, is suitable for use in contact with human and lower animal tissues without excessive toxicity, irritation, or allergic reactions, and that has a reasonable benefit-risk ratio. Examples of pharmaceutically acceptable acid addition salts include, but are not limited to, salts formed from inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or salts formed from organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or salts formed by other methods used in the art, such as ion exchange.
[0025] "Leaving group" is a term understood in the art to refer to a molecular fragment that leaves with a pair of electrons during unequal bond cleavage, and this molecular fragment can be an anion or a neutral molecule. See, for example, Smith, March Advanced Organic Chemistry 6th ed. (501-502). Examples of leaving groups include, but are not limited to, halos (e.g., chloro, bromo, iodo) and sulfonyl-substituted hydroxyl groups (e.g., -O-tosyl, -O-mesyl, and -O-besyl).
[0026] "Patient" or "subject" are used interchangeably herein and refer to mammals such as humans, mice, rats, guinea pigs, dogs, cats, horses, cattle, pigs, etc., or non-human primates such as monkeys, chimpanzees, baboons, or rhesus macaques. In some embodiments, the patient or subject is human.
[0027] "Effective dose" refers to the amount of a compound or a pharmaceutically acceptable salt thereof sufficient to provide a benefit in the treatment of the disease or disorder in question. The effective dose of a compound or a pharmaceutically acceptable salt thereof may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, health, and condition of the subject.
[0028] The terms "disease" and "disorder" are used interchangeably in this specification.
[0029] "To treat," "to treat," or "to cure" describes the management and care of an object in need of such treatment for the purpose of addressing a disease or disorder in that object, and includes administering a compound or a pharmaceutically acceptable salt thereof described herein to alleviate one or more symptoms or complications of a disease or disorder, or to eliminate the disease or disorder from the object. The term "to treat" may also include in vitro treatment of cells or treatment of animal models (in vivo).
[0030] As used herein, the terms “prevent,” “prevent,” or “protect against” describe the management and care of an object that may or may have a predisposition to a disease or disorder but has not yet experienced or exhibited any symptoms or complications of the disease or disorder, and which may require such management and care, and which include administering any of the compounds described herein or any pharmaceutically acceptable salts thereof.
[0031] "Inhibition," "the act of inhibiting," "to inhibit," and "inhibitor" refer to the ability of a compound or a pharmaceutically acceptable salt thereof to reduce, delay, halt, or prevent the activity of a particular biological process in a cell (e.g., NLRP3 activity) relative to a vehicle.
[0032] The phrase "at least one" refers to either a single entity or multiple entities.
[0033] In this disclosure, the articles "a" and "an" are used to refer to one or more (i.e., at least one) grammatical objects of the article.
[0034] Unless otherwise suggested, the terms “and / or” are used in this disclosure to mean either “and” or “or.” [Modes for carrying out the invention]
[0035] (i) Compound In this specification, the following compounds of formula (I): [ka] and its pharmaceutically acceptable salts are provided. During the ceremony, R 1 These are halo, C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl. R 7 and R 2These combine to form a 5-10 member monocyclic or bicyclic heterocyclil or a 5-10 member monocyclic or bicyclic heteroaryl, and the heterocyclil or heteroaryl consists of one or more R 7a It may also be replaced with each R 7a These are independently halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C6 aryl, 5-6 membered heteroaryl, C3-C5 cycloalkyl, or 4-5 membered heterocyclil, and alkyl, haloalkyl, alkoxy, haloalkoxy, aryl, heteroaryl, cycloalkyl, and heterocyclil are one or more R 7b It may also be replaced with R 7b These are halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy. R 3 It is either absent, or H, C1-C6 alkyl, or C1-C6 haloalkyl. R 4 is one or more R 4a It is a C1-C6 alkylene which may be substituted with, in the formula each R 4a These are independently: halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C 3-4 It is either a cycloalkyl or a 4-5 membered heterocycline, or two R 4a These combine to form a C3-C5 cycloalkyl or 4-6 membered heterocyclyl ring, and alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl and heterocyclyl are composed of one or more R 4b It may also be replaced with R 4b These are halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy. Z is -CO2H or -CO2PG, PG is C1-C6 alkyl, C6 aryl, or (C6 aryl)(C1-C6 alkyl), and the alkyl and aryl may be substituted with one or more halo, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy. Each R 5 These are independently halo, C1-C6 alkyl, or C1-C6 haloalkyl, Each R 6 , R 6’ , or R 6’’ These are independently H, halo, -OH, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkyl, or C1-C6 haloalkyl.
[0036] In some embodiments, the compound is a compound of the following formula (I), or a pharmaceutically acceptable salt thereof, where, R 1 These are halo, C1-C6 haloalkyl, or C3-C4 cycloalkyl. R 7 and R 2 These combine to form a 5-10 member monocyclic or bicyclic heteroaryl, and the heteroaryl consists of one or more R 7a It may also be replaced with each R 7a These are independently C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl. R 3 It does not exist, R 4 It is a -C1-C6 alkylene-, Z is -CO2H, Each R 5 These are independently C1-C6 alkyl groups, Each R 6 , R 6’ , or R 6’’ These are independently H, halo, or -OH.
[0037] In some embodiments, the compound is a compound of the following formula (I), or a pharmaceutically acceptable salt thereof, where, R 1 is halo, C1-C6 haloalkyl, or C3-C4 cycloalkyl, R 7 and R 2 are joined to form a 6-membered monocyclic heteroaryl, wherein the heteroaryl is optionally substituted with one or more R 7a groups, and each R 7a is independently C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl, R 3 is absent, R 4 is -C1-C6 alkylene-, Z is -CO2H, each R 5 is independently C1-C6 alkyl, each R 6 , R 6’ , or R 6’’ is independently H, halo, or -OH.
[0038] In some embodiments, the compound is a compound of the following formula (I), or a pharmaceutically acceptable salt thereof, wherein R 1 is halo, C1-C6 haloalkyl, or C3-C4 cycloalkyl, R 7 and R 2 are joined to form a 5-10 membered monocyclic or bicyclic heterocyclyl, wherein the heterocyclyl is optionally substituted with one or more R 7a groups, and each R 7a is independently C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl or C3-C5 cycloalkyl, R 3 is absent, R 4 is -C1-C6 alkylene-, Z is -CO2H, each R 5 is independently C1-C6 alkyl, each R 6, R 6’ , or R 6’’ These are independently H, halo, or -OH.
[0039] In some embodiments, the compound is a compound of the following formula (I), or a pharmaceutically acceptable salt thereof, where, R 1 These are halo, C1-C6 haloalkyl, or C3-C4 cycloalkyl. R 7 and R 2 These combine to form a 5-membered monocyclic heterocycline, and the heterocycline consists of one or more R 7a It may also be replaced with each R 7a These are independently C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl. R 3 It does not exist, R 4 It is a -C1-C6 alkylene-, Z is -CO2H, Each R 5 These are independently C1-C6 alkyl groups, Each R 6 , R 6’ , or R 6’’ These are independently H, halo, or -OH.
[0040] If the valency is acceptable, R 3 The absence of R 3 The fact that it is hydrogen means that it can be used interchangeably (for example, R 3 It is understood that the carbon bonded to it allows for the presence of hydrogen. To avoid any doubt, it should be added that the valency is R 3 If hydrogen at position R 3 To define that it does not exist is R 3 It can be replaced with hydrogen.
[0041] For the compound of formula (I), R 1 , R 2 , R 3 , R 4 , R4a , R 4b , R 5 , R 6 , R 6’ , R 6’’ , R 7 , R 7a , R 7b Z, and Z may be selected from the group described herein, if applicable, and R 1 , R 2 , R 3 , R 4 , R 4a , R4 b , R 5 , R 6 , R 6’ , R 6’’ , R 7 , R 7a , R 7b Any base described herein for any of , and Z, if applicable, R 1 , R 2 , R 3 , R 4 , R 4a , R 4b , R 5 , R 6 , R 6’ , R 6’’ , R 7 , R 7a , R 7b It will be further understood that one or more of the remaining parts of Z can be combined with any of the groups described herein.
[0042] Additional embodiments are described below and further herein. (a)R 1 , R 2 , R 3 , R 5 , R 6 , R 6’ , R 6’’ , and R 7
[0043] As generally described herein, R 1 These are halo, C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl.
[0044] In some embodiments, R 1 is a halo. In some embodiments, R 1 is F, Br, Cl, or I. In some embodiments, R 1 is F, Br, or Cl. In some embodiments, R 1 F is F. In some embodiments, R 1 is Br. In some embodiments, R 1 is Cl. In some embodiments, R 1 It is I.
[0045] In some embodiments, R 1 These are C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl.
[0046] In some embodiments, R 1 It is a C1-C6 alkyl group.
[0047] In some embodiments, R 1 is methyl. In some embodiments, R 1 is ethyl. In some embodiments, R 1 is propyl. In some embodiments, R 1 is butyl. In some embodiments, R 1 is pentill. In some embodiments, R 1 is hexyl. In some embodiments, R 1 is isopropyl. In some embodiments, R 1 isobutyl. In some embodiments, R 1 is isopentyl. In some embodiments, R 1 is isohexyl. In some embodiments, R 1 secbutyl is used in some embodiments. 1 secpentyl is used in some embodiments. 1 sec hexyl is used in some embodiments.1 It is tert-butyl.
[0048] In some embodiments, R 1 It is a C1-C6 haloalkyl group.
[0049] In some embodiments, R 1 is a halomethyl. In some embodiments, R 1 is haloethyl. In some embodiments, R 1 is a halopropyl. In some embodiments, R 1 is halobutyl. In some embodiments, R 1 is halopentyl. In some embodiments, R 1 It is a halohexyl.
[0050] In some embodiments, R 1 It is a C3-C6 cycloalkyl group.
[0051] In some embodiments, R 1 It is a C3-C4 cycloalkyl group.
[0052] In some embodiments, R 1 is a C3 cycloalkyl group. In some embodiments, R 1 is a C4 cycloalkyl group. In some embodiments, R 1 is a C5 cycloalkyl. In some embodiments, R 1 It is a C6 cycloalkyl group.
[0053] In some embodiments, R 1 These are halo, C1-C6 haloalkyl, or C3-C6 cycloalkyl.
[0054] In some embodiments, R 1 It is Br, Cl, CF3, or cyclopropyl.
[0055] In some embodiments, R 1It is CF3 or cyclopropyl.
[0056] As generally described herein, R 3 It is either absent, or H, C1-C6 alkyl, or C1-C6 haloalkyl.
[0057] In some embodiments, R 3 It does not exist.
[0058] In some embodiments, R 3 It is H or C1-C6 alkyl.
[0059] In some embodiments, R 3 H is H.
[0060] In some embodiments, R 3 It is a C1-C6 alkyl group.
[0061] In some embodiments, R 3 is methyl. In some embodiments, R 3 is ethyl. In some embodiments, R 3 is propyl. In some embodiments, R 3 is butyl. In some embodiments, R 3 is pentill. In some embodiments, R 3 is hexyl. In some embodiments, R 3 is isopropyl. In some embodiments, R 3 isobutyl. In some embodiments, R 3 is isopentyl. In some embodiments, R 3 is isohexyl. In some embodiments, R 3 secbutyl is used in some embodiments. 3 secpentyl is used in some embodiments. 3 sec hexyl is used in some embodiments. 3 It is tert-butyl.
[0062] In some embodiments, R 3 It is a C1-C6 haloalkyl group.
[0063] In some embodiments, R 3 is a halomethyl. In some embodiments, R 3 is haloethyl. In some embodiments, R 3 is a halopropyl. In some embodiments, R 3 is halobutyl. In some embodiments, R 3 is halopentyl. In some embodiments, R 3 It is a halohexyl.
[0064] As generally described herein, each R 5 These are independently halo, C1-C6 alkyl, or C1-C6 haloalkyl.
[0065] In some embodiments, R 5 Each entity is the same base.
[0066] In some embodiments, R 5 Each entity is a halo. For example, in some embodiments, R 5 Each entity is fluoro.
[0067] Several embodiments, each R 5 In some embodiments, each R is independently a halo. 5 R is independently F, Br, Cl, or I. In some embodiments, each R 5 R is independently F, Br, or Cl. In some embodiments, each R 5 Independently, F. In some embodiments, each R 5 Independently, each R is Br. In some embodiments, each R 5 Independently, each R is Cl. In some embodiments, each R 5 Independently, it is I.
[0068] In some embodiments, R 5 Each entity is the same, possibly substituted C1-C6 alkyl group, for example, -CH3. In some embodiments, R 5 Each entity is different.
[0069] In some embodiments, R 5 Each entity is independently a C1-C6 alkyl group.
[0070] In some embodiments, R 5 At least one entity of is methyl (-CH3). In some embodiments, R 5 At least one entity of is ethyl. In some embodiments, R 5 At least one entity of is propyl. In some embodiments, R 5 At least one entity of is butyl. In some embodiments, R 5 At least one entity of is pentyl. In some embodiments, R 5 At least one entity of is hexyl. In some embodiments, R 5 At least one entity of isopropyl. In some embodiments, R 5 At least one entity of isobutyl. In some embodiments, R 5 At least one entity of isopentyl. In some embodiments, R 5 At least one entity of isohexyl. In some embodiments, R 5 At least one entity of is secbutyl. In some embodiments, R 5 At least one entity of is secpentyl. In some embodiments, R 5 At least one entity of is sechexyl. In some embodiments, R 5 At least one entity of it is tertbutyl.
[0071] Several embodiments, each R5 R is independently methyl (-CH3). In some embodiments, each R 5 R is independently ethyl. In some embodiments, each R 5 In some embodiments, each R is independently propyl. 5 R is independently butyl. In some embodiments, each R 5 In some embodiments, each R is independently a pentill. 5 In some embodiments, each R is independently hexyl. 5 In some embodiments, each R is isopropyl. 5 R is independently isobutyl. In some embodiments, each R 5 R is independently isopentyl. In some embodiments, each R 5 is independently isohexyl. In some embodiments, each R 5 In some embodiments, each R is independently secbutyl. 5 In some embodiments, each R is independently secpentyl. 5 In some embodiments, each R is independently sec hexyl. 5 It is independently tertbutyl.
[0072] Several embodiments, each R 5 These are independently C1-C6 haloalkyl groups.
[0073] Several embodiments, each R 5 R is independently a halomethyl compound. In some embodiments, each R 5 In some embodiments, each R is independently a haloethyl. 5 In some embodiments, each R is independently a halopropyl. 5 Independently, each R is a halobutyl. In some embodiments, each R 5 In some embodiments, each R is independently a halopentyl. 5 It is independently a halohexyl.
[0074] As generally described herein, each R 6 , R 6’ , or R 6’’ These are independently H, halo, -OH, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkyl, or C1-C6 haloalkyl.
[0075] As generally described herein, R 6 This is H, halo, -OH, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkyl, or C1-C6 haloalkyl.
[0076] In some embodiments, R 6 H is H.
[0077] In some embodiments, R 6 These are halo, -OH, C1-C6 alkyl, or C1-C6 haloalkyl.
[0078] In some embodiments, R 6 These are C1-C6 alkoxy or C1-C6 haloalkoxy.
[0079] In some embodiments, R 6 This is a halo, or -OH.
[0080] In some embodiments, R 6 It is a halo.
[0081] In some embodiments, R 6 is F, Cl, Br, or I. In some embodiments, R 6 It is F, Cl, or Br.
[0082] In some embodiments, R 6 F is F. In some embodiments, R 6 is Cl. In some embodiments, R 6 is Br. In some embodiments, R 6 It is I.
[0083] In some embodiments, R 6 It is -OH.
[0084] In some embodiments, R 6 It is a C1-C6 alkoxy.
[0085] In some embodiments, R 6 It is a C1-C6 haloalkoxy.
[0086] In some embodiments, R 6 It is a C1-C6 alkyl group.
[0087] In some embodiments, R 6 is methyl. In some embodiments, R 6 is ethyl. In some embodiments, R 6 is propyl. In some embodiments, R 6 is butyl. In some embodiments, R 6 is pentill. In some embodiments, R 6 is hexyl. In some embodiments, R 6 is isopropyl. In some embodiments, R 6 isobutyl. In some embodiments, R 6 is isopentyl. In some embodiments, R 6 is isohexyl. In some embodiments, R 6 secbutyl is used in some embodiments. 6 secpentyl is used in some embodiments. 6 sec hexyl is used in some embodiments. 6 It is tert-butyl.
[0088] In some embodiments, R 6 It is a C1-C6 haloalkyl group.
[0089] In some embodiments, R6 is a halomethyl. In some embodiments, R 6 is haloethyl. In some embodiments, R 6 is a halopropyl. In some embodiments, R 6 is halobutyl. In some embodiments, R 6 is halopentyl. In some embodiments, R 6 It is a halohexyl.
[0090] As generally described herein, R 6’ This is H, halo, -OH, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkyl, or C1-C6 haloalkyl.
[0091] In some embodiments, R 6’ H is H.
[0092] In some embodiments, R 6’ These are halo, -OH, C1-C6 alkyl, or C1-C6 haloalkyl.
[0093] In some embodiments, R 6’ These are C1-C6 alkoxy or C1-C6 haloalkoxy compounds.
[0094] In some embodiments, R 6’ This is a halo or -OH.
[0095] In some embodiments, R 6’ It is a halo.
[0096] In some embodiments, R 6’ is F, Cl, Br, or I. In some embodiments, R 6’ It is F, Cl, or Br.
[0097] In some embodiments, R 6’ F is F. In some embodiments, R 6’is Cl. In some embodiments, R 6’ is Br. In some embodiments, R 6’ It is I.
[0098] In some embodiments, R 6’ It is -OH.
[0099] In some embodiments, R 6’ It is a C1-C6 alkoxy.
[0100] In some embodiments, R 6’ It is a C1-C6 haloalkoxy.
[0101] In some embodiments, R 6’ It is a C1-C6 alkyl group.
[0102] In some embodiments, R 6’ is methyl. In some embodiments, R 6’ is ethyl. In some embodiments, R 6’ is propyl. In some embodiments, R 6’ is butyl. In some embodiments, R 6’ is pentill. In some embodiments, R 6’ is hexyl. In some embodiments, R 6’ is isopropyl. In some embodiments, R 6’ isobutyl. In some embodiments, R 6’ is isopentyl. In some embodiments, R 6’ is isohexyl. In some embodiments, R 6’ secbutyl is used in some embodiments. 6’ secpentyl is used in some embodiments. 6’ sec hexyl is used in some embodiments. 6’ It is tert-butyl.
[0103] In some embodiments, R6’ It is a C1-C6 haloalkyl group.
[0104] In some embodiments, R 6’ is a halomethyl. In some embodiments, R 6’ is haloethyl. In some embodiments, R 6’ is a halopropyl. In some embodiments, R 6’ is halobutyl. In some embodiments, R 6’ is halopentyl. In some embodiments, R 6’ It is a halohexyl.
[0105] In some embodiments, R 6’ It is either F or OH.
[0106] As generally described herein, R 6’’ This is H, halo, -OH, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkyl, or C1-C6 haloalkyl.
[0107] In some embodiments, R 6’’ H is H.
[0108] In some embodiments, R 6’’ These are halo, -OH, C1-C6 alkyl, or C1-C6 haloalkyl.
[0109] In some embodiments, R 6’’ These are C1-C6 alkoxy or C1-C6 haloalkoxy compounds.
[0110] In some embodiments, R 6’’ This is a halo or -OH.
[0111] In some embodiments, R 6’’ It is a halo.
[0112] In some embodiments, R 6’’is F, Cl, Br, or I. In some embodiments, R 6’’ It is F, Cl, or Br.
[0113] In some embodiments, R 6’’ F is F. In some embodiments, R 6’’ is Cl. In some embodiments, R 6’’ is Br. In some embodiments, R 6’’ It is I.
[0114] In some embodiments, R 6’’ It is -OH.
[0115] In some embodiments, R 6’’ It is a C1-C6 alkoxy.
[0116] In some embodiments, R 6’’ It is a C1-C6 haloalkoxy.
[0117] In some embodiments, R 6’’ It is a C1-C6 alkyl group.
[0118] In some embodiments, R 6’’ is methyl. In some embodiments, R 6’’ is ethyl. In some embodiments, R 6’’ is propyl. In some embodiments, R 6’’ is butyl. In some embodiments, R 6’’ is pentill. In some embodiments, R 6’’ is hexyl. In some embodiments, R 6’’ is isopropyl. In some embodiments, R 6’’ isobutyl. In some embodiments, R 6’’ is isopentyl. In some embodiments, R 6’’ is isohexyl. In some embodiments, R 6’’secbutyl is used in some embodiments. 6’’ secpentyl is used in some embodiments. 6’’ sec hexyl is used in some embodiments. 6’’ It is tert-butyl.
[0119] In some embodiments, R 6’’ It is a C1-C6 haloalkyl group.
[0120] In some embodiments, R 6’’ is a halomethyl. In some embodiments, R 6’’ is haloethyl. In some embodiments, R 6’’ is a halopropyl. In some embodiments, R 6’’ is halobutyl. In some embodiments, R 6’’ is halopentyl. In some embodiments, R 6’’ It is a halohexyl.
[0121] In some embodiments, R 6’’ It is either H or F.
[0122] In some embodiments, R 6’ It is a halo, and also R 6’’ H is H. In some embodiments, R 6’ F is also R 6’’ H is H.
[0123] In some embodiments, R 6’ H is also R 6’’ is a halo. In some embodiments, R 6’ H is also R 6’’ It is F.
[0124] In some embodiments, R 6’ and R 6’’ Each of them is independently a halo. In some embodiments, R 6’ and R 6’’Each of these is F.
[0125] As generally described herein, R 7 and R 2 These combine to form a 5-10 member monocyclic or bicyclic heterocycline or a 5-10 member monocyclic or bicyclic heteroaryl, and each alkyl, haloalkyl, alkoxy, haloalkoxy, heterocycline, or heteroaryl is composed of one or more R 7a It may be substituted with, and in the formula, each R 7a These are independently halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C6 aryl, 5-6 membered heteroaryl, C3-C5 cycloalkyl, or 4-5 membered heterocyclil, and alkyl, haloalkyl, alkoxy, haloalkoxy, aryl, heteroaryl, cycloalkyl, and heterocyclil are one or more R 7b It may also be replaced with R 7b These are halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0126] In some embodiments, R 7 and R 2 These combine to form a 5-10 membered monocyclic or bicyclic heterocycline.
[0127] In some embodiments, R 7 and R 2 These are combined into one or more R 7a They form 5-10 member monocyclic or bicyclic heterocyclines, which may be substituted with other compounds.
[0128] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a 5-10 member monocyclic or bicyclic heterocycline that is substituted by the other members.
[0129] In some embodiments, R7 and R 2 These combine to form a 5-10 membered monocyclic heterocycline.
[0130] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a 5-10 member monocyclic heterocycline, which may be substituted with other compounds.
[0131] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a 5-10 member monocyclic heterocycline that is substituted by [the other component].
[0132] In some embodiments, R 7 and R 2 They combine to form a five-membered monocyclic heterocycline.
[0133] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a five-membered monocyclic heterocycline, which may be substituted with [another compound].
[0134] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a five-membered monocyclic heterocycline that is substituted by [the specified component].
[0135] In some embodiments, R 7 and R 2 These combine to form a 5-10 membered bicyclic heterocycline.
[0136] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a 5-10 membered bicyclic heterocycline, which may be substituted with other compounds.
[0137] In some embodiments, R7 and R 2 These are combined into one or more R 7a It forms a 5-10 membered bicyclic heterocycline that is substituted by [the specified component].
[0138] In some embodiments, R 7 and R 2 These combine to form a 5-10 member monocyclic or bicyclic heteroaryl.
[0139] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a 5-10 member monocyclic or bicyclic heteroaryl, which may be substituted with the other compounds.
[0140] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a 5-10 member monocyclic or bicyclic heteroaryl by substitution.
[0141] In some embodiments, R 7 and R 2 These combine to form a 5-10 membered monocyclic heteroaryl.
[0142] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a 5-10 member monocyclic heteroaryl, which may be substituted with [another compound].
[0143] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a 5-10 member monocyclic heteroaryl that is substituted.
[0144] In some embodiments, R 7 and R 2 These combine to form a 5-10 membered bicyclic heteroaryl molecule.
[0145] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a 5-10 membered bicyclic heteroaryl, which may be substituted with [another compound].
[0146] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a 5-10 membered bicyclic heteroaryl by substitution.
[0147] In some embodiments, R 7 and R 2 They combine to form a six-membered monocyclic heteroaryl molecule.
[0148] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a six-membered monocyclic heteroaryl, which may be substituted with [another compound].
[0149] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a six-membered monocyclic heteroaryl by substitution.
[0150] In some embodiments, R 7 and R 2 They combine to form a 10-membered bicyclic heteroaryl molecule.
[0151] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a 10-membered bicyclic heteroaryl, which may be substituted with [another compound].
[0152] In some embodiments, R 7 and R 2 These are combined into one or more R 7a It forms a 10-membered bicyclic heteroaryl by substitution.
[0153] In some embodiments, the six-membered monocyclic heteroaryl contains one nitrogen atom.
[0154] In some embodiments, the six-membered monocyclic heteroaryl contains two nitrogen atoms.
[0155] In some embodiments, the 10-membered bicyclic heteroaryl contains one nitrogen atom.
[0156] As generally described herein, each R 7a These are independently halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C6 aryl, 5-6 membered heteroaryl, C3-C5 cycloalkyl, or 4-5 membered heterocyclil, and alkyl, haloalkyl, alkoxy, haloalkoxy, aryl, heteroaryl, cycloalkyl, and heterocyclil are one or more R 7b It may be replaced with .
[0157] Several embodiments, each R 7a These are independently: halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C6 aryl, 5-6 membered heteroaryl, C 3- C5 cycloalkyl or 4-5 membered heterocyclyl, wherein alkyl, haloalkyl, alkoxy, haloalkoxy, aryl, heteroaryl, cycloalkyl, and heterocyclyl are one or more R 7b It has been replaced with.
[0158] Several embodiments, each R 7a These are independently: halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C6 aryl, 5-6 membered heteroaryl, C 3- It is a C5 cycloalkyl or a 4- to 5-membered heterocycline.
[0159] In some embodiments, at least one R 7a It is a separate entity, a halo.
[0160] In some embodiments, at least one R 7a It is independently -CN.
[0161] In some embodiments, at least one R 7a It is independently -OH.
[0162] In some embodiments, at least one R 7a Each is independent of one or more R 7b It is a C1-C6 alkyl group which may be substituted with [another molecule].
[0163] In some embodiments, at least one R 7a These are independently C1-C6 alkyl groups.
[0164] In some embodiments, R 7a is methyl. In some embodiments, R 7a is ethyl. In some embodiments, R 7a is propyl. In some embodiments, R 7a is butyl. In some embodiments, R 7a is pentill. In some embodiments, R 7a is hexyl. In some embodiments, R 7a is isopropyl. In some embodiments, R 7a isobutyl. In some embodiments, R 7a is isopentyl. In some embodiments, R 7a is isohexyl. In some embodiments, R 7a secbutyl is used in some embodiments. 7a secpentyl is used in some embodiments. 7a sec hexyl is used in some embodiments. 7a It is tert-butyl.
[0165] In some embodiments, at least one R 7a Each is independent of one or more R 7b It is a C1-C6 haloalkyl that may be substituted with [another compound].
[0166] In some embodiments, at least one R 7a These are independently C1-C6 haloalkyl groups.
[0167] In some embodiments, R 7a is a halomethyl. In some embodiments, R 7a is haloethyl. In some embodiments, R 7a is a halopropyl. In some embodiments, R 7a is halobutyl. In some embodiments, R 7a is halopentyl. In some embodiments, R 7a It is a halohexyl.
[0168] In some embodiments, at least one R 7a Each is independent of one or more R 7b It is a C1-C6 alkoxy that may be substituted with [another compound].
[0169] In some embodiments, at least one R 7a These are independently C1-C6 alkoxy compounds.
[0170] In some embodiments, at least one R 7a Each is independent of one or more R 7b It is a C1-C6 haloalkoxy that may be substituted with [another compound].
[0171] In some embodiments, at least one R 7a These are independently C1-C6 haloalkoxy compounds.
[0172] In some embodiments, at least one R 7aThese are independently C6 aryl or 5-6 member heteroaryl compounds, and aryl and heteroaryl compounds are one or more R 7b It may be replaced with .
[0173] In some embodiments, at least one R 7a It is independently a C6 aryl.
[0174] In some embodiments, at least one R 7a Each is independent of one or more R 7b It is a C6 aryl that may be substituted with [another C6 aryl
[0175] In some embodiments, at least one R 7a Each is independent of one or more R 7b It is a C6 aryl that is substituted with [this].
[0176] In some embodiments, at least one R 7a These are independently 5-6 member heteroaryl compounds.
[0177] In some embodiments, at least one R 7a Each is independent of one or more R 7b It is a 5-6 member heteroaryl that may be substituted with [another compound].
[0178] In some embodiments, at least one R 7a Each is independent of one or more R 7b It is a 5-6 member heteroaryl that is substituted with [the specified compound].
[0179] In some embodiments, at least one R 7a C 3- C5 cycloalkyl or 4-5 membered heterocycline, and cycloalkyl and heterocycline are one or more R 7b It may be replaced with .
[0180] In some embodiments, at least one R 7a C 3-It is a C5 cycloalkyl group.
[0181] In some embodiments, at least one R 7a Each is independent of one or more R 7b Even if replaced by C 3- It is a C5 cycloalkyl group.
[0182] In some embodiments, at least one R 7a Each is independent of one or more R 7b C is replaced by 3- It is a C5 cycloalkyl group.
[0183] In some embodiments, at least one R 7a It is independently cyclopropyl.
[0184] In some embodiments, at least one R 7a Each is independent of one or more R 7b It is a cyclopropyl that may be substituted with [another compound].
[0185] In some embodiments, at least one R 7a Each is independent of one or more R 7b It is a cyclopropyl substituted with [a specific compound].
[0186] In some embodiments, at least one R 7a These are independently 4-5 member heterocyclines.
[0187] In some embodiments, at least one R 7a Each is independent of one or more R 7b It is a 4-5 member heterocycline that may be substituted with .
[0188] In some embodiments, at least one R 7a Each is independent of one or more R 7b It is a 4-5 member heterocycline that is substituted with [a specific compound].
[0189] In some embodiments, at least one R 7a These are independently C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl.
[0190] In some embodiments, at least one R 7a These are independently methyl, -CF3, C6 aryl, or cyclopropyl.
[0191] As generally described herein, R 7b These are halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0192] In some embodiments, R 7b It is a halo.
[0193] In some embodiments, R 7b It is -CN.
[0194] In some embodiments, R 7b It is -OH.
[0195] In some embodiments, R 7b It is a C1-C6 alkyl group.
[0196] In some embodiments, R 7b It is a C1-C6 haloalkyl group.
[0197] In some embodiments, R 7b It is a C1-C6 alkoxy.
[0198] In some embodiments, R 7b It is a C1-C6 haloalkoxy.
[0199] In some embodiments, R 7 and R 2 They combine into one R 7aIt forms a 5-10 member monocyclic or bicyclic heteroaryl, which may be substituted with R 7a These are C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl.
[0200] In some embodiments, R 7 and R 2 They combine into one R 7a It forms a 6-membered monocyclic heteroaryl which may be substituted with R 7a These are C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl.
[0201] In some embodiments, R 7 and R 2 They combine into one R 7a It forms a 6-membered monocyclic heteroaryl which may be substituted with R 7a These are methyl, -CF3, C6 aryl, or cyclopropyl.
[0202] In some embodiments, R 7 and R 2 They combine into one R 7a It forms a 10-membered bicyclic heteroaryl which may be substituted with R 7a These are C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl.
[0203] (b)R 4 and Z As generally described herein, R 4 is one or more R 4a It may be a -C1-C6 alkylene- which may be substituted with each R 4a These are independently: halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C 3-4 It is either a cycloalkyl or a 4-5 membered heterocycline, or two R 4aThese combine to form a C3-C5 cycloalkyl or 4-6 membered heterocyclyl ring, and alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl and heterocyclyl are one or more R 4b It may also be replaced with R 4b These are halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0204] In some embodiments, R 4 is either unsubstituted or independently of one or two R 4a It will be replaced with.
[0205] In some embodiments, R 4 This is a non-substitution.
[0206] In some embodiments, R 4 These are independently one or two R 4a It will be replaced with.
[0207] In some embodiments, R 4 Each is independently of one R 4a It will be replaced with.
[0208] In some embodiments, R 4 These are independent of the two R 4a It will be replaced with.
[0209] In some embodiments, R 4 is one or more R 4a It may be a -C1-C6 alkylene- which may be substituted with each R 4a These are independently: halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C 3-4 Cycloalkyl or 4-5 membered heterocyclyl, and alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, and heterocyclyl are one or more R 4b It may also be replaced with R 4bThese are halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0210] In some embodiments, R 4 is one or more R 4a It may be a -C1-C6 alkylene- which may be substituted with each R 4a These are independently: halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C 3-4 They are cycloalkyl or 4-5 membered heterocyclines.
[0211] In some embodiments, R 4 is one or more R 4a It is a -C1-C6 alkylene- which may be substituted with two R 4a These combine to form a C3-C5 cycloalkyl or 4-6 membered heterocyclyl ring, and the cycloalkyl and heterocyclyl rings contain one or more R 4b It may also be replaced with R 4b These are halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0212] In some embodiments, R 4 is one or more R 4a It is a -C1-C6 alkylene- which may be substituted with two R 4a These atoms bond to form a C3-C5 cycloalkyl or 4-6 membered heterocyclyl ring.
[0213] In some embodiments, R 4 It is a -C1-C6 alkylene.
[0214] In some embodiments, R 4 is -C1 alkylene-. In some embodiments, R 4 is -C2 alkylene-. In some embodiments, R 4is -C3 alkylene-. In some embodiments, R 4 is -C4 alkylene-. In some embodiments, R 4 is -C5 alkylene-. In some embodiments, R 4 It is a -C6 alkylene-.
[0215] In some embodiments, R 4 is one or more R 4a It is a -C1 alkylene- which may be substituted with R 4 is one or more R 4a It is a C2 alkylene which may be substituted with R 4 is one or more R 4a It is a C3 alkylene which may be substituted with R 4 is one or more R 4a It is a C4 alkylene which may be substituted with R 4 is one or more R 4a It is a C5 alkylene which may be substituted with R 4 is one or more R 4a It is a -C6 alkylene- which may be substituted with
[0216] As generally described herein, each R 4a These are independently: halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C 3-4 It is either a cycloalkyl or a 4-5 membered heterocycline, or two R 4a These combine to form a C3-C5 cycloalkyl or 4-6 membered heterocyclyl ring, and alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, and heterocyclyl are one or more R 4b It may be replaced with .
[0217] Several embodiments, each R 4aThese are independently: halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C 3-4 A cycloalkyl or 4-5 membered heterocyclyl ring, wherein alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, and heterocyclyl are one or more R 4b It may be replaced with .
[0218] In some embodiments, two R 4a These combine to form a C3-C5 cycloalkyl or 4-6 membered heterocyclyl ring, and the cycloalkyl and heterocyclyl rings contain one or more R 4b It may be replaced with .
[0219] In some embodiments, at least one R 4a It is a separate entity, a halo.
[0220] In some embodiments, at least one R 4a It is independently -CN.
[0221] In some embodiments, at least one R 4a It is independently -OH.
[0222] In some embodiments, at least one R 4a Each is independent of one or more R 4b It is a C1-C6 alkyl which may be substituted with. In some embodiments, at least one R 4a Independently, are C1-C3 alkyl groups. In some embodiments, at least one R 4a It is methyl (-CH3).
[0223] In some embodiments, at least one R 4a These are independently C1-C6 alkyl groups.
[0224] In some embodiments, at least one R 4a Each is independent of one or more R4b It is a C1-C6 haloalkyl that may be substituted with [another compound].
[0225] In some embodiments, at least one R 4a These are independently C1-C6 haloalkyl groups.
[0226] In some embodiments, at least one R 4a Each is independent of one or more R 4b It is a C1-C6 alkoxy that may be substituted with [another compound].
[0227] In some embodiments, at least one R 4a These are independently C1-C6 alkoxy compounds.
[0228] In some embodiments, at least one R 4a Each is independent of one or more R 4b It is a C1-C6 haloalkoxy that may be substituted with [another compound].
[0229] In some embodiments, at least one R 4a These are independently C1-C6 haloalkoxy compounds.
[0230] In some embodiments, at least one R 4a C 3-4 They are cycloalkyl or 4-5 membered heterocyclines, and the cycloalkyl and heterocyclines are one or more R 4b It may be replaced with .
[0231] In some embodiments, at least one R 4a C 3-4 It is a cycloalkyl group.
[0232] In some embodiments, at least one R 4a Each is independent of one or more R 4b Even if replaced by C 3-4 It is a cycloalkyl group.
[0233] In some embodiments, at least one R 4a Each is independent of one or more R 4b C is replaced by 3-4 It is a cycloalkyl group.
[0234] In some embodiments, at least one R 4a These are independently 4-5 member heterocyclines.
[0235] In some embodiments, at least one R 4a Each is independent of one or more R 4b It is a 4-5 member heterocycline that may be substituted with .
[0236] In some embodiments, at least one R 4a Each is independent of one or more R 4b It is a 4-5 member heterocycline that is substituted with [a specific compound].
[0237] In some embodiments, two R 4a These combine to form a C3-C5 cycloalkyl group.
[0238] In some embodiments, two R 4a These are combined into one or more R 4b It forms a C3-C5 cycloalkyl group which may be substituted with a different compound.
[0239] In some embodiments, two R 4a These are combined into one or more R 4b It forms a C3-C5 cycloalkyl group that is substituted with [the specified group].
[0240] In some embodiments, two R 4a These combine to form a C5 cycloalkyl group.
[0241] In some embodiments, two R 4a These are combined into one or more R 4b It forms a C5 cycloalkyl group which may be substituted with a different compound.
[0242] In some embodiments, two R 4a These are combined into one or more R 4b It forms a C5 cycloalkyl group that is substituted with [the specified character].
[0243] In some embodiments, two R 4a They combine to form a 4-6 membered heterocyclyl ring.
[0244] In some embodiments, two R 4a These are combined into one or more R 4b It forms a 4-6 member heterocyclyl ring, which may be substituted with other elements.
[0245] In some embodiments, two R 4a These are combined into one or more R 4b It forms a 4-6 member heterocyclyl ring that is substituted by [a specific component].
[0246] As generally described herein, R 4b These are halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0247] In some embodiments, at least one R 4b It is a halo.
[0248] In some embodiments, at least one R 4b It is -CN.
[0249] In some embodiments, at least one R 4b It is -OH.
[0250] In some embodiments, at least one R 4b It is a C1-C6 alkyl group.
[0251] In some embodiments, at least one R 4b It is a C1-C6 haloalkyl group.
[0252] In some embodiments, at least one R 4b It is a C1-C6 alkoxy.
[0253] In some embodiments, at least one R 4b It is a C1-C6 haloalkoxy.
[0254] As generally described herein, Z is -CO2H or -CO2PG, where PG is C1-C6 alkyl, C6 aryl, or (C6 aryl)(C1-C6 alkyl), and the alkyl and aryl may be substituted with one or more halo, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0255] In some embodiments, Z is -CO2H.
[0256] In some embodiments, Z is -CO2PG.
[0257] As generally described herein, the PG is a C1-C6 alkyl, a C6 aryl, or (C6 aryl)(C1-C6 alkyl), where the alkyl and aryl may be substituted with one or more halos, C1-C6 alkyls, C1-C6 alkoxys, or C1-C6 haloalkoxys.
[0258] In some embodiments, PG is C1-C6 alkyl, C6 aryl, or (C6 aryl)(C1-C6 alkyl).
[0259] In some embodiments, the PG is a C1-C6 alkyl, a C6 aryl, or (C6 aryl)(C1-C6 alkyl), where the alkyl and aryl are substituted with one or more halo, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0260] In some embodiments, PG is a C1-C6 alkyl which may be substituted with one or more halos, C1-C6 alkyls, C1-C6 alkoxys, or C1-C6 haloalkoxys.
[0261] In some embodiments, PG is a C1-C6 alkyl group.
[0262] In some embodiments, the PG is a C1-C6 alkyl, a C1-C6 alkoxy, or a C1-C6 alkyl substituted with one or more halo, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0263] In some embodiments, PG is a C6 aryl which may be substituted with one or more halos, C1-C6 alkyls, C1-C6 alkoxys, or C1-C6 haloalkoxys.
[0264] In some embodiments, PG is C6 aryl.
[0265] In some embodiments, PG is a C6 aryl substituted with one or more halo, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0266] In some embodiments, PG is (C6 aryl)(C1-C6 alkyl), and the alkyl and aryl may be substituted with one or more halo, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0267] In some embodiments, PG is (C6 aryl)(C1-C6 alkyl).
[0268] In some embodiments, the PG is (C6 aryl)(C1-C6 alkyl), where the alkyl and aryl are substituted with one or more halo, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0269] (c) Additional embodiments In some embodiments of formula (I) where Z is -CO2H, the compound is the compound of the following formula (IA): [ka] or a pharmaceutically acceptable salt thereof.
[0270] In some embodiments of formula (IA) or its pharmaceutically acceptable salts, R 1 It is a halo, R 3 It does not exist, R 7 and R 2 They combine to form a 5-10 member monocyclic or bicyclic heteroaryl or a 5-10 member monocyclic or bicyclic heterocyclil, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ is a halo or OH, and R 6’’ H is H.
[0271] In some embodiments of formula (IA) or its pharmaceutically acceptable salts, R 1 It is a halo, R 3 It does not exist, R 7 and R 2 They combine to form a 5-10 member monocyclic or bicyclic heteroaryl, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ is H or halo or OH, and R 6’’ is H. In some embodiments, R 1 is Br or Cl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H, F, or OH, and R6’’ is H. In some embodiments, R 1 is Br, R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is H. In some embodiments, R 1 is Cl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or OH, and R 6’’ H is H.
[0272] In some embodiments of formula (IA) or its pharmaceutically acceptable salts, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 These combine to form a 5-10 member monocyclic or bicyclic heteroaryl which may be substituted with one or more C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is H or halo. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R 4 is -C3 alkylene-, and each R5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is H. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is H. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ It is F.
[0273] In some embodiments of formula (IA) or its pharmaceutically acceptable salts, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, or R 7 and R 2They bond to form a 6-membered monocyclic heteroaryl which may be substituted with one or more C1-C6 alkyl groups, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 It binds to form a 6-membered monocyclic heteroaryl that is substituted with methyl, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 It is bonded to form a 6-membered monocyclic heteroaryl which may be substituted with one or more C1-C6 haloalkyl groups, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl substituted with -CF3, and R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7and R 2 They combine to form a 6-membered monocyclic heteroaryl which may be substituted with one or more C6 aryls, 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They bond to form a phenyl-substituted 6-membered monocyclic heteroaryl, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They bond to form a 6-membered monocyclic heteroaryl which may be substituted with one or more C3-C5 cycloalkyl groups, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 It binds to form a cyclopropyl-substituted 6-membered monocyclic heteroaryl, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ It is F.
[0274] In some embodiments of Formula (I-A) or a pharmaceutically acceptable salt thereof, R 1 is C3-C4 cycloalkyl, R 3 is absent, R 7 and R 2 join to form a 10-membered bicyclic heteroaryl, R 4 is -C1-C6 alkylene-, each R 5 is independently C1-C6 alkyl, R 6 is H, R 6’ is H or halo, and R 6’’ is halo. In some embodiments, R 1 is cyclopropyl, R 3 is absent, R 7 and R 2 join to form a 10-membered bicyclic heteroaryl, R 4 is -C3 alkylene-, each R 5 is independently methyl, R 6 is H, R 6’ is H or F, and R 6’’ is F.
[0275] In some embodiments of Formula (I-A) or a pharmaceutically acceptable salt thereof, R 1 is halo, R 3 is absent, R 7 and R 2 join to form a 5 to 10-membered heterocyclyl, R 4 is -C1-C6 alkylene-, each R 5 is independently C1-C6 alkyl, R 6 is H, R 6’ is H or halo or OH, and R 6’’ is H. In some embodiments, R 1 is Br or Cl, R 3 is absent, R 7 and R 2 join to form a 5-membered heterocyclyl, R 4 is -C3 alkylene-, each R 5 is independently methyl, R 6 is H, R 6’is H or F or OH, and R 6’’ is H. In some embodiments, R 1 is Br, and R 3 is absent, and R 7 and R 2 are joined to form a 5-membered heterocyclyl, and R 4 is -C3 alkylene-, and each R 5 is independently methyl, and R 6 is H, and R 6’ is H or F, and R 6’’ is H. In some embodiments, R 1 is Cl, and R 3 is absent, and R 7 and R 2 are joined to form a 5-membered heterocyclyl, and R 4 is -C3 alkylene-, and each R 5 is independently methyl, and R 6 is H, and R 6’ is H or OH, and R 6’’ is H.
[0276] In some embodiments of Formula (I-A) or a pharmaceutically acceptable salt thereof, R 1 is C3-C4 cycloalkyl, and R 3 is absent, and R 7 and R 2 are joined to form a 5-10 membered monocyclic or bicyclic heterocyclyl, which may be optionally substituted with one or more C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl or C3-C5 cycloalkyl, and R 4 is -C1-C6 alkylene-, and each R 5 is independently C1-C6 alkyl, and R 6 is H, and R 6’ is H or halo, and R 6’’ is H or halo. In some embodiments, R 1 is C3-C4 cycloalkyl, and R 3 is absent, and R 7 and R 2 are joined to form a 5-membered monocyclic heterocyclyl, and R 4is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is H. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 5-membered monocyclic heterocycline, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 5-membered monocyclic heterocycline, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is H. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 5-membered monocyclic heterocycline, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ It is F.
[0277] In some embodiments of formula (IA) or its pharmaceutically acceptable salts, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2are bonded to form a 5-membered monocyclic heterocyclyl which may be substituted with one or more C1-C6 alkyl, R 4 is -C3 alkylene-, and each R 5 is independently C1-C6 alkyl, R 6 is H, R 6’ is H or halo, R 6’’ is halo. In some embodiments, R 1 is cyclopropyl, R 3 is absent, R 7 and R 2 are bonded to form a 5-membered monocyclic heterocyclyl substituted with methyl, R 4 is -C3 alkylene-, and each R 5 is independently methyl, R 6 is H, R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 is C3-C4 cycloalkyl, R 3 is absent, R 7 and R 2 are bonded to form a 5-membered monocyclic heterocyclyl which may be substituted with one or more C1-C6 haloalkyl, R 4 is -C3 alkylene-, and each R 5 is independently C1-C6 alkyl, R 6 is H, R 6’ is H or halo, R 6’’ is halo. In some embodiments, R 1 is cyclopropyl, R 3 is absent, R 7 and R 2 are bonded to form a 5-membered monocyclic heterocyclyl substituted with -CF3, R 4 is -C3 alkylene-, and each R 5 is independently methyl, R 6 is H, R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 is C3-C4 cycloalkyl, R 3 is absent, R7 and R 2 They combine to form a 5-membered monocyclic heterocycline which may be substituted with one or more C6 aryls, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They bond to form a phenyl-substituted 5-membered monocyclic heterocycline, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They bond to form a 5-membered monocyclic heterocycline which may be substituted with one or more C3-C5 cycloalkyl groups, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 It binds to form a cyclopropyl-substituted 5-membered monocyclic heterocycline, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ It is F.
[0278] R4 In some embodiments of formula (IA) where is -C3 alkylene-, the compound is the compound of the following formula (I-A'): [ka] or a pharmaceutically acceptable salt thereof, with 0 R 4a Base (Therefore, R 4a (None exist), or 1, 2, 3, 4, 5, or 6 independent R 4a Includes the base.
[0279] In some embodiments of formula (I-A') or its pharmaceutically acceptable salt, R 1 It is a halo, R 3 It does not exist, R 7 and R 2 They combine to form a 5-10 member monocyclic heteroaryl or 5-10 member monocyclic heterocyclil, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ is H, halo, or -OH, and R 6’’ H is H.
[0280] In some embodiments of formula (I-A') or its pharmaceutically acceptable salt, R 1 It is a halo, R 3 It does not exist, R 7 and R 2 They combine to form a 5-10 member monocyclic heteroaryl, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ is H, halo, or -OH, and R 6’’ is H. In some embodiments, R 1 is Br or Cl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R 4a It does not exist, each R 5R is independently methyl, 6 H is R 6’ is H, F, or -OH, and R 6’’ is H. In some embodiments, R 1 is Br, R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is H. In some embodiments, R 1 is Cl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or -OH, and R 6’’ H is H.
[0281] In some embodiments of formula (I-A') or its pharmaceutically acceptable salt, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 These combine to form a 5-10 member monocyclic heteroaryl which may be substituted with one or more C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl molecules, and R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is H or halo. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is H. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is H. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ It is F.
[0282] In some embodiments of formula (I-A') or its pharmaceutically acceptable salt, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They bond to form a 6-membered monocyclic heteroaryl which may be substituted with one or more C1-C6 alkyl groups, R4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They bond to form a methyl-substituted 6-membered monocyclic heteroaryl, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They bond to form a 6-membered monocyclic heteroaryl which may be substituted with one or more C1-C6 haloalkyl groups, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl substituted with -CF3, and R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 6-membered monocyclic heteroaryl which may be substituted with one or more C6 aryls, 4aIt does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They bond to form a phenyl-substituted 6-membered monocyclic heteroaryl, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They bond to form a 6-membered monocyclic heteroaryl which may be substituted with one or more C3-C5 cycloalkyl groups, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 It binds to form a cyclopropyl-substituted 6-membered monocyclic heteroaryl, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ It is F.
[0283] In some embodiments of formula (I-A') or its pharmaceutically acceptable salt, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2They combine to form a 10-membered bicyclic heteroaryl, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 10-membered bicyclic heteroaryl, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ It is F.
[0284] In some embodiments of formula (I-A') or its pharmaceutically acceptable salt, R 1 It is a halo, R 3 It does not exist, R 7 and R 2 They combine to form a 5-10 member heterocycline, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ is H, halo, or -OH, and R 6’’ is H. In some embodiments, R 1 is Br or Cl, and R 3 It does not exist, R 7 and R 2 They combine to form a 5-membered heterocycline, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H, F, or -OH, and R 6’’ is H. In some embodiments, R 1 is Br, R 3 It does not exist, R 7 and R 2 They combine to form a 5-membered heterocycline, R 4aIt does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is H. In some embodiments, R 1 is Cl, and R 3 It does not exist, R 7 and R 2 They combine to form a 5-membered heterocycline, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or -OH, and R 6’’ H is H.
[0285] In some embodiments of formula (I-A') or its pharmaceutically acceptable salt, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 These combine to form a 5-10 membered heterocycline which may be substituted with one or more C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl groups, and R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is H or halo. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 5-membered heterocycline, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is H. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2They combine to form a 5-membered heterocycline, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 5-membered heterocycline, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is H. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 5-membered heterocycline, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ It is F.
[0286] In some embodiments of formula (I-A') or its pharmaceutically acceptable salt, R 1 It is a C3-C4 cycloalkyl, and R 3 R is absent, 7 and R 2 They bond to form a 5-membered monocyclic heterocycline which may be substituted with one or more C1-C6 alkyl groups, R 4a is absent, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2They bond to form a methyl-substituted 5-membered monocyclic heterocycline, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They bond to form a 5-membered monocyclic heterocycline which may be substituted with one or more C1-C6 haloalkyl groups, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 5-membered monocyclic heterocycline substituted with -CF3, and R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They combine to form a 5-membered monocyclic heterocycline which may be substituted with one or more C6 aryls, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2The bonds combine to form a phenyl-substituted 5-membered monocyclic heterocycline, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 3 It does not exist, R 7 and R 2 They bond to form a 5-membered monocyclic heterocycline which may be substituted with one or more C3-C5 cycloalkyl groups, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 3 It does not exist, R 7 and R 2 It binds to form a cyclopropyl-substituted 5-membered monocyclic heterocycline, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ It is F.
[0287] R 3 It does not exist, R 2 and R 7 In some embodiments of formula (IA), in which the atoms are bonded to form a 5-10 membered monocyclic or bicyclic heteroaryl ring, the compound is a compound of the following formulas: (IB), (IC), (ID), (IE), (IF), or (IG): [ka] or a pharmaceutically acceptable salt thereof, with 0 R 7a Base (Therefore, R 7a (None exist), or 1, 2, 3, 4, or 5 independent R7a Includes the base.
[0288] In embodiments of formulas (IB), (IC), (ID), (IE), (IF), or (IG), or their pharmaceutically acceptable salts, R 1 It is a halo, R 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ is H, halo, or -OH, and R 6’’ is H. In some embodiments, R 1 is Br or Cl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H, F, or -OH, and R 6’’ is H. In some embodiments, R 1 is Br, R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is H. In some embodiments, R 1 is Cl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or -OH, and R 6’’ H is H.
[0289] In some embodiments of formulas (IB), (IC), (ID), (IE), (IF), or (IG), or their pharmaceutically acceptable salts, R 1 It is a C3-C4 cycloalkyl, and R 7aR is a C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl, 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is H or halo. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is H. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ It is F.
[0290] In some embodiments of formulas (IB), (IC), (ID), (IE), (IF), or (IG), or their pharmaceutically acceptable salts, R 1 It is a C3-C4 cycloalkyl, and one R 7a It exists, and this is a C1-C6 alkyl, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a There exists, and this is methyl, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and one R 7a There exists a C1-C6 haloalkyl, and R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a There exists, which is -CF3, and R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and one R 7a It exists, and this is a C6 aryl, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group.6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a It exists, and this is phenyl, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and one R 7a There exists which is a C3-C5 cycloalkyl, and R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a There exists which is cyclopropyl, and R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ It is F.
[0291] In some embodiments, the compound of formula (I) is a compound of formula (IC), (ID), or (IE), or a pharmaceutically acceptable salt thereof.
[0292] In some embodiments of the formulas (IB), (IC), (ID), (IE), (IF), or (IG), R 4 It is a -C3 alkylene-, and the compounds are those of the following formulas: (I-B'), (I-C'), (I-D'), (I-E'), (I-F'), or (I-G'). [ka] or a pharmaceutically acceptable salt thereof, with 0 R 7a Base (Therefore, R 7a (None exist), or 1, 2, 3, 4, or 5 independent R 7a Includes base, 0 R 4a Base (Therefore, R 4a (None exist), or 1, 2, 3, 4, 5, or 6 independent R 4a It further includes the base.
[0293] In some embodiments of formulas (I-B'), (I-C'), (I-D'), (I-E'), (I-F'), or (I-G'), or pharmaceutically acceptable salts thereof, R 1 It is a halo, R 7a It does not exist, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ is H, halo, or -OH, and R 6’’ is H. In some embodiments, R 1 is Br or Cl, and R 7a It does not exist, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H, F, or -OH, and R 6’’ is H. In some embodiments, R 1 is Br, R 7a It does not exist, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is H. In some embodiments, R 1 is Cl, and R 7a It does not exist, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or -OH, and R 6’’ H is H.
[0294] In some embodiments of formulas (I-B'), (I-C'), (I-D'), (I-E'), (I-F'), or (I-G'), or pharmaceutically acceptable salts thereof, R 1 It is a C3-C4 cycloalkyl, and R 7a R is a C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl, 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is H or halo. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 7a It does not exist, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is H. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 7a It does not exist, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’is H or F, R 6’’ It is F.
[0295] In some embodiments of formulas (I-B'), (I-C'), (I-D'), (I-E'), (I-F'), or (I-G'), or pharmaceutically acceptable salts thereof, R 1 It is a C3-C4 cycloalkyl, and one R 7a It exists, and this is a C1-C6 alkyl, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a There exists, and this is methyl, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and one R 7a There exists a C1-C6 haloalkyl, and R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a There exists, which is -CF3, and R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and one R 7a It exists, and this is a C6 aryl, R 4a It does not exist, each R5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a It exists, and this is phenyl, R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and one R 7a There exists which is a C3-C5 cycloalkyl, and R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a There exists which is cyclopropyl, and R 4a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is H or F, R 6’’ It is F.
[0296] In some embodiments, the compound of formula (I) is a compound of formula (I-C'), (I-D'), or (I-E'), or a pharmaceutically acceptable salt thereof.
[0297] In some embodiments, the expression (IB), (IC), (ID), (IE), (IF), or (IG) is R 6 The compound is hydrogen, and the compound is a compound of the following formulas: (IBa), (ICa), (IDa), (IEa), (IFa), or (IGa): [ka] or a pharmaceutically acceptable salt thereof, with 0 R 7a Base (Therefore, R 7a (None exist), or 1, 2, 3, 4, or 5 independent R 7a Includes the base.
[0298] In some embodiments of formulas (IBa), (ICa), (IDa), (IEa), (IFa), or (IGa), or their pharmaceutically acceptable salts, R 1 It is a halo, R 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ is H, halo, or -OH, and R 6’’ is H. In some embodiments, R 1 is Br or Cl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is H, F, or -OH, and R 6’’ is H. In some embodiments, R 1 is Br, R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is H or F, R 6’’ is H. In some embodiments, R 1 is Cl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is H or -OH, and R 6’’ H is H.
[0299] In some embodiments of formulas (IBa), (ICa), (IDa), (IEa), (IFa), or (IGa), or their pharmaceutically acceptable salts, R1 It is a C3-C4 cycloalkyl, and R 7a R is a C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl, 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ H is H or halo, and R 6’’ is H or halo. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ H is H or halo, and R 6’’ is H. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is H or F, R 6’’ is H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is H or F, R 6’’ It is F.
[0300] In some embodiments of formulas (IBa), (ICa), (IDa), (IEa), (IFa), or (IGa), or their pharmaceutically acceptable salts, R 1It is a C3-C4 cycloalkyl, and one R 7a It exists, and this is a C1-C6 alkyl, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a There exists, and this is methyl, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and one R 7a There exists a C1-C6 haloalkyl, and R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a There exists, which is -CF3, and R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and one R 7a It exists, and this is a C6 aryl, R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a It exists, and this is phenyl, R 4 is -C3 alkylene-, and each R 5R is independently methyl, 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and one R 7a There exists which is a C3-C5 cycloalkyl, and R 4 is -C3 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a There exists which is cyclopropyl, and R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is H or F, R 6’’ It is F.
[0301] In some embodiments, the compound of formula (I) is a compound of formula (ICa), (IDa), or (IEa), or a pharmaceutically acceptable salt thereof.
[0302] R 6 is hydrogen, R 4 In some embodiments of formulas (IB), (IC), (ID), (IE), (IF), or (IG), where is -C3 alkylene-, the compound is a compound of the following formulas: (I-B'-a), (I-C'-a), (I-D'-a), (I-E'-a), (I-F'-a), or (I-G'-a): [ka] or a pharmaceutically acceptable salt thereof, with 0 R 7a Base (Therefore, R 7a (None exist), or 1, 2, 3, 4, or 5 independent R 7a Includes base, 0 R 4a Base (Therefore, R 4a (None exist), or 1, 2, 3, 4, 5, or 6 independent R4a It further includes the base.
[0303] In some embodiments of formulas (I-B'-a), (I-C'-a), (I-D'-a), (I-E'-a), (I-F'-a), or (I-G'-a), or their pharmaceutically acceptable salts, R 1 It is a halo, R 7a It does not exist, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ is H, halo, or -OH, and R 6’’ is H. In some embodiments, R 1 is Br or Cl, and R 7a It does not exist, R 4a It does not exist, each R 5 R is independently methyl, 6’ is H, F, or -OH, and R 6’’ is H. In some embodiments, R 1 is Br, R 7a It does not exist, R 4a It does not exist, each R 5 R is independently methyl, 6’ is H or F, R 6’’ is H. In some embodiments, R 1 is Cl, and R 7a It does not exist, R 4a It does not exist, each R 5 R is independently methyl, 6’ is H or -OH, and R 6’’ H is H.
[0304] In some embodiments of formulas (I-B'-a), (I-C'-a), (I-D'-a), (I-E'-a), (I-F'-a), or (I-G'-a), or their pharmaceutically acceptable salts, R 1 It is a C3-C4 cycloalkyl, and R 7a R is a C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl, 4a It does not exist, each R 5R is independently a C1-C6 alkyl group. 6’ H is H or halo, and R 6’’ is H or halo. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 7a It does not exist, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ H is H or halo, and R 6’’ is H. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and R 7a It does not exist, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4a It does not exist, each R 5 R is independently methyl, 6’ is H or F, R 6’’ is H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4a It does not exist, each R 5 R is independently methyl, 6’ is H or F, R 6’’ It is F.
[0305] In some embodiments of formulas (I-B'-a), (I-C'-a), (I-D'-a), (I-E'-a), (I-F'-a), or (I-G'-a), or their pharmaceutically acceptable salts, R 1 It is a C3-C4 cycloalkyl group, with one R 7a It exists, and this is a C1-C6 alkyl, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R1 It is cyclopropyl, and one R 7a There exists, and this is methyl, R 4a It does not exist, each R 5 R is independently methyl, 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and one R 7a There exists, and this is R 7a It is a C1-C6 haloalkyl, and R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a There exists, which is -CF3, and R 4a It does not exist, each R 5 R is independently methyl, 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and one R 7a It exists, and this is a C6 aryl, R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a It exists, and this is phenyl, R 4a It does not exist, each R 5 R is independently methyl, 6’ is H or F, R 6’’ is F. In some embodiments, R 1 It is a C3-C4 cycloalkyl, and one R 7a There exists which is a C3-C5 cycloalkyl, and R 4a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’H is H or halo, and R 6’’ is a halo. In some embodiments, R 1 It is cyclopropyl, and one R 7a There exists which is cyclopropyl, and R 4a It does not exist, each R 5 R is independently methyl, 6’ is H or F, R 6’’ It is F.
[0306] In some embodiments, the compound of formula (I) is a compound of formula (I-C'-a), (I-D'-a), or (I-E'-a), or a pharmaceutically acceptable salt thereof.
[0307] In some embodiments of formula (IA), R 3 It does not exist (or R 3 (is hydrogen), R 2 and R 7 These bonds to form a 5-membered monocyclic heterocycline ring, and the compound is a compound of the following formula (IJ): [ka] or a pharmaceutically acceptable salt thereof, with 0 R 7a Base (Therefore, R 7a (There is no such thing as) or 1 or 2 independent R 7a Includes the base.
[0308] In some embodiments of formula (IJ) or its pharmaceutically acceptable salts, R 1 R is a C1-C6 haloalkyl or C3-C5 cycloalkyl, 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ is a halo or H, and R 6’’ This is a halo or H.
[0309] In some embodiments of formula (IJ) or its pharmaceutically acceptable salts, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ is a halo or H, and R 6’’ is a halo or H. In some embodiments, R 1 CF3 and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is F or H, and R 6’’ is F or H. In some embodiments, R 1 CF3 and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is F or H, and R 6’’ is F. In some embodiments, R 1 CF3 and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is F or H, and R 6’’ H is H.
[0310] In some embodiments of formula (IJ) or its pharmaceutically acceptable salts, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ It is a halo, R 6’’is a halo or H. In some embodiments, R 1 CF3 and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ F is R 6’’ is F or H. In some embodiments, R 1 CF3 and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ F is R 6’’ is F. In some embodiments, R 1 CF3 and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ F is R 6’’ H is H.
[0311] In some embodiments of formula (IJ) or its pharmaceutically acceptable salts, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is R 6’’ is a halo or H. In some embodiments, R 1 CF3 and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ H is R 6’’ is F or H. In some embodiments, R 1 CF3 and R 7aIt does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ H is R 6’’ is F. In some embodiments, R 1 CF3 and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ H is R 6’’ H is H.
[0312] In some embodiments of formula (IJ) or its pharmaceutically acceptable salts, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ is a halo or H, and R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is F or H, and R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ is F or H, and R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R5 R is independently methyl, 6 H is R 6’ is F or H, and R 6’’ H is H.
[0313] In some embodiments of formula (IJ) or its pharmaceutically acceptable salts, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ It is a halo, R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ F is R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ F is R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ F is R 6’’ H is H.
[0314] In some embodiments of formula (IJ) or its pharmaceutically acceptable salts, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, R 4is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ H is R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ H is R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6 H is R 6’ H is R 6’’ H is H.
[0315] In some embodiments of formula (IJ), R 4 is a -C3 alkylene-, and the compound is the compound of the following formula (I-J'): [ka] or a pharmaceutically acceptable salt thereof, with 0 R 7a Base (Therefore, R 7a (There is no such thing as) or 1 or 2 independent R 7a Includes base, 0 R 4a Base (Therefore, R 4a (None exist), or 1, 2, 3, 4, 5, or 6 independent R 4aIt further includes the base.
[0316] In some embodiments of formula (I-J') or its pharmaceutically acceptable salts, R 1 R is a C1-C6 haloalkyl or C3-C5 cycloalkyl, 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ is a halo or H, and R 6’’ This is a halo or H.
[0317] In some embodiments of formula (I-J') or its pharmaceutically acceptable salts, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ is a halo or H, and R 6’’ is a halo or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is F or H, and R 6’’ is F or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is F or H, and R 6’’ is F. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is F or H, and R 6’’ H is H.
[0318] In some embodiments of formula (I-J') or its pharmaceutically acceptable salts, R1 It is a C1-C6 haloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ It is a halo, R 6’’ is a halo or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ F is R 6’’ is F or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ F is R 6’’ is F. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ F is R 6’’ H is H.
[0319] In some embodiments of formula (I-J') or its pharmaceutically acceptable salts, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is R 6’’ is a halo or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ H is R 6’’ is F or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R5 R is independently methyl, 6 H is R 6’ H is R 6’’ is F. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ H is R 6’’ H is H.
[0320] In some embodiments of formula (I-J') or its pharmaceutically acceptable salts, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ is a halo or H, and R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is F or H, and R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is F or H, and R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ is F or H, and R 6’’ is H. In some embodiments, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group.6 H is R 6’ It is a halo, R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ F is R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ F is R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ F is R 6’’ H is H.
[0321] In some embodiments of formula (I-J') or its pharmaceutically acceptable salts, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6 H is R 6’ H is R 6’’ H is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ H is R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ H is R6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6 H is R 6’ H is R 6’’ H is H.
[0322] In some embodiments of formula (IJ), R 6 is hydrogen, and the compound is the compound of the following formula (IJa), [ka] or a pharmaceutically acceptable salt thereof, with 0 R 7a Base (Therefore, R 7a (There is no such thing as) or 1 or 2 independent R 7a Includes the base.
[0323] In some embodiments of formula (IJa) or its pharmaceutically acceptable salts, R 1 R is a C1-C6 haloalkyl or C3-C5 cycloalkyl, 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ is a halo or H, and R 6’’ This is a halo or H.
[0324] In some embodiments of formula (IJa) or its pharmaceutically acceptable salts, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ is a halo or H, and R 6’’ is a halo or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, R 4is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F. In some embodiments, R 1 is -CF3, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is F or H, and R 6’’ H is H.
[0325] In some embodiments of formula (IJa) or its pharmaceutically acceptable salts, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ It is a halo, R 6’’ is a halo or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ F is R 6’’ is F or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ F is R 6’’ is F. In some embodiments, R 1 is -CF3, and R 7a It does not exist, R4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ F is R 6’’ H is H.
[0326] In some embodiments of formula (IJa) or its pharmaceutically acceptable salts, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ H is R 6’’ is a halo or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ H is R 6’’ is F or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ H is R 6’’ is F. In some embodiments, R 1 is -CF3, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ H is R 6’’ H is H.
[0327] In some embodiments of formula (IJa) or its pharmaceutically acceptable salts, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ is a halo or H, and R6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ is F or H, and R 6’’ H is H.
[0328] In some embodiments of formula (IJa) or its pharmaceutically acceptable salts, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ It is a halo, R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ F is R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5R is independently methyl, 6’ F is R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ F is R 6’’ H is H.
[0329] In some embodiments of formula (IJa) or its pharmaceutically acceptable salts, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, R 4 is -C1-C6 alkylene-, and each R 5 R is independently a C1-C6 alkyl group. 6’ H is R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ H is R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ H is R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, R 4 is -C3 alkylene-, and each R 5 R is independently methyl, 6’ H is R 6’’ H is H.
[0330] In some embodiments of the formula (IJa), R 6 is hydrogen, R4 It is a -C3 alkylene-, and the compound is the compound of the following formula (I-J'-a), [ka] or a pharmaceutically acceptable salt thereof, with 0 R 7a Base (Therefore, R 7a (There is no such thing as) or 1 or 2 independent R 7a Includes base, 0 R 4a Base (Therefore, R 4a (None exist), or 1, 2, 3, 4, 5, or 6 independent R 4a It further includes the base.
[0331] In some embodiments of formula (I-J'-a) or its pharmaceutically acceptable salt, R 1 R is a C1-C6 haloalkyl or C3-C5 cycloalkyl, 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ is a halo or H, and R 6’’ This is a halo or H.
[0332] In some embodiments of formula (I-J'-a) or its pharmaceutically acceptable salt, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ is a halo or H, and R 6’’ is a halo or H. In some embodiments, R 1 CF3 and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F or H. In some embodiments, R 1 CF3 and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’is F. In some embodiments, R 1 CF3 and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ H is H.
[0333] In some embodiments of formula (I-J'-a) or its pharmaceutically acceptable salt, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ It is a halo, R 6’’ is a halo or H. In some embodiments, R 1 CF3 and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ is F or H. In some embodiments, R 1 CF3 and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ is F. In some embodiments, R 1 CF3 and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ H is H.
[0334] In some embodiments of formula (I-J'-a) or its pharmaceutically acceptable salt, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ H is R 6’’ is a halo or H. In some embodiments, R 1 CF3 and R 7a It does not exist, each R 5 R is independently methyl, 6’H is R 6’’ is F or H. In some embodiments, R 1 CF3 and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ is F. In some embodiments, R 1 CF3 and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ H is H.
[0335] In some embodiments of formula (I-J'-a) or its pharmaceutically acceptable salt, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ is a halo or H, and R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ H is H.
[0336] In some embodiments of formula (I-J'-a) or its pharmaceutically acceptable salt, R 1 It is a C3-C5 cycloalkyl, and R 7aIt does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ It is a halo, R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ H is H.
[0337] In some embodiments of formula (I-J'-a) or its pharmaceutically acceptable salt, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ H is R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5R is independently methyl, 6’ H is R 6’’ H is H.
[0338] In some embodiments of formula (I-J'-a), the compound has the following (R) configuration and is a compound of the following formula (I-J'-aR): [ka] or provide a pharmaceutically acceptable salt thereof, with 0 R 7a Base (Therefore, R 7a (There is no such thing as) or 1 or 2 independent R 7a Includes base, 0 R 4a Base (Therefore, R 4a (None exist), or 1, 2, 3, 4, 5, or 6 independent R 4a It further includes the base.
[0339] In some embodiments of formula (I-J'-aR) or its pharmaceutically acceptable salt, R 1 R is a C1-C6 haloalkyl or C3-C5 cycloalkyl, 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ is a halo or H, and R 6’’ This is a halo or H.
[0340] In some embodiments of formula (I-J'-aR) or its pharmaceutically acceptable salt, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ is a halo or H, and R 6’’ is a halo or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F or H. In some embodiments, R1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ H is H.
[0341] In some embodiments of formula (I-J'-aR) or its pharmaceutically acceptable salt, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ It is a halo, R 6’’ is a halo or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ is F or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ is F. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ H is H.
[0342] In some embodiments of formula (I-J'-aR) or its pharmaceutically acceptable salt, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ H is R6’’ is a halo or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ is F or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ is F. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ H is H.
[0343] In some embodiments of formula (I-J'-aR) or its pharmaceutically acceptable salt, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ is a halo or H, and R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ H is H.
[0344] In some embodiments of formula (I-J'-aR) or its pharmaceutically acceptable salt, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ It is a halo, R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ H is H.
[0345] In some embodiments of formula (I-J'-aR) or its pharmaceutically acceptable salt, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ H is R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5R is independently methyl, 6’ H is R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ H is H.
[0346] In some embodiments of formula (I-J'-a), the compound has the following (S) configuration stereochemistry, and is a compound of the following formula (I-J'-aS): [ka] or provide a pharmaceutically acceptable salt thereof, with 0 R 7a Base (Therefore, R 7a (There is no such thing as) or 1 or 2 independent R 7a Includes base, 0 R 4a Base (Therefore, R 4a (None exist), or 1, 2, 3, 4, 5, or 6 independent R 4a It further includes the base.
[0347] In some embodiments of formula (I-J'-aS) or its pharmaceutically acceptable salt, R 1 R is a C1-C6 haloalkyl or C3-C5 cycloalkyl, 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ is a halo or H, and R 6’’ This is a halo or H.
[0348] In some embodiments, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ is a halo or H, and R 6’’ is a halo or H. In some embodiments, R 1 is -CF3, and R7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ H is H.
[0349] In some embodiments of formula (I-J'-aS) or its pharmaceutically acceptable salt, R 1 It is a C1-C6 haloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ It is a halo, R 6’’ is a halo or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ is F or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ is F. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ H is H.
[0350] In some embodiments of formula (I-J'-aS) or its pharmaceutically acceptable salt, R1 It is a C1-C6 haloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ H is R 6’’ is a halo or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ is F or H. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ is F. In some embodiments, R 1 is -CF3, and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ H is H.
[0351] In some embodiments of formula (I-J'-aS) or its pharmaceutically acceptable salt, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ is a halo or H, and R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ is F. In some embodiments, R 1It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ is F or H, and R 6’’ H is H.
[0352] In some embodiments of formula (I-J'-aS) or its pharmaceutically acceptable salt, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ It is a halo, R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ F is R 6’’ H is H.
[0353] In some embodiments of formula (I-J'-aS) or its pharmaceutically acceptable salt, R 1 It is a C3-C5 cycloalkyl, and R 7a It does not exist, each R 5 R is independently a C1-C6 alkyl group. 6’ H is R 6’’ is a halo or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’H is R 6’’ is F or H. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ is F. In some embodiments, R 1 It is cyclopropyl, and R 7a It does not exist, each R 5 R is independently methyl, 6’ H is R 6’’ H is H.
[0354] In some embodiments, the compound of formula (I) is the compound of formula (I-J'-aR) or a pharmaceutically acceptable salt thereof.
[0355] In some embodiments, the compound of formula (I) is selected from any one of the compounds in Tables 1 and 2A-2B, or from a pharmaceutically acceptable salt thereof. Tables 1 and 2A-2B below also provide the location of the compounds in Example (Ex) or in Table B (TA) of the Example, for each Example number (Ex). An asterisk (*) next to the compound number (#) indicates that the stereochemistry is arbitrarily or reasonably attributed.
[0356] In some embodiments, the compound of formula (I) is a non-ionized compound (e.g., a free acid) selected from any one of the compounds in Table 1 or 2A-2B.
[0357] In some embodiments, the compound of formula (I) is a salt (e.g., a pharmaceutically acceptable salt) selected from any one of the compounds in Table 1 or Tables 2A-2B. [Table 1-1] [Table 1-2] [Table 1-3] Table 1-4 Table 1-5 Table 1-6 Table 1-7 Table 1-8 Table 1-9 Table 1-10 Table 2-1 Table 2-2 Table 2-3 Table 2-4 Table 3-1 Table 3-2 Table 3-3 Table 3-4 Table 3-5 Table 3-6
[0358] (ii) Pharmaceutical composition Pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers are further intended herein.
[0359] For example, in some embodiments, a pharmaceutical composition is provided comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
[0360] Examples of pharmaceutically acceptable carriers include diluents such as purified water, triglyceride oils such as hydrogenated or partially hydrogenated vegetable oils, or mixtures thereof, corn oil, olive oil, sunflower oil, saffron oil, fish oil such as EPA or DHA, or esters or triglycerides or mixtures thereof, omega-3 fatty acids or their derivatives, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose, and / or glycine.
[0361] Administration to the target can be achieved via any mode of administration, for example, by oral administration, topical administration, or injection. Depending on the intended mode of administration, the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof may be in solid, semi-solid, or liquid dosage form.
[0362] The compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered alone in a pharmaceutical composition as the sole therapeutic agent, or in combination with another therapeutic agent. Combination therapy may be achieved by simultaneous administration (e.g., the two drugs are administered together) or sequential administration (e.g., one drug is administered first, followed by the other). In the case of simultaneous administration, the compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered in the same pharmaceutical composition as the other therapeutic agent, or in a separate pharmaceutical composition. The choice of the other therapeutic agent will depend on the diagnosis of the participating physician, as well as the physician's judgment regarding the patient's condition and an appropriate treatment protocol.
[0363] (iii) Treatment method Compounds of formula (I) and their pharmaceutically acceptable salts have been shown to be useful as inhibitors of NLRP3 activity.
[0364] In some embodiments, a method is provided for treating or preventing a disease or disorder in a subject requiring its use, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, to the subject. In some embodiments, a method is provided for treating or preventing a disease or disorder in a subject requiring its use, comprising administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, to the subject. In some embodiments, a method is provided for treating or preventing a disease or disorder in a subject requiring its use, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, to the subject. In some embodiments, the disease or disorder is associated with abnormal NLRP3 activity, and the method comprises inhibiting the abnormal NLRP3 activity so that the subject is treated.
[0365] In some embodiments, the disease or disorder is a disease or disorder of the central nervous system (CNS), a disease or disorder of the peripheral nervous system (PNS), a primary neurological disease of the muscle, an inflammatory disease, an autoimmune disease, cancer, an infection, a metabolic disease, a cardiovascular disease, a respiratory disease, a kidney disease, a liver disease, an eye disease, a skin disease, a lymphatic system disease, a rheumatic disease, a psychological disorder, a graft-versus-host disease, pain (including disorders related to pain processing), an NLRP3-related disease in subjects determined to carry germline or somatic non-silent mutations in NLRP3, or obesity.
[0366] In some embodiments, the disease or disorder is a disease or disorder of the central nervous system and / or peripheral nervous system ("PNS"), such as dementia, Alzheimer's disease ("AD"), epilepsy, traumatic brain injury ("TBI"), multiple sclerosis ("MS"), developmental disorders, acute disseminated encephalopathy, transverse myelitis, Parkinson's disease ("PD"), amyotrophic lateral sclerosis ("ALS"), Huntington's disease ("HD"), spinal cord injury, or obesity associated with neuroinflammation.
[0367] In some embodiments, the disease or disorder is a primary neurological disorder of the muscles, such as muscular dystrophy or spinal muscular atrophy.
[0368] In some embodiments, the disease or disorder is an inflammatory disease, such as gout or anemia due to inflammation.
[0369] In some embodiments, the disease or disorder is an autoimmune disease, such as ulcerative colitis.
[0370] In some embodiments, the disease or disorder is cancer, such as skin cancer or colon cancer.
[0371] In some embodiments, the disease or disorder is an infection, such as a neurological infection.
[0372] In some embodiments, the disease or disorder is a metabolic disorder, such as diabetes, for example, type 2 diabetes.
[0373] In some embodiments, the disease or disorder is obesity. In some embodiments, obesity is associated with neuroinflammation, such as inflammation of the hypothalamus and / or gliosis. In some embodiments, obesity is associated with metabolic disorders, such as diabetes.
[0374] In some embodiments, the disease or disorder is a cardiovascular disease, such as stroke, atherosclerosis, or atherosclerotic cardiovascular disease (ASCVD).
[0375] In some embodiments, the disease or disorder is a respiratory disease, such as asthma (e.g., steroid-resistant asthma, severe steroid-resistant asthma) or chronic obstructive pulmonary disease ("COPD").
[0376] In some embodiments, the disease or disorder is a kidney disease, such as acute kidney disease, chronic kidney disease, or rare kidney disease. In some embodiments, chronic kidney disease is chronic renal failure.
[0377] In some embodiments, the disease or disorder is a liver disease, such as non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (also known as NASH, MASH, or metabolic disorder-associated steatohepatitis).
[0378] In some embodiments, the disease or disorder is an eye disease such as optic neuritis or macular degeneration.
[0379] In some embodiments, the disease or disorder is a skin condition, such as psoriasis, hidradenitis suppurativa (HS), or atopic dermatitis.
[0380] In some embodiments, the disease or disorder is a lymphatic system disorder.
[0381] In some embodiments, the disease or disorder is a rheumatic disease, such as osteoarthritis, dermatomyositis, Still's disease, or juvenile idiopathic arthritis.
[0382] In some embodiments, the disease or disorder is a psychological disorder, such as a neuropsychiatric condition including depression, major depressive disorder, or treatment-resistant depression.
[0383] In some embodiments, the disease or disorder is a graft-versus-host disease.
[0384] In some embodiments, the disease or disorder is pain (including disorders related to pain treatment), such as headache pain, pain treatment dependence, osteoarthritis pain, or allodynia.
[0385] In some embodiments, the NLRP3-related disease in subjects determined to carry germline or somatic non-silent mutations in NLRP3 is cryopyrin-associated autoinflammatory syndrome. In some embodiments, the cryopyrin-associated autoinflammatory syndrome is familial cold autoinflammatory syndrome, Muckle-Wells syndrome, or neonatal onset multiorgan inflammatory disease (NOMID).
[0386] In some embodiments, the disease or disorder is dementia, Alzheimer's disease ("AD"), epilepsy, traumatic brain injury ("TBI"), multiple sclerosis ("MS"), developmental disorders, acute disseminated encephalopathy, transverse myelitis, Parkinson's disease ("PD"), amyotrophic lateral sclerosis ("ALS"), spinal muscular atrophy, Huntington's disease ("HD"), spinal cord injury, muscular dystrophy, neurological infection, pain (e.g., headache pain, osteoarthritis pain, or allodynia, pain treatment dependence), neuropsychiatric conditions (e.g., depression, major depressive disorder, treatment-resistant depression), neonatal onset multiorgan inflammatory disease ("NOMID"), asthma, osteoarthritis, ulcerative colitis, gout, anemia due to inflammation, Still's disease, chronic obstructive pulmonary disease ("COPD"), osteoarthritis pain, or hidradenitis suppurativa.
[0387] In other embodiments, methods are provided for modulating (e.g., inhibiting) NLRP3 activity in cells (e.g., in vitro, or in vivo within cells or subjects), comprising contacting cells with a compound of formula (I) or a pharmaceutically acceptable salt thereof, or administering it to a subject. In some embodiments, the compound or a pharmaceutically acceptable salt thereof is administered to cells or subjects in an effective amount.
[0388] (iv) Preparation method The compounds of formula (I), their intermediates, and any of the aforementioned salts may be synthesized according to a general method scheme A, as provided below, which involves the coupling of a substituted indolinone (i) or a salt thereof with a lactam of formula (ii) or a salt thereof, where R 7 and R 2 The combination involves the bonding of a 5-10 member monocyclic or bicyclic heterocycline or a 5-10 member monocyclic or bicyclic heteroaryl, where X is a leaving group and Z is CO2PG, to obtain a compound of formula (I) or a salt thereof, where Z is CO2PG, and subsequently, by optional deprotection, to obtain a compound of formula (I) or a salt thereof, where Z is CO2H. The examples further illustrate non-limiting examples of this synthesis and other general synthesis. General Method Scheme A [ka]
[0389] (v) Biological assays Compounds designed, selected, and / or optimized by the methods described above, once generated, can be characterized using a variety of assays known to those skilled in the art to determine whether the compounds have biological activity. For example, compounds can be characterized by conventional assays, including but not limited to those described below, to determine whether they have predicted activity, binding activity, and / or binding specificity. The efficacy of the compounds of this disclosure can be determined by industry-accepted assays / disease models in accordance with standard practices that reveal the same ones described in the art, and also as is common knowledge today.
[0390] Furthermore, high-throughput screening can be used to expedite analysis using such assays. As a result, it may be possible to rapidly screen for the activity of the molecules described herein using techniques known in the art. Conventional methodologies for performing high-throughput screening are described, for example, Devlin (1998) High Throughput Screening, Marcel Dekker, and U.S. Patent No. 5,763,263. High-throughput assays can be one or more different assay techniques, including but not limited to those described below.
[0391] Various in vitro or in vivo biological assays may be suitable for detecting the effects of the compounds of this disclosure. These in vitro or in vivo biological assays may include, but are not limited to, enzyme activity assays, electrophoretic mobility shift assays, reporter gene assays, binding assays, cell assays (cell lines, primary cells, and whole blood), in vitro cell viability assays, and assays for determining NLRP3 inhibitory activity, unbound clearance, and solubility.
[0392] In some embodiments, the compounds of this disclosure may be tested for their human-NLRP3 inhibitory activity using known procedures, such as the methodology reported in Coll et al. Nat Med. (2015) 21(3):248-255. See also the Examples and the description of the NLRP3 assay using human whole blood (hWB).
[0393] In some embodiments, the compounds of the present disclosure may be tested for unbound clearance (Clu) according to known procedures, such as those described in Miller et al., J.Med.Chem. (2020) 63:12156-12170. For example, unbound clearance (Clu) may be calculated by dividing the total clearance ("CL" in mL / min / kg units) measured in blood or plasma by the unbound fraction (fu) in plasma.
[0394] In some embodiments, the solubility of the compounds of this disclosure may be determined by known procedures, for example, Alsenz and Kansy, Advanced Drug Delivery Reviews (2007) 59:546-567 and Wang et al. J Mass Spectrom. (2000) 35:71-76. For example, the kinetic solubility in physiologically relevant media may be measured by serial dilutions, with a two-hour incubation period followed by filtration, and reported in mM units by LC-MS / MS. The thermodynamic solubility in physiologically relevant media may be measured by LC-MS / MS after a 24-hour incubation period followed by filtration, and reported in mg / mL units.
[0395] Additional Embodiments Embodiments 1 to 53 are intended herein.
[0396] Embodiment 1. Compounds of the following formula (I): [ka] or a pharmaceutically acceptable salt thereof, in the formula, R 1 These are halo, C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl. R 7 and R 2 These combine to form a 5-10 member monocyclic or bicyclic heterocyclil or a 5-10 member monocyclic or bicyclic heteroaryl, and the heterocyclil or heteroaryl consists of one or more R 7a It may also be replaced with each R 7a These are independently halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C6 aryl, 5-6 membered heteroaryl, C3-C5 cycloalkyl, or 4-5 membered heterocyclil, and alkyl, haloalkyl, alkoxy, haloalkoxy, aryl, heteroaryl, cycloalkyl, and heterocyclil are one or more R 7b It may also be replaced with R 7b These are halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy. R 3 It is either absent, or H, C1-C6 alkyl, or C1-C6 haloalkyl. R 4 is one or more R 4a It may be a -C1-C6 alkylene- which may be substituted with each R 4a These are independently: halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C 3-4 It is either a cycloalkyl or a 4-5 membered heterocycline, or two R 4a These are bonded to form a C3-C5 cycloalkyl or 4-6 membered heterocyclyl ring, and alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, and heterocyclyl are one or more R 4b It may also be replaced with R 4bThese are halo, -CN, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy. Z is -CO2H or -CO2PG, PG is C1-C6 alkyl, C6 aryl, or (C6 aryl)(C1-C6 alkyl), and the alkyl and aryl may be substituted with one or more halo, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy. Each R 5 These are independently halo, C1-C6 alkyl, or C1-C6 haloalkyl, Each R 6 , R 6’ , or R 6’’ A compound or a pharmaceutically acceptable salt thereof in which is independently H, halo, -OH, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkyl, or C1-C6 haloalkyl.
[0397] Embodiment 2. R 1 These are halo, C1-C6 haloalkyl, or C3-C4 cycloalkyl. R 7 and R 2 These combine to form a 5-10 member monocyclic or bicyclic heteroaryl, and the heteroaryl consists of one or more R 7a It may also be replaced with each R 7a These are independently C1-C6 alkyl, C1-C6 haloalkyl, C6 aryl, or C3-C5 cycloalkyl. R 3 It does not exist, R 4 It is a -C1-C6 alkylene-, Z is -CO2H, Each R 5 These are independently C1-C6 alkyl groups, Each R 6 , R 6’ , or R 6’’ A compound or a pharmaceutically acceptable salt thereof described in Embodiment 1, wherein is independently H, halo, or -OH.
[0398] Embodiment 3. R 1 The compound described in any one of the above embodiments or a pharmaceutically acceptable salt thereof, wherein is Br, Cl, CF3, or cyclopropyl.
[0399] Embodiment 4. R 3 The compound described in any of the above embodiments or a pharmaceutically acceptable salt thereof does not exist.
[0400] Embodiment 5. R 5 Each entity is the same group as the compound described in any one of the embodiments described above, or a pharmaceutically acceptable salt thereof.
[0401] Embodiment 6. Each R 5 The compound or a pharmaceutically acceptable salt thereof described in any one of the above embodiments, wherein is independently methyl (-CH3).
[0402] Embodiment 7. R 6 A compound or a pharmaceutically acceptable salt thereof described in any one of the embodiments described above, wherein H is present.
[0403] Embodiment 8. R 6’ The compound or a pharmaceutically acceptable salt thereof described in any one of the above embodiments, wherein is F or -OH.
[0404] Embodiment 9. R 6’’ A compound or a pharmaceutically acceptable salt thereof described in any one of the above embodiments, wherein is H or F.
[0405] Embodiment 10. R 7 and R 2 These combine to form one or more R7 aA compound or a pharmaceutically acceptable salt thereof from any one of the above embodiments, which forms a six-membered monocyclic heteroaryl that may be substituted with .
[0406] Embodiment 11. R 7 and R 2 A compound or a pharmaceutically acceptable salt thereof according to any one of Embodiments 1 to 9, wherein the compounds combine to form a 10-membered bicyclic heteroaryl.
[0407] Embodiment 12. R 7a The compound or a pharmaceutically acceptable salt thereof described in any one of the above embodiments, wherein the compound is methyl, CF3, C6 aryl, or cyclopropyl.
[0408] Embodiment 13. R 4 The compound or a pharmaceutically acceptable salt thereof described in any one of the above embodiments, wherein the compound is a -C3 alkylene-.
[0409] Embodiment 14. Z is CO2H, the compound or a pharmaceutically acceptable salt thereof described in any one of the above embodiments.
[0410] Embodiment 15. The compound is the compound of the following formula (IA): [ka] The compound according to any one of the above embodiments, or a pharmaceutically acceptable salt thereof.
[0411] Embodiment 16. The compound is the compound of the following formula (IAa), [ka] The compound according to any one of the above embodiments, or a pharmaceutically acceptable salt thereof.
[0412] Embodiment 17. The compounds are those with the following formulas: (IB), (IC), (ID), (IE), (IF), or (IG): [ka] The compound according to any one of the above embodiments, or a pharmaceutically acceptable salt thereof.
[0413] Embodiment 18. The compounds are those of the following formulas: (I-B'), (I-C'), (I-D'), (I-E'), (I-F'), or (I-G'): [ka] The compound according to any one of the above embodiments, or a pharmaceutically acceptable salt thereof.
[0414] Embodiment 19. The compounds are those with the following formulas: (IBa), (ICa), (IDa), (IEa), (IFa), or (IGa): [ka] The compound according to any one of the above embodiments, or a pharmaceutically acceptable salt thereof.
[0415] Embodiment 20. The compounds are those of the following formulas: (I-B'-a), (I-C'-a), (I-D'-a), (I-E'-a), (I-F'-a), or (I-G'-a): [ka] The compound according to any one of the above embodiments, or a pharmaceutically acceptable salt thereof.
[0416] Embodiment 21. The compound is the compound of the following formula (IJ): [ka] The compound according to any one of the above embodiments, or a pharmaceutically acceptable salt thereof.
[0417] Embodiment 22. The compound is the compound of the following formula (I-J'): [ka] The compound according to any one of the above embodiments, or a pharmaceutically acceptable salt thereof.
[0418] Embodiment 23. The compound is the compound of the following formula (IJa): [ka] The compound according to any one of the above embodiments, or a pharmaceutically acceptable salt thereof.
[0419] Embodiment 24. The compound is the compound of the following formula (I-J'-a): [ka] The compound according to any one of the above embodiments, or a pharmaceutically acceptable salt thereof.
[0420] Embodiment 25. The compound is one of the compounds described in any one of Embodiments 1 to 24, selected from the compounds listed in Table 1 or Table 2A, or pharmaceutically acceptable salts thereof.
[0421] Embodiment 26. A method for preparing a compound of formula (I) described in any of the embodiments described above, or a pharmaceutically acceptable salt thereof, or an intermediate thereof, wherein the compound or intermediate is synthesized according to the general method scheme A.
[0422] Embodiment 27. A pharmaceutical composition comprising a compound described in any one of Embodiments 1 to 25 or Embodiments 1A to 6A, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
[0423] Embodiment 28. A method for adjusting NLRP3, comprising administering a compound described in any one of Embodiments 1 to 25 or Embodiments 1A to 6A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described in Embodiment 27.
[0424] Embodiment 29. A method for treating or preventing a disease or disorder, comprising administering a compound described in any one of Embodiments 1 to 25 or Embodiments 1A to 6A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described in Embodiment 27, to a subject.
[0425] Embodiment 30. A compound according to any one of Embodiments 1 to 25 or Embodiments 1A to 6A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to Embodiment 27, for use in the treatment or prevention of a disease or disorder.
[0426] Embodiment 31. Use of any one of the compounds described in Embodiments 1 to 25 or Embodiments 1A to 6A or a pharmaceutically acceptable salt thereof in the manufacture of a drug for the treatment or prevention of a disease or disorder.
[0427] Embodiment 32. Use of any one of the compounds described in Embodiments 1 to 25 or Embodiments 1A to 6A or a pharmaceutically acceptable salt thereof for the treatment or prevention of a disease or disorder.
[0428] Embodiment 33. The disease or disorder is an NLRP3-related disease or disorder, as described by any one of Embodiments 29 to 32, the compound, or use thereof.
[0429] Embodiment 34. The subject is a human, and the method, compound, or use described in any one of embodiments 28 to 29.
[0430] Embodiment 35. The disease or disorder is a disease or disorder of the central nervous system (CNS), a disease or disorder of the peripheral nervous system (PNS), a primary neurological disease of the muscle, an inflammatory disease, an autoimmune disease, cancer, an infection, a metabolic disease, a cardiovascular disease, a respiratory disease, a kidney disease, a liver disease, an eye disease, a skin disease, a lymphatic system disease, a rheumatic disease, a psychological disorder, a graft-versus-host disease, pain (including disorders related to pain processing), or an NLRP3-related disease in a subject determined to harbor a germline or somatic non-silent mutation in NLRP3, as described in any one of Embodiments 29 to 34.
[0431] Embodiment 36. The central nervous system disorder or disorder is dementia, Alzheimer's disease ("AD"), epilepsy, traumatic brain injury ("TBI"), multiple sclerosis ("MS"), developmental disorder, acute disseminated encephalopathy, transverse myelitis, Parkinson's disease ("PD"), amyotrophic lateral sclerosis ("ALS"), Huntington's disease ("HD"), or spinal cord injury, as described in any one of Embodiments 29 to 35.
[0432] Embodiment 37. The primary neurological disorder of the muscle is muscular dystrophy or spinal muscular atrophy, according to any one of embodiments 29 to 35, by the method, compound, or use thereof.
[0433] Embodiment 38. The inflammatory disease is gout or anemia due to inflammation, according to any one of embodiments 29 to 35, the method, compound, or use thereof.
[0434] Embodiment 39. The autoimmune disease is ulcerative colitis, according to the method, compound, or use described in any one of embodiments 29 to 35.
[0435] Embodiment 40. The cancer is skin cancer or colon cancer, according to the method, compound, or use described in any one of Embodiments 29 to 35.
[0436] Embodiment 41. The infection is a neurological infection, as described in any one of embodiments 29-35, by the method, compound, or use thereof.
[0437] Embodiment 42. The metabolic disorder is diabetes, according to any one of embodiments 29 to 35, by the method, compound, or use thereof.
[0438] Embodiment 43. Cardiovascular disease is stroke, according to any one of embodiments 29 to 35, the method, compound, or use thereof.
[0439] Embodiment 44. The respiratory disease is asthma or chronic obstructive pulmonary disease, according to any one of embodiments 29 to 35, the method, compound, or use thereof.
[0440] Embodiment 45. The kidney disease is acute kidney disease, chronic kidney disease, or rare kidney disease, as described in any one of Embodiments 29 to 35, the compound, or use thereof.
[0441] Embodiment 46. The liver disease is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), according to any one of embodiments 29 to 35, the method, compound, or use.
[0442] Embodiment 47. The eye disease is optic neuritis or macular degeneration, according to any one of embodiments 29 to 35, the method, compound, or use thereof.
[0443] Embodiment 48. The skin condition is psoriasis, hidradenitis suppurativa (HS), or atopic dermatitis, according to any one of embodiments 29 to 35, the method, compound, or use thereof.
[0444] Embodiment 49. The rheumatic disease is osteoarthritis, dermatomyositis, Still's disease, or juvenile idiopathic arthritis, according to any one of embodiments 29 to 35, the method, compound, or use thereof.
[0445] Embodiment 50. The method, compound, or use described in any one of Embodiments 29 to 35 is a neuropsychiatric condition selected from the group consisting of depression, major depressive disorder, and treatment-resistant depression.
[0446] Embodiment 51. The pain is pain treatment-dependent, osteoarthritis pain, or allodynia, according to any one of embodiments 29 to 35, the method, compound, or use.
[0447] Embodiment 52. In subjects determined to harbor germline or somatic non-silent mutations in NLRP3, NLRP3-related disease is cryopyrin-associated autoinflammatory syndrome, as described by any one of Embodiments 29-35, the method, compound, or use thereof.
[0448] Embodiment 53. The disease or disorder is dementia, Alzheimer's disease ("AD"), epilepsy, traumatic brain injury ("TBI"), multiple sclerosis ("MS"), developmental disorder, acute disseminated encephalopathy, transverse myelitis, Parkinson's disease ("PD"), amyotrophic lateral sclerosis ("ALS"), spinal muscular atrophy, Huntington's disease ("HD"), spinal cord injury, muscular dystrophy, neuroinfection, pain treatment dependence, neuropsychiatric conditions (e.g., depression, major depressive disorder, treatment-resistant depression), neonatal onset multiorgan inflammatory disease ("NOMID"), asthma, osteoarthritis, ulcerative colitis, gout, anemia due to inflammation, Still's disease, chronic obstructive pulmonary disease ("COPD"), osteoarthritis pain, or hidradenitis suppurativa, according to any one of Embodiments 29-34.
[0449] Additional embodiments 1A to 9A are also contemplated herein.
[0450] Embodiment 1A. The compound is the compound of the following formula (I-J'-aR): [ka] The compound according to Embodiment 24, or a pharmaceutically acceptable salt thereof.
[0451] Embodiment 2A. R 4a The compound described in any one of Embodiments 16, 18, 20, 22, 24, or 1A, or a pharmaceutically acceptable salt thereof, does not exist.
[0452] Embodiment 3A. R 7a The compound described in any one of embodiments 16, 18, 20, 22, 24, or 1A to 2A, or a pharmaceutically acceptable salt thereof, does not exist.
[0453] Embodiment 4A. R 1 The compound described in any one of Embodiments 16, 18, 20, 22, 24, or 1A to 3A, or a pharmaceutically acceptable salt thereof, wherein is -CF3 or cyclopropyl.
[0454] Embodiment 5A. R 6’ It is a halo, R 6’’ is H or R 6’ and R 6’’ Each of the compounds described in any one of Embodiments 16, 18, 20, 22, 24, or 1A to 4A, or a pharmaceutically acceptable salt thereof, is independently a halo.
[0455] Embodiment 6A. The compound is selected from the compounds listed in Table 1 or Tables 2A-2B, or pharmaceutically acceptable salts thereof, as described in any one of the embodiments described above.
[0456] Embodiment 7A. The disease or disorder is obesity, according to any one of the methods, compounds, or uses described in Embodiments 29-34 and Embodiments 1A-6A.
[0457] Embodiment 8A. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, the method comprising coupling the following substituted indolinone (i) or a salt thereof with a lactam of formula (ii) or a salt thereof, [ka] In the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 6’ , and R 6’’ A method for obtaining a compound of formula (I) or a salt thereof, wherein Z is -CO2PG, and Z is -CO2PG, as defined in claim 1, by coupling.
[0458] Embodiment 9A. The method according to Embodiment 8A, further comprising deprotecting a compound of formula (I) or a salt thereof, in which Z is -CO2PG, to obtain a compound of formula (I) or a salt thereof, in which Z is -CO2H.
[0459] Examples To enable a more complete understanding of this disclosure, the following examples are provided. These examples are for illustrative purposes only and should not be construed as limiting this disclosure in any way.
[0460] Analysis method Nuclear magnetic resonance (NMR) spectra are recorded at 400 megahertz (MHz) and 300.3 K as described, unless otherwise specified, and their chemical shifts (δ) are reported in parts per million (ppm). Spectra were recorded using a Bruker Avance 400 instrument with 8, 16, or 32 scans. Exemplary NMR solvents include deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD), and deuterated chloroform (CDCl3). Other abbreviations: s=singlet, d=doublet, t=triplet, m=multiplet, br=broad.
[0461] Liquid chromatography-mass spectrometry (LCMS) and spectra were recorded using a Shimadzu LCMS-2020. Injection volumes were 0.7–8.0 μl, and flow rates were typically 0.8 or 1.2 ml / min. Detection methods included diode array (DAD) or evaporative light scattering (ELSD) as well as cation electrospray ionization (ESI). The MS range was 100–1000 Da. The solvent was a gradient of water (H2O) and / or acetonitrile (MeCN), and may contain modifiers (typically 0.01–0.04%) such as formic acid (FA), trifluoroacetic acid (TFA), or ammonium carbonate (NH4HCO3). ESI or ES = electrospray ionization, m / z = mass / charge number, RT = retention time (min).
[0462] Gas chromatography-mass spectrometry (GCMS) chromatograms and spectra were recorded using an Agilent GCMS 8890-5977 and FID detector channel. GC parameters: DB-5MS, 12m × 0.20mm × 0.33um; column oven temperature: 50.0°C; injection volume: 0.5 μL; column flow rate: 1.2 mL / min; injection temperature: 300°C; injection mode: split; split ratio: 20:1; detector temperature: 300°C; initial temperature: 50°C for 1 minute, then 40°C / min to 300°C for 1.75 minutes. Makeup gas: He; makeup flow rate: 25.0 mL / min; H2; flow rate: 30.0 mL / min; airflow: 400.0 mL / min; final temperature: 300°C. MS detector in acquisition mode: Start time: 2.00 min; End time: 9.00 min; Acquisition mode: Scan; Interface type: EI threshold: 150; Scan rate: 1562; Start m / z: 50.00; End m / z: 550.00; MS source: 230.00°C, MS quadrupole: 150.00°C; Solvent cut time: 2.00 min.
[0463] Purification / separation method. For synthesis methods, describe the purification and / or separation chromatography method used for the purification and / or isolation of the exemplary compound. Rf = retention factor, RT = retention time (minutes), Preparative HPLC (Prep-HPLC) = preparative high-performance liquid chromatography, Preparative SFC (Prep-SFC) = preparative supercritical fluid chromatography, TLC = thin-layer chromatography.
[0464] If the stereochemical position is arbitrarily or reasonably assigned, an asterisk (*) is included as part of the compound number. A reasonable assignment means that there is a correlation between the indicated assignment, such as activity, and the known (e.g., absolute) assignment. The prefix "Rac" in the compound number signifies a mixture of two or more stereoisomers, either equimolar or unequal. The future tense ("may be prepared / synthesized") indicates examples that have not yet been carried out.
[0465] intermediate Intermediate Example 1: 5-bromo-7-fluoro-3,3-dimethyl-1H-indole-2-one (Intermediate 1) [ka] Step 1: To a solution of 7-fluoro-1,3-dihydroindole-2-one (2 g, 13.23 mmol, 1 equivalent) and lithium chloride (1.40 g, 33.08 mmol, 2.5 equivalents) in tetrahydrofuran (THF) (40 mL) at 0°C, n-butyllithium (n-BuLi) (2.5 M in hexane, 10.5 mL, 26.46 mmol, 2 equivalents) was added dropwise in several portions under a nitrogen atmosphere. The resulting mixture was stirred at 0°C for 30 minutes. Methyl iodide (MeI) (4.69 g, 33.08 mmol, 2.5 equivalents) was then slowly added, and the mixture was stirred at 0°C for 2 hours, followed by further stirring at ambient temperature for 16 hours. The reaction was monitored by LC-MS. The reaction was quenched with saturated NH4Cl (40 mL). The aqueous layer was extracted with ethyl acetate (siRNA) (4 × 50 mL). The combined organic layers were washed with brine (1 × 50 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 10% to 50% over 30 minutes, detector: UV 254 nm) to obtain 7-fluoro-3,3-dimethyl-1H-indole-2-one (1.3 g, yield 54%). LCMS: (ES, m / z): RT = 0.73 min, m / z = 180 [M + H] + .
[0466] Step 2: Bromine (Br2) (892 mg, 5.58 mmol, 1 equivalent) was added dropwise over 4 minutes at 0°C to a solution of 7-fluoro-3,3-dimethyl-1H-indole-2-one (1 g, 5.58 mmol, 1 equivalent) in acetic acid (AcOH) (4 mL) and dichloromethane (DCM) (40 mL). The resulting mixture was stirred at room temperature for a further 2 hours. The reaction was monitored by LC-MS. The reaction was quenched with saturated aqueous NaHSO3 (20 mL) at 0°C. The aqueous layer was extracted with ethyl acetate ( Depositphotos) (3 × 50 mL). The combined organic layers were washed with brine (1 × 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with petroleum ether / ethyl acetate (4:1) to obtain 5-bromo-7-fluoro-3,3-dimethyl-1H-indole-2-one (intermediate 1) (1.10 g, yield 73%). LCMS: (ES, m / z): RT=0.83 min, m / z=258 [M+H] + .
[0467] Intermediate Example 2: 5-Cyclopropyl-7-fluoro-3,3-dimethylindoline-2-one (Intermediate 2) [ka] To a solution of 5-bromo-7-fluoro-3,3-dimethyl-1H-indole-2-one (intermediate 1) (170.0 mg, 0.66 mmol, 1 equivalent) and cyclopropylboronic acid (170.3 mg, 1.98 mmol, 3 equivalents) in dioxane (6 mL) and H2O (1.20 mL), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex (Pd(dppf)Cl2-DCM) (107.8 mg, 0.13 mmol, 0.20 equivalents) with Na2CO3 (209.9 mg, 1.98 mmol, 3 equivalents) and dichloromethane was added. The resulting mixture was stirred overnight at 80°C under a nitrogen atmosphere. The reaction was monitored by LC-MS. The resulting mixture was diluted with water (60 mL) and extracted with ethyl acetate (SiO) (3 × 50 mL). The combined organic layers were washed with brine (1 × 50 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with petroleum ether / ethyl acetate (5:1) to obtain 5-cyclopropyl-7-fluoro-3,3-dimethylindorin-2-one (intermediate 2) (70 mg, yield 48%). LCMS: (ES, m / z): RT = 0.81 min, m / z = 220 [M + H] + .
[0468] Intermediate Examples 3. 5-Cyclopropyl-4,7-difluoro-3,3-dimethylindorin-2-one (Intermediate 3) and 5-bromo-4,7-difluoro-3,3-dimethylindorin-2-one (Intermediate 5) [ka] Step 1: TiCl4 (3.79 mL, 27.3 mmol, 5 equivalents) was added in several portions at 0°C under a nitrogen atmosphere to a stirred mixture of Zn powder (3.21 g, 49.1 mmol, 9 equivalents) in tetrahydrofuran (THF) (100 mL). The resulting mixture was stirred at 70°C for 2 hours under a nitrogen atmosphere. 4,7-difluoro-1H-indole-2,3-dione (1 g, 5.46 mmol, 1 equivalent) was added dropwise to the mixture at room temperature. The resulting mixture was stirred at room temperature for a further 12 hours. The reaction was monitored by LC-MS. The reaction was quenched with water (150 mL). The resulting mixture was extracted with CH2Cl2 (3 × 300 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with petroleum ether / ethyl acetate (9:1) to obtain 4,7-difluoro-1,3-dihydroindole-2-one (450 mg, 27% yield). LCMS (LCMS,ESI): RT=0.72 min, m / z=168 [MH] - .
[0469] Step 2: A solution of 4,7-difluoro-1,3-dihydroindole-2-one (450 mg, 25 mmol, 1 equivalent) and tetramethylethylenediamine (TMEDA) (805 mg, 8.26 mmol, 2.5 equivalents) in tetrahydrofuran (THF) (50 mL) was treated with n-butyllithium (n-BuLi) (3.3 mL, 8.26 mmol, 2.5 equivalents, 2.5 M in THF) under a nitrogen atmosphere at 0°C for 30 minutes, and then methyl iodide (MeI) (785 mg, 6.52 mmol, 2 equivalents) was added dropwise at room temperature. The resulting mixture was stirred under a nitrogen atmosphere at room temperature for 1 hour. The reaction was monitored by LC-MS. The reaction was quenched by adding water (200 mL) at room temperature. The resulting mixture was extracted with ethyl acetate ( Depositphotos) (3 × 150 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography eluted with petroleum ether / ethyl acetate (6:1) to obtain 4,7-difluoro-3,3-dimethyl-1H-indole-2-one (230 mg, 41% yield). LCMS (ESI): RT=0.92 min, m / z=196 [MH] - .
[0470] Step 3: To a stirred mixture of 4,7-difluoro-3,3-dimethyl-1H-indole-2-one (230 mg, 1.31 mmol, 1 equivalent) and acetic acid (AcOH) (2 mL) in dichloromethane (DCM) (10 mL), Br2 (1.05 g, 6.59 mmol, 5 equivalents, in 3 mL of DCM) was added dropwise at 0°C. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 1 hour. The reaction was monitored by LC-MS, and once complete, it was quenched by adding saturated NaHCO3 (aqueous solution) (50 mL) at room temperature. The resulting mixture was extracted with ethyl acetate ( Depositphotos) (3 × 200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by silica gel column chromatography eluting with petroleum ether / ethyl acetate (5:1) to obtain 5-bromo-4,7-difluoro-3,3-dimethylindorin-2-one (intermediate 5) (300 mg, yield 69%). LCMS (LCMS,ESI): RT=1.05 min, m / z=274 [MH] - .
[0471] Step 4: Intermediate 5 (1 g, 3.62 mmol, 1 equivalent), cyclopropylboronic acid (3.11 g, 36.2 mmol, 10 equivalents), 1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (Pd(dppf)Cl2-DCM) (0.53 g, 0.72 mmol, 0.20 equivalents), Na2CO3 (1.15 g, 10.9 mmol, 3 equivalents), dioxane (20 mL), and H2O (4 mL) were stirred at 100°C for 12 hours under a nitrogen atmosphere. The reaction was monitored by LC-MS. The reaction was quenched by adding water (100 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (SiO) (3 × 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with petroleum ether / ethyl acetate (7:1) to obtain 5-cyclopropyl-4,7-difluoro-3,3-dimethylindorin-2-one (intermediate 3) (800 mg, yield 75%). LCMS (LCMS,ESI): RT=0.84 min, m / z=238.1 [M+H] + .
[0472] Intermediate Examples 4. 5-Chloro-7-iodo-3,3-dimethylindorin-2-one (Intermediate 4) and 5-Chloro-3,3-dimethylindorin-2-one (Intermediate 18) [ka] Step 1: In a 250 mL three-necked round-bottom flask, 5-chloro-1,3-dihydroindole-2-one (5 g, 29.83 mmol, 1 equivalent), LiCl (3.79 g, 89.5 mmol, 3 equivalents), and tetrahydrofuran (THF) (100 mL) were added at room temperature, and then n-butyllithium (2.5 M n-BuLi in n-hexane, 29.8 mL, 74.6 mmol, 2.5 equivalents) was added dropwise at -78 °C. The resulting mixture was stirred under a nitrogen atmosphere at 0 °C for 30 minutes. Methyl iodide (MeI) (8.47 g, 59.7 mmol, 2 equivalents) was added dropwise to the above mixture over 5 minutes at -78 °C. The resulting mixture was stirred under a nitrogen atmosphere at 0 °C for 2 hours. The reaction was monitored by LC-MS. The reaction was quenched by adding NH4Cl (aqueous solution, 150 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (SiO2) (3 × 150 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with petroleum ether / ethyl acetate (1:1) to obtain 5-chloro-3,3-dimethylindorin-2-one (intermediate 18) (3.80 g, yield 65%). LCMS: (ES, m / z): RT = 0.788 min, m / z = 195.6 [M + H] + .
[0473] Step 2: Intermediate 18 (2 g, 10.22 mmol, 1 equivalent), N-iodosuccinimide (NIS) (13.8 g, 61.3 mmol, 6 equivalents), and acetic acid (HOAc) (40 mL) were added to a 40 mL vial at room temperature. The resulting mixture was stirred overnight at 80°C. The reaction was monitored by LC-MS. The reaction was quenched by adding NH4Cl (aqueous solution, 100 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (SiO4) (3 × 100 mL), and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV254 / 220nm) to obtain 5-chloro-7-iodo-3,3-dimethylindorin-2-one (intermediate 4) (2.4 g, yield 73%). LCMS: (ES, m / z): RT=0.854 min, m / z=321.9 [M+H] + .
[0474] Intermediate Example 5. 5-Bromo-3,3,7-trifluoroindorin-2-one (Intermediate 6) [ka] Step 1: 7-Fluoro-1H-Indole-2,3-dione (5 g, 30.3 mmol, 1 equivalent), dichloromethane (DCM) (15 mL), and acetic acid (AcOH) (3 mL) were added to a 40 mL sealed tube at room temperature. Br2 (9.68 g, 60.6 mmol, 2 equivalents) was added to the solution at 0°C. The resulting mixture was stirred at 40°C for 16 hours under a nitrogen atmosphere. The reaction was monitored by LC-MS. The reaction was quenched by adding sodium thiosulfate (aqueous solution) (100 mL) at room temperature. The resulting mixture was extracted with ethyl acetate ( Depositphotos) (3 × 100 mL). The combined organic layers were washed with water (100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This yielded 5-Bromo-7-Fluoro-1H-Indole-2,3-dione (5.60 g, 76% yield). LCMS:(ES,m / z):RT=0.598 min, m / z=243.9[M+H]+ .
[0475] Step 2: 5-bromo-7-fluoro-1H-indole-2,3-dione (10.0 g, 41.0 mmol, 1 equivalent) and dichloromethane (DCM) (100 mL) were added to a 250 mL three-necked flask at room temperature. Diethylaminosulfur trifluoride (DAST) (16.5 g, 102 mmol, 2.50 equivalents) was added to the above solution at 0°C. The resulting mixture was stirred at room temperature for 16 hours. The reaction was monitored by LC-MS. The reaction was quenched with water (200 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (ELISA) (3 × 200 mL). The combined organic layers were washed with water (100 mL) and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with petroleum ether / ethyl acetate (1:1) to obtain 5-bromo-3,3,7-trifluoroindorin-2-one (intermediate 6) (8.50 g, yield 78%). LCMS: (ES, m / z): RT=0.745 min, m / z=266.9 [M+H] + .
[0476] Intermediate Examples 6. 5-Bromo-7-iodo-3,3-dimethylindorin-2-one (Intermediate 7) and 5-bromo-3,3-dimethylindorin-2-one (Intermediate 19) [ka] To an ice-cold solution of compound 24a) of 5-bromo-3,3-dimethylindorin-2-one (intermediate 19) (400 mg, 1.66 mmol, 1 equivalent) (Fensome et al., J. Med. Chem. (2008) 1861-1873) in acetic acid (AcOH) (4 mL), N-iodosuccinimide (NIS) (450 mg, 1.99 mmol, 1.2 equivalents) was added in small increments, and the mixture was stirred at 50°C for 3 hours. Then, concentrated H2SO4 (49.01 mg, 0.50 mmol, 0.3 equivalents) was added at room temperature. The resulting mixture was stirred at 50°C for a further 2 hours. The reaction mixture was quenched with ice / water (10 mL). The resulting mixture was extracted with ethyl acetate (SiO4) (5 × 10 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with petroleum ether / ethyl acetate (5:1) to obtain 5-bromo-7-iodo-3,3-dimethylindorin-2-one (intermediate 7) (500 mg, yield 82%). LCMS: (ES, m / z): RT=0.85 min, m / z=366 [M+H] + .
[0477] Intermediate Example 7. 5-bromo-6-methoxy-3,3-dimethylindorin-2-one (Intermediate 8) [ka] Step 1: To a stirred solution of 6-methoxy-1,3-dihydroindole-2-one (1 g, 6.12 mmol, 1 equivalent) and LiCl (649 mg, 15.32 mmol, 2.5 equivalents) in tetrahydrofuran (THF) (100 mL), n-butyllithium (n-BuLi) (2.5N) (6.13 mL, 15.32 mmol, 2.5 equivalents) was added dropwise at 0°C under a nitrogen atmosphere. The resulting mixture was stirred at 0°C for 30 minutes under a nitrogen atmosphere. MeI (1739.70 mg, 12.25 mmol, 2 equivalents) was added dropwise to the above mixture over 20 minutes at 0°C. The resulting mixture was stirred for a further 1 hour at 0°C. The reaction was quenched by adding water / ice (20 mL) at 0°C. The aqueous layer was extracted with ethyl acetate ( Depositphotos) (3 × 200 mL) and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with petroleum ether / ethyl acetate (8:1) to obtain 6-methoxy-3,3-dimethyl-1H-indole-2-one (200 mg, yield 17%).
[0478] Step 2: 6-Methoxy-3,3-dimethyl-1H-indole-2-one (200 mg, 1.04 mmol, 1 equivalent), N,N-dimethylformamide (DMF) (8 mL), and N-bromosuccinimide (NBS) (186 mg, 1.046 mmol, 1 equivalent) were added to a 20 mL vial at room temperature. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours. The reaction was quenched by adding water / ice (20 mL) at 0°C. The aqueous layer was extracted with ethyl acetate ( Depositphotos) (3 × 20 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with petroleum ether / ethyl acetate (2:1) to obtain 5-bromo-6-methoxy-3,3-dimethylindolin-2-one (intermediate 8) (190 mg, yield 67%). LCMS (LCMS, ESI): RT=0.735 min, m / z 270[M+H] + .
[0479] Intermediate Examples 8.7-Iodo-3,3-dimethyl-5-(trifluoromethyl)indorin-2-one (Intermediate 17) and 3,3-dimethyl-5-(trifluoromethyl)indorin-2-one (Intermediate 11) [ka] Step 1: 5-bromo-3,3-dimethyl-1H-indole-2-one (4 g, 16.7 mmol, 1 equivalent), methyl[2-(methylamino)ethyl]amine (2.94 g, 33.3 mmol, 2 equivalents), CuI (6.35 g, 33.3 mmol, 2 equivalents), NaI (4.99 g, 33.3 mmol, 2 equivalents), and dioxane (20 mL) were added to a 40 mL sealed tube at room temperature. The resulting mixture was stirred at 120 °C for 2 hours under a nitrogen atmosphere, and then quenched with water (100 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (SiO) (3 × 150 mL), and the combined organic layers were washed with water (100 mL) and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV254 / 220nm) to obtain 5-iodo-3,3-dimethyl-1H-indole-2-one (2.50 g, yield 52%). LCMS: (ES, m / z): RT=0.507 min, m / z=288.0 [M+H] + .
[0480] Step 2: 5-iodo-3,3-dimethyl-1H-indole-2-one (2.50 g, 8.70 mmol, 1 equivalent), K2CO3 (3.61 g, 26.1 mmol, 3 equivalents), KI (1.45 g, 8.70 mmol, 1 equivalent), N,N-dimethylformamide (DMF) (20 mL), and p-methoxybenzyl chloride (PMBCl) (4.09 g, 26.1 mmol, 3 equivalents) were added to a 40 mL sealed tube at room temperature. The resulting mixture was stirred at 100 °C for 2 hours, then quenched with water (80 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 120 mL), and the combined organic layers were washed with water (80 mL) and dried over anhydrous sodium 2 SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV254 / 220nm) to obtain 5-iodo-1-[(4-methoxyphenyl)methyl]-3,3-dimethylindole-2-one (2g, yield 56%). LCMS: (ES, m / z): RT=0.857 min, m / z=408.0 [M+H] + .
[0481] Step 3: 5-iodo-1-[(4-methoxyphenyl)methyl]-3,3-dimethylindole-2-one (2 g, 4.91 mmol, 1 equivalent), 2,2-difluoro-2-sulfoacetate methyl (1.89 g, 9.82 mmol, 2 equivalents), CuI (2.81 g, 14.7 mmol, 3 equivalents), and N,N-dimethylformamide (DMF) (15 mL) were added to a 40 mL sealed tube at room temperature. The resulting mixture was stirred at 100 °C for 2 hours under a nitrogen atmosphere, and then quenched with water (50 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (SiO) (3 × 100 mL), and the combined organic layers were washed with water (50 mL) and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV254 / 220nm) to obtain 1-[(4-methoxyphenyl)methyl]-3,3-dimethyl-5-(trifluoromethyl)indole-2-one (1g, yield 58%). LCMS: (ES, m / z): RT=0.820 min, m / z=350.1 [M+H] + .
[0482] Step 4: 1-[(4-methoxyphenyl)methyl]-3,3-dimethyl-5-(trifluoromethyl)indole-2-one (1 g, 2.86 mmol, 1 equivalent), trifluoroacetic acid (TFA) (9 mL), and trifluoromethanesulfonic acid (3 mL) were added to a 40 mL sealed tube at room temperature. The resulting mixture was stirred overnight at 50°C and then quenched with water (50 mL) at room temperature. The resulting mixture was extracted with dichloromethane (DCM) (3 × 100 mL), and the combined organic layers were washed with water (50 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV254 / 220nm) to obtain 3,3-dimethyl-5-(trifluoromethyl)indorin-2-one (intermediate 11) (520.0 mg, yield 79%). LCMS: (ES, m / z): RT=0.675 min, m / z=230.1 [M+H] + .
[0483] Step 5: Intermediate 11 (520.0 mg, 2.26 mmol, 1 equivalent), acetic acid (AcOH) (8 mL), and N-iodosuccinimide (NIS) (1.02 g, 4.53 mmol, 2 equivalents) were added to a 40 mL sealed tube at room temperature. The resulting mixture was stirred at 80°C for 2 hours under a nitrogen atmosphere, and then the reaction was quenched at room temperature with Na₂S₂O₃ (aqueous solution) (50 mL). The resulting mixture was extracted with ethyl acetate (SiO₂) (3 × 60 mL), and the combined organic layers were washed with water (50 mL) and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV254 / 220nm) to obtain 7-iodo-3,3-dimethyl-5-(trifluoromethyl)indorin-2-one (intermediate 17) (420.0 mg, yield 52%). LCMS: (ES, m / z): RT=0.843 min, m / z=356.1 [M+H] + .
[0484] Intermediate Example 9. 5-Chloro-4,7-difluoro-3,3-dimethylindorin-2-one (Intermediate 23) [ka] 4,7-difluoro-3,3-dimethyl-1H-indole-2-one (Intermediate Example 3, product of Step 2) (300 mg, 1.52 mmol, 1 equivalent), concentrated H2SO4 (3.0 mL), water (0.30 mL), and N-chlorosuccinimide (NCS) (607 mg, 4.56 mmol, 3 equivalents) were added to a 20 mL vial at room temperature. The resulting mixture was stirred at room temperature for 4 hours, then diluted with water (20 mL) and extracted with ethyl acetate (siRNA) (3 × 30 mL). The combined organic layers were washed with brine (20 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by silica gel column chromatography eluting with petroleum ether / siRNA (1:1) to obtain 5-chloro-4,7-difluoro-3,3-dimethyl-1H-indole-2-one (intermediate 23) (300 mg, yield 85%). LCMS (LCMS,ESI): RT=0.72 min, m / z=232.1 [M+H] + , 1 H NMR (400MHz, DMSO-d6) δ11.23 (s, 1H), 7.55 (dd, J = 9.2Hz, 1H), 1.36 (d, J = 6.4Hz, 6H).
[0485] Intermediate Example 10. 4,7-difluoro-3,3-dimethyl-5-(trifluoromethyl)indorin-2-one (Intermediate 9) and 4,7-difluoro-5-iodo-3,3-dimethylindorin-2-one (Intermediate 24) [ka] Step 1: 4,7-difluoro-3,3-dimethyl-1H-indole-2-one (Intermediate Example 3, product of Step 2) (360.00 mg, 1.82 mmol, 1 equivalent), N-iodosuccinimide (NIS) (821.51 mg, 3.65 mmol, 2 equivalents), and acetic acid (AcOH) (4 mL) were added to an 8 mL vial at room temperature. The resulting mixture was stirred at 60°C for 16 hours, and then quenched by adding water (20 mL) at room temperature. The resulting mixture was extracted with CH2Cl2 (3 × 20 mL), and the combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV254 / 220nm) to obtain 4,7-difluoro-5-iodo-3,3-dimethylindorin-2-one (intermediate 24) (350 mg, yield 59%). LCMS: (ES, m / z): RT=0.775 min, m / z=324.1 [M+H] + .
[0486] Step 2: Intermediate 24 (350 mg, 1.08 mmol, 1 equivalent), CuI (1.03 g, 5.41 mmol, 5 equivalents), DMF (3 mL), and methyl 2,2-difluoro-2-sulfoacetate (1.04 g, 5.41 mmol, 5 equivalents) were added to a 20 mL vial at room temperature. The resulting mixture was stirred at 100 °C for 16 hours under a nitrogen atmosphere, and then quenched by adding water (20 mL) at room temperature. The resulting mixture was extracted with CH₂Cl₂ (3 × 20 mL), and the combined organic layers were dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV254 / 220nm) to obtain 4,7-difluoro-3,3-dimethyl-5-(trifluoromethyl)-1H-indole-2-one (intermediate 9) (140 mg, yield 49%). LCMS: (ES, m / z): RT=0.810 min, m / z=266.2 [M+H] + .
[0487] Further intermediates can be prepared as provided in Table A below. [Table 4-1] [Table 4-2]
[0488] final product Example 1. 4-(3-(5-bromo-7-fluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyridine-1(2H)-yl)butanoic acid (compound 1) and 4-(3-(5-bromo-7-fluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyridine-1(2H)-yl)butanoic acid tert-butyl (compound 1-OtBu) [ka] Step 1: 3-iodo-1H-pyridine-2-one (500.0 mg, 2.26 mmol, 1 equivalent), K2CO3 (938.1 mg, 6.79 mmol, 3 equivalents), and N,N-dimethylformamide (DMF) (4 mL) were added to an 8 mL vial. The resulting mixture was stirred at 80°C for 2 hours and then diluted with water (40 mL). The aqueous layer was extracted with ethyl acetate (siRNA) (3 × 30 mL), and the organic layer was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile (0.1% TFA) in water, gradient from 10% to 50% over 10 minutes, detector: UV 254 nm) to obtain tert-butyl 4-(3-iodo-2-oxopyridine-1-yl)butanoate (480.0 mg, yield 56%). LCMS:(ES,m / z):RT=1.02 min, m / z=308[M+H] + .
[0489] Step 2: In a 20 mL vial, tert-butyl 4-(3-iodo-2-oxopyridine-1-yl)butanoate (337.7 mg, 0.93 mmol, 1.20 equivalents), 5-bromo-7-fluoro-3,3-dimethyl-1H-indole-2-one (intermediate 1) (200 mg, 0.78 mmol, 1 equivalent), Cs2CO3 (757.5 mg, 2.32 mmol, 3 equivalents), and N,N-dimethylformamide (DMF) (5 mL, 0.12 mmol) were added. The resulting mixture was stirred at 120°C for 2 hours, and then diluted with water (60 mL). The aqueous layer was extracted with ethyl acetate (ELISA) (3 × 50 mL), and the organic layer was concentrated under reduced pressure to obtain the residue. This residue was purified by silica gel column chromatography eluted with petroleum ether / ethyl acetate (4:1) to obtain tert-butyl 4-(3-(5-bromo-7-fluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyridine-1(2H)-yl)butanoate (compound 1-OtBu) (160.0 mg, yield 38%). LCMS: (ES, m / z): RT = 1.039 min, m / z = 438 [M + H] + .
[0490] Step 3: Compound 1-OtBu (130.0 mg, 0.26 mmol, 1 equivalent), trifluoroacetic acid (TFA) (0.60 mL), and dichloromethane (DCM) (3 mL) were added to an 8 mL vial. The resulting mixture was stirred at room temperature for 2 hours, then concentrated under reduced pressure to obtain the crude product, which was purified by preparative HPLC (30*150 mm, 5 μm XBridge Prep OBD C18 column, mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile, flow rate: 60 mL / min, gradient: 22%B to 30%B, 30%B over 9 minutes, wavelength: 220 nm) to obtain 4-(3-(5-bromo-7-fluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyridine-1(2H)-yl)butanoic acid (compound 1) (72.2 mg, yield 63%).
[0491] Compound 1: LCMS: (ES, m / z): RT=1.22 min, m / z=438[M+H]+ . 1 H NMR(400MHz,DMSO-d6)δ7.81(dd,J=6.8,2.0Hz,1H),7.67(dd,J=7.1,2.0Hz,1H),7.58(d,J=1.8Hz,1H),7.39(dd,J=10.8,1.8H z,1H),6.37(t,J=6.9Hz,1H),4.04(m,1H),3.88(m,1H),2.17(t,J=7.4Hz,2H),1.85(p,J=7.4Hz,2H),1.41(s,3H),1.37(s,3H).
[0492] Example 2.4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-4-methyl-2-oxopyridine-1(2H)-yl)butanoic acid (compound 4, rac-4), 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-4-methyl-2-oxopyridine-1(2H)-yl)butanoate methyl (compound 4-OMe) (Sa)-4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-4-methyl-2-oxopyridine-1(2H)-yl)butanoic acid (compound 4A*), and (Ra)-4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-4-methyl-2-oxopyridine-1(2H)-yl)butanoic acid (compound 4B*) [ka] Step 1: 3-bromo-4-methyl-1,2-dihydropyridine-2-ol (400.0 mg, 2.11 mmol, 1 equivalent), methyl 4-iodobutanoate (959.9 mg, 4.21 mmol, 2 equivalents), K2CO3 (855.6 mg, 6.33 mmol, 3 equivalents), and N,N-dimethylformamide (DMF) (5 mL) were added to a 20 mL vial at room temperature. The resulting mixture was stirred at 100 °C for 1 hour under a nitrogen atmosphere, and the reaction was then quenched by adding water (100 mL) at room temperature. The resulting mixture was extracted with ethyl acetate ( Depositphotos) (3 × 80 mL) and dried over anhydrous sodium 2 SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 30% to 60% over 25 minutes, detector: UV 220 nm) to obtain methyl 4-(3-bromo-4-methyl-2-oxopyridine-1-yl)butanoate (450 mg, yield 74%). LCMS (LCMS,ESI): RT=0.56 min, m / z=228.1 [M+H] + .
[0493] Step 2: Methyl 4-(3-bromo-4-methyl-2-oxopyridine-1-yl)butanoate (100.0 mg, 0.35 mmol, 1 equivalent), 5-cyclopropyl-4,7-difluoro-3,3-dimethylindorin-2-one (intermediate 3) (164.7 mg, 0.70 mmol, 2 equivalents), Cs2CO3 (339.2 mg, 1.04 mmol, 3 equivalents), and N,N-dimethylformamide (DMF) (4 mL) were added at room temperature to an 8 mL sealed tube. The resulting mixture was stirred at 120 °C for 2 hours, and then quenched by adding water (150 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 100 mL) and dried over anhydrous sodium 2 SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 30% to 50% over 20 minutes, detector: UV 254nm / 220nm) to obtain methyl 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-4-methyl-2-oxopyridine-1(2H)-yl)butanoate (compound 4-OMe) (70 mg, yield 43%).
[0494] Step 3: Compound 4-OMe (60.0 mg, 0.14 mmol, 1 equivalent), LiOH (16.2 mg, 0.66 mmol, 5 equivalents), H2O (2 mL), and MeOH (2 mL) were added to an 8 mL vial at room temperature. The resulting mixture was stirred at room temperature for 2 hours, and then the pH of the mixture was adjusted to pH 4 with HCl (4 M). The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 20% to 40% over 20 minutes, detector: UV 254 nm / 220 nm) to obtain the crude product (50 mg), which was then preparatively HPLC (30 × 150 mm, 5 μm XBridge Prep OBD). Purification by C18 column, mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile, flow rate: 60 mL / min, gradient: 25% B to 35% B over 10 minutes, wavelength: 254 nm / 220 nm, RT (min): 8.53) yielded 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-4-methyl-2-oxopyridine-1(2H)-yl)butanoic acid (compound 4, rac-4) (32 mg, 54% yield) as a mixture of separable atropisomers. LCMS (LCMS,ESI): RT=0.91 min, m / z=431.1 [M+H] + , 1 H NMR (400MHz, methanol-d4) δ7.68(d,J=7.2Hz,1H),6.64(dd,J=12.0,5.6Hz,1H),6.41(d,J=7.2Hz,1H),4.06(dd,J=45.2,13.2Hz,2 H),2.29(t,J=7.2Hz,2H),2.14(s,3H),2.04(d,J=14.4Hz,3H),1.59(d,J=10.4Hz,6H),0.99(d,J=9.6Hz,2H),0.76-0.62(m,2H).
[0495] Step 4: The mixture of compound 4 from Step 3 (32 mg) was separated by preparative chiral HPLC (CHIRALPAK ID 2*25 cm, 5 μm, mobile phase A: hexane (0.1% TFA), mobile phase B: ethanol:dichloromethane = 1:1, flow rate: 20 mL / min, gradient: 30% B to 30% B over 7.5 minutes, wavelength: 220 / 254 nm) and the first elution peak was (Sa)-4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-4-methyl-2-oxopyriol). Din-1(2H)-yl)butanoic acid (compound 4A*) (6.2 mg, yield 19%, RT(min): 4.37) was obtained as the second elution peak, and (Ra)-4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-4-methyl-2-oxopyridine-1(2H)-yl)butanoic acid (compound 4B*) (6.7 mg, yield 21%, RT(min): 5.77) was obtained. *Stereochemistry was arbitrarily assigned.
[0496] Compound 4A*: LCMS (LCMS, ESI): RT=0.89 min, m / z=431.1[M+H] + , 1 H NMR (400MHz, methanol-d4) δ7.67(d,J=7.2Hz,1H),6.64(dd,J=12.0,5.8Hz,1H),6.41(d,J=7.2Hz,1H),4.12(d,J=7.2Hz,1H),4.01(t,J =13.2Hz,1H),2.28(t,J=7.2Hz,2H),2.14(s,3H),2.10-1.96(m,3H),1.59(d,J=9.6Hz,6H),1.03-0.96(m,2H),0.68(q,J=4.8Hz,2H).
[0497] Compound 4B*: LCMS (LCMS, ESI): RT=0.90 min, m / z=431.1[M+H] + , 1H NMR (400MHz, methanol-d4) δ7.68(d,J=7.2Hz,1H),6.63(d,J=6.0Hz,2H),2.14(s,3H), 2.03(d,J=18.4Hz,3H),1.59(d,J=9.6Hz,6H),1.05-0.92(m,2H),0.72-0.61(m,2H).
[0498] Example 3.4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-5-methyl-2-oxopyridine-1(2H)-yl)butanoic acid (compound 5) and 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-5-methyl-2-oxopyridine-1(2H)-yl)butanoic acid methyl (compound 5-OMe) [ka] Step 1: 3-iodo-2-methoxy-5-methyl-1,2-dihydropyridine (200.0 mg, 0.79 mmol, 1 equivalent), tetrahydrofuran (THF) (0.3 mL), and HCl (4 M, 3 mL) were added to an 8 mL vial at room temperature. The resulting mixture was stirred at 90°C for 1 hour under a nitrogen atmosphere. The reaction was monitored by LC-MS. The resulting mixture was concentrated under reduced pressure to obtain 3-iodo-5-methyl-1H-pyridine-2-one (200 mg, 92% yield), which was used directly in the next step without purification. LC-MS: (ES, m / z): RT = 0.576 min, m / z = 236.1 [M + H] + .
[0499] Step 2: 3-iodo-5-methyl-1H-pyridine-2-one (200.0 mg, 0.85 mmol, 1 equivalent), methyl 4-bromobutanoate (308.10 mg, 1.70 mmol, 2 equivalents), K2CO3 (352.8 mg, 2.55 mmol, 3 equivalents), and N,N-dimethylformamide (DMF) (2 mL) were added to an 8 mL vial at room temperature. The resulting mixture was stirred at 90°C for 1 hour under a nitrogen atmosphere, and then quenched by adding water (20 mL) at room temperature. The resulting mixture was extracted with ethyl acetate ( Depositphotos) (3 × 40 mL), and the combined organic layers were washed with water (3 × 20 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 20% to 30% over 12 minutes, detector: UV 220 nm) to obtain methyl 4-(3-iodo-5-methyl-2-oxopyridine-1-yl)butanoate (140 mg, yield 49%). LCMS: (ES, m / z): RT=0.65 min, m / z=336.1 [M+H] + .
[0500] Step 3: A solution of methyl 4-(3-iodo-5-methyl-2-oxopyridine-1-yl)butanoate (100.0 mg, 0.29 mmol, 1 equivalent), 5-cyclopropyl-4,7-difluoro-3,3-dimethylindorin-2-one (intermediate 3) (70.8 mg, 0.29 mmol, 1 equivalent), and Cs2CO3 (291.7 mg, 0.89 mmol, 3 equivalents) in N,N-dimethylformamide (DMF) (3 mL) was stirred at 120 °C for 1 hour under a nitrogen atmosphere, and the reaction was then quenched with water (15 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 30 mL). The combined organic layers were washed with water (2 × 10 mL) and dried over anhydrous sodium 2 SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 40% to 50% over 10 minutes, detector: UV254nm / UV220nm) to obtain methyl 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-5-methyl-2-oxopyridine-1(2H)-yl)butanoate (compound 5-OMe) (50 mg, yield 38%). LCMS: (ES, m / z): RT=0.94 min, m / z=445.2 [M+H] + .
[0501] Step 4: A solution of compound 5-OMe (40.0 mg, 0.09 mmol, 1 equivalent) and acetic acid (AcOH) (0.5 mL) in HCl (6 M, 0.5 mL) was stirred overnight at 40°C, then quenched with water (10 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 20 mL), and the combined organic layers were washed with water (2 × 10 mL) and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 35% to 45% over 10 minutes, detector: UV254 nm / UV220 nm) to obtain the crude product (20 mg), which was then preparatively HPLC (30 × 150 mm, 5 μm XBridge Prep OBD). The compound was purified by a C18 column, mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile, flow rate: 60 mL / min, gradient: 25%B to 35%B over 10 minutes, wavelength: 254 nm / 220 nm, RT (min): 8.98, to obtain 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-5-methyl-2-oxopyridine-1(2H)-yl)butanoic acid (compound 5) (14.4 mg, yield 37%).
[0502] Compound 5: LCMS: (ES, m / z): RT=1.497 min, m / z=431.1[M+H] + . 1 H NMR (400MHz, methanol-d4) δ7.63-7.56(m,2H),6.63(d,J=11.8Hz,1H),4.14(d,J=12.8Hz,1H),4.01(d,J=13.4Hz,1H),2.29 (t,J=7.2Hz,2H),2.21(s,3H),2.04(q,J=7.6Hz,3H),1.58(d,J=4.6Hz,6H),1.00(d,J=9.8Hz,2H),0.68(d,J=4.0Hz,2H).
[0503] Example 4.4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-6-methyl-2-oxopyridine-1(2H)-yl)butanoic acid (compound 6) and 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-6-methyl-2-oxopyridine-1(2H)-yl)butanoic acid methyl (compound 6-OMe) [ka] Step 1: 2-Fluoro-3-iodo-6-methylpyridine (2 g, 8.43 mmol, 1 equivalent) and sodium methoxide (60% Na in MeOH) (20 mL) were added to a 40 mL vial at room temperature. The resulting mixture was stirred at 80°C for 1 hour, and the reaction was then quenched by adding water (100 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 200 mL), and the combined organic layers were washed with water (3 × 50 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by silica gel column chromatography eluting with petroleum ether / ethyl acetate (1:1) to obtain 3-iodo-2-methoxy-6-methylpyridine (800.0 mg, yield 38%). LCMS: (ES, m / z): RT = 1.09 min, m / z = 250 [M + H] + .
[0504] Step 2: 3-iodo-6-methylpyridine-2-ol (700 mg, 2.97 mmol, 1 equivalent), tetrahydrofuran (THF) (0.8 mL), and 4M HCl (8 mL) were added to a 40 mL vial at room temperature. The resulting mixture was stirred at 90°C for 1 hour under a nitrogen atmosphere, and then quenched by adding water (100 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 140 mL), and the combined organic layers were washed with water (3 × 50 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 20% to 30% over 13 minutes, detector: UV 220 nm) to obtain 3-iodo-6-methyl-1H-pyridine-2-one (600.0 mg, yield 86%). LCMS:(ES,m / z):RT=0.60min, m / z=236[M+H] + .
[0505] Step 3: 3-iodo-6-methyl-1H-pyridine-2-one (550.0 mg, 2.34 mmol, 1 equivalent), methyl 4-iodobutanoate (1067 mg, 4.68 mmol, 2 equivalents), K2CO3 (970.3 mg, 7.02 mmol, 3 equivalents), and N,N-dimethylformamide (DMF) (6 mL) were added to a 40 mL vial at room temperature. The resulting mixture was stirred at 100°C for 1 hour under a nitrogen atmosphere, and then quenched by adding water (100 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 100 mL). The combined organic layers were washed with water (3 × 50 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 10% to 20% over 15 minutes, detector: UV 220 nm) to obtain methyl 4-(3-iodo-6-methyl-2-oxopyridine-1-yl)butanoate (130.0 mg, yield 17%). LCMS: (ES, m / z): RT=0.71 min, m / z=336 [M+H] + .
[0506] Step 4: Methyl 4-(3-iodo-6-methyl-2-oxopyridine-1-yl)butanoate (120.0 mg, 0.35 mmol, 1 equivalent), 5-cyclopropyl-4,7-difluoro-3,3-dimethylindorin-2-one (intermediate 3) (42.5 mg, 0.17 mmol, 0.50 equivalents), Cs2CO3 (349.99 mg, 1.07 mmol, 3 equivalents), and N,N-dimethylformamide (DMF) (1 mL) were added at room temperature to a 4 mL sealed tube. The reaction mixture was irradiated with microwave radiation at 120 °C for 2 hours, and then quenched by adding water (20 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 20 mL), and the combined organic layers were washed with water (2 × 10 mL) and dried over anhydrous sodium SiO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 40% to 50% over 12 minutes, detector: UV 220 nm) to obtain methyl 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-6-methyl-2-oxopyridine-1(2H)-yl)butanoate (compound 6-OMe) (40.0 mg, yield 25%). LCMS: (ES, m / z): RT=0.83 min, m / z=445 [M+H] + .
[0507] Step 5: Compound 6-OMe (35.0 mg, 0.08 mmol, 1 equivalent), LiOH (5.7 mg, 0.24 mmol, 3 equivalents), H2O (0.3 mL), and methanol (MeOH) (0.3 mL) were added to an 8 mL vial at room temperature. The resulting mixture was stirred at room temperature for 1 hour, and then the pH of the mixture was adjusted to pH 6 with 6 M HCl (aqueous solution). The resulting mixture was extracted with ethyl acetate (RINKAN) (3 × 15 mL), and the combined organic layers were washed with water (2 × 10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase acetonitrile in water, 30% to 40% gradient over 11 minutes, UV 220 nm detector) to obtain the crude product (30 mg), which was then subjected to preparative HPLC (30 × 150 mm, 5 μm Xselect CSH). The compound was purified by an OBD column using mobile phase A: water (0.05% TFA), mobile phase B: acetonitrile, flow rate: 60 mL / min, gradient: 5%B to 5%B over 2 minutes, 35%B to 45%B over 10 minutes, wavelength: 254 nm / 220 nm, RT (min): 9.4~10.4 to obtain 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-6-methyl-2-oxopyridine-1(2H)-yl)butanoic acid (compound 6) (4.2 mg, yield 12%).
[0508] Compound 6: LCMS: (ES, m / z): RT=0.78 min, m / z=431.2[M+H] + . 1 H NMR(400MHz,DMSO-d6)δ7.54(d,J=7.4Hz,1H),6.73(d,J=11.8Hz,1H),6.25(d,J=7.4Hz,1H),4.05(d,J=15.2Hz,1H),3.97-3.87(m,1H),2. 47(s,3H),2.30(t,J=7.2Hz,2H),2.04(d,J=29.3Hz,1H),1.80(q,J=7.4Hz,2H),1.48(s,3H),1.43(s,3H),0.97-0.91(m,2H),0.70(s,2H).
[0509] Example 5.4-(3-(5-chloro-7-hydroxy-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyridine-1(2H)-yl)butanoic acid (compound 7) and 4-(3-(5-chloro-7-iodo-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyridine-1(2H)-yl)butanoic acid tert-butyl (compound 7-OtBu) [ka] Step 1: In an 8 mL vial, tert-butyl 4-(3-iodo-2-oxopyridine-1-yl)butanoate (product of Step 1 of Example 1) (2.03 g, 5.59 mmol, 2 equivalents), 5-chloro-7-iodo-3,3-dimethylindorin-2-one (intermediate 4) (900.0 mg, 2.79 mmol, 1 equivalent), Cs2CO3 (2.74 g, 8.39 mmol, 3 equivalents), and N,N-dimethylformamide (DMF) (6 mL) were added at room temperature. The resulting mixture was stirred at 120 °C for 24 hours and then quenched with 20 mL of water at room temperature. The aqueous phase was extracted with dichloromethane (DCM) (3 × 100 mL), the organic phase was washed with water (100 mL), then dried over Na₂SO₄, filtered, and concentrated to obtain the residue. This residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 40 minutes, detector: UV254 / 220 nm) to obtain tert-butyl 4-(3-(5-chloro-7-iodo-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyridine-1(2H)-yl)butanoate (compound 7-OtBu) (75.0 mg, yield 5%). LCMS: (ES, m / z): RT = 0.965 min, m / z = 557.1 [M + H] + .
[0510] Step 2: Compound 7-OtBu (75.0 mg, 0.14 mmol, 1 equivalent), N,N-bis(4-hydroxy-2,6-dimethylphenyl)oxamide (BHMPO) (44.23 mg, 0.14 mmol, 1 equivalent), copper(II) acetate (35.3 mg, 0.14 mmol, 1 equivalent), dimethyl sulfoxide (DMSO) (3 mL), H2O (1 mL), and KOH (151.1 mg, 2.70 mmol, 20 equivalents) were added to an 8 mL sealed tube at room temperature. The reaction mixture was stirred at 60°C for 24 hours, then the pH was adjusted to 4 with HCl (1M), and extracted with dichloromethane (DCM) (3 × 15 mL). The organic phase was dried over Na₂SO₄, then concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water (5 mmol NH₄HCO₃), gradient from 0% to 100% over 30 minutes, detector: UV254 / 220 nm) to obtain the crude product (15 mg), which was then subjected to preparative HPLC (30 × 150 mm, 5 μm Xselect CSH). The compound was further purified by an OBD column, mobile phase A: water (0.05% TFA), mobile phase B: acetonitrile, flow rate: 60 mL / min, gradient: 5%B to 5%B over 2 minutes, 22%B to 32%B over 10 minutes, wavelength: 254 / 220 nm, RT (min): 8.3) to obtain 4-(3-(5-chloro-7-hydroxy-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyridine-1(2H)-yl)butanoic acid (compound 7) (5.90 mg, yield 11%).
[0511] Compound 7: LCMS: (ES, m / z): RT=0.698 min, m / z=391.1[M+H] + . 1 H NMR(400MHz,DMSO-d6)δ12.16(s,1H),9.66(s,1H),7.78-7.62(m,1H),7.50-7.40(m,1H),6.99(d,J=2.0Hz,1H),6.66(d,J=2.0 Hz,1H),6.29(t,J=6.8Hz,1H),4.06-3.90(m,1H),3.88-3.77(m,1H),2.24(t,J=7.6Hz,2H),1.87(p,J=7.2Hz,2H),1.33(s,6H).
[0512] Example 6.4-(5-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-6-oxopyrimidine-1(6H)-yl)butanoic acid (compound 8) and 4-(5-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-6-oxopyrimidine-1(6H)-yl)butanoic acid methyl (compound 8-OMe) [ka] Step 1: A solution of 5-iodopyrimidine-4-ol (1 g, 4.50 mmol, 1 equivalent), methyl 4-iodobutanoate (2.05 g, 9.01 mmol, 2 equivalents), and K2CO3 (1.87 g, 13.5 mmol, 3 equivalents) in N,N-dimethylformamide (DMF) (10 mL) was stirred at 100 °C for 1 hour, and then quenched by adding water (1 mL) at room temperature. The resulting mixture was concentrated under vacuum to obtain a residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase acetonitrile in water, gradient from 15% to 25% over 10 minutes, detector UV254 / 220 nm) to obtain methyl 4-(5-iodo-6-oxopyrimidine-1-yl)butanoate (800 mg, yield 55%). LCMS:(ES,m / z):RT=0.57min, m / z=323.1[M+H] + .
[0513] Step 2: A solution of methyl 4-(5-iodo-6-oxopyrimidine-1-yl)butanoate (325.8 mg, 1.01 mmol, 3 equivalents), 5-cyclopropyl-4,7-difluoro-3,3-dimethylindorin-2-one (intermediate 3) (80.0 mg, 0.33 mmol, 1 equivalent), and Cs2CO3 (329.6 mg, 1.01 mmol, 3 equivalents) in N,N-dimethylformamide (DMF) (1 mL) was stirred at 120 °C for 1 hour, and then quenched with water (150 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (SiO) (3 × 100 mL), and the combined organic layers were washed with water (3 × 30 mL) and dried over anhydrous sodium 2 SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 40% to 50% over 15 minutes, detector: UV 220 nm) to obtain methyl 4-(5-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-6-oxopyrimidine-1(6H)-yl)butanoate (compound 8-OMe) (70.0 mg, yield 48%). LCMS: (ES, m / z): RT=0.85 min, m / z=432.1 [M+H] + .
[0514] Step 3: A solution of compound 8-OMe (60.0 mg, 0.13 mmol, 1 equivalent), LiOH (16.7 mg, 0.69 mmol, 5 equivalents), and H2O (0.5 mL) in methanol (MeOH) (0.5 mL) was stirred at 40°C for 1 hour, and the pH of the mixture was adjusted to pH 5 with 6 M HCl (aqueous solution). The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 80 mL), the combined organic layers were washed with water (2 × 20 mL), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 20% to 30% over 12 minutes, detector: UV 220 nm) to obtain the crude product (34 mg), which was then subjected to preparative HPLC (30 × 150 mm 5 μm Xselect CSH C18). The compound was further purified by an OBD column, mobile phase A: water (0.05% TFA), mobile phase B: acetonitrile, flow rate: 60 mL / min, gradient: 5%B to 5%B over 2 minutes, 30%B to 40%B over 10 minutes, wavelength: 254 / 220 nm, RT (min): 9.2) to obtain 4-(5-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-6-oxopyrimidine-1(6H)-yl)butanoic acid (compound 8) (12.2 mg).
[0515] Compound 8:LCMS:(ES,m / z):RT=1.31 min, m / z=418.1[M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.60(s,1H),8.23(s,1H),6.80(d,J=11.8Hz,1H),3.99(d,J=47.8Hz,2H),2.25(t,J=7.4 Hz,2H),2.23-1.97(m,1H),1.90(t,J=7.2Hz,2H),1.48(d,J=22.6Hz,6H),0.98-0.90(m,2H),0.75-0.67(m,2H).
[0516] Example 7.4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxoquinoline-1(2H)-yl)butanoic acid (compound 9) and 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxoquinoline-1(2H)-yl)methyl butanoate (compound 9-OMe) [ka] Step 1: A solution of 3-iodo-1H-quinoline-2-one (500.0 mg, 1.84 mmol, 1 equivalent), methyl 4-bromobutanoate (667.9 mg, 3.69 mmol, 2 equivalents), and K2CO3 (764.8 mg, 5.53 mmol, 3 equivalents) in N,N-dimethylformamide (DMF) (5 mL) was stirred at 100 °C for 1 hour, and then quenched by adding water (1 mL) at room temperature. The resulting mixture was concentrated under vacuum to obtain a residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase acetonitrile in water, gradient from 10% to 20% over 12 minutes, detector UV 220 nm) to obtain methyl 4-(3-iodo-2-oxoquinoline-1-yl)butanoate (380.0 mg, yield 56%). LCMS:(ES,m / z):RT=0.79 min, m / z=372.1[M+H] + .
[0517] Step 2: A solution of methyl 4-(3-iodo-2-oxoquinoline-1-yl)butanoate (156.5 mg, 0.42 mmol, 1 equivalent), 5-cyclopropyl-4,7-difluoro-3,3-dimethylindorin-2-one (intermediate 3) (100.0 mg, 0.42 mmol, 1 equivalent), (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (18.0 mg, 0.12 mmol, 0.30 equivalents), CuI (24.1 mg, 0.12 mmol, 0.30 equivalents), and K2CO3 (174.8 mg, 1.26 mmol, 3 equivalents) in acetonitrile (1.5 mL) was stirred overnight at 80°C under a nitrogen atmosphere, and then quenched by adding water (100 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 100 mL), and the combined organic layers were washed with water (2 × 30 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 60% to 70% over 13 minutes, detector: UV 220 nm) to obtain methyl 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxoquinoline-1(2H)-yl)butanoate (compound 9-OMe) (26.0 mg, yield 13%). LCMS: (ES, m / z): RT = 1.00 min, m / z = 481.3 [M + H] + .
[0518] Step 3: A solution of compound 9-OMe (20.0 mg, 0.04 mmol, 1 equivalent), LiOH (4.98 mg, 0.20 mmol, 5 equivalents), and H2O (0.5 mL) in MeOH (0.5 mL) was stirred at 40°C for 1 hour, and then the pH of the mixture was adjusted to pH 5 with 6 M HCl (aqueous solution). The resulting mixture was extracted with ethyl acetate (HCl) (3 × 50 mL), and the combined organic layers were washed with water (2 × 10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the crude product (12.0 mg), which was purified by preparative HPLC (30*150 mm 5 μm Xselect CSH C18 OBD column, mobile phase A: water (0.05% TFA), mobile phase B: acetonitrile, flow rate: 60 mL / min, gradient: 5% B to 5% B over 2 minutes, 6% B to 16% B over 10 minutes, wavelength: 254 / 220 nm, RT (min): 9.2) to obtain 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxoquinoline-1(2H)-yl)butanoic acid (compound 9) (5.60 mg).
[0519] Compound 9: LCMS: (ES, m / z): RT=1.21 min, m / z=467.1[M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.27(s,1H),7.86(d,J=7.8Hz,1H),7.75(d,J=7.6Hz,2H),7.38(t,J=7.4Hz,1H),6.79-6.66(m,1H),4 .31(d,J=7.0Hz,2H),2.36(q,J=7.4Hz,2H),2.15-1.92(m,1H),1.85(s,2H),1.51(d,J=21.4Hz,6H),0.96(s,2H),0.73(s,2H).
[0520] Example 8.4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrazine-1(2H)-yl)butanoic acid (compound 10) and 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrazine-1(2H)-yl)butanoic acid tert-butyl (compound 10-OtBu) [ka] Step 1: A solution of bis(3-chloro-1H-pyrazine-2-one) (1.70 g, 6.51 mmol, 1 equivalent), tert-butyl 4-bromobutanoate (2.91 g, 13.0 mmol, 2 equivalents), and K2CO3 (2.70 g, 19.5 mmol, 3 equivalents) in N,N-dimethylformamide (DMF) (20 mL) was stirred at 100 °C for 1 hour, and the reaction was then quenched with water (800 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (SiO) (3 × 800 mL), and the combined organic layers were washed with water (3 × 100 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 30% to 40% over 15 minutes, detector: UV 220 nm) to obtain tert-butyl 4-(3-chloro-2-oxopyrazine-1(2H)-yl)butanoate (2 g, yield 56%). LCMS: (ES, m / z): RT=0.72 min, m / z=217.1 [M+H] + .
[0521] Step 2: A solution of tert-butyl 4-(3-chloro-2-oxopyrazine-1-yl)butanoate (500.0 mg, 1.83 mmol, 1 equivalent), (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (782.4 mg, 5.49 mmol, 3 equivalents), NaI (549.6 mg, 3.66 mmol, 2 equivalents), and CuI (698.3 mg, 3.66 mmol, 2 equivalents) in dioxane (5 mL) was stirred at 100 °C for 2 hours under a nitrogen atmosphere, and then quenched by adding water (200 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (SiO) (3 × 200 mL), and the combined organic layers were washed with water (2 × 50 mL) and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 40% to 50% over 12 minutes, detector: UV 220 nm) to obtain tert-butyl 4-(3-iodo-2-oxopyrazine-1-yl)butanoate (260.0 mg, yield 39%). LCMS: (ES, m / z): RT = 0.69 min, m / z = 309.1 [M + H] + .
[0522] Step 3: A solution of tert-butyl 4-(3-iodo-2-oxopyrazine-1-yl)butanoate (214.9 mg, 0.59 mmol, 2 equivalents), 5-cyclopropyl-4,7-difluoro-3,3-dimethylindorin-2-one (intermediate 3) (70.0 mg, 0.29 mmol, 1 equivalent), (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (12.6 mg, 0.08 mmol, 0.30 equivalents), CuI (16.9 mg, 0.08 mmol, 0.30 equivalents), and K2CO3 (122.3 mg, 0.88 mmol, 3 equivalents) in acetonitrile (1 mL) was stirred at 80°C for 2 hours under a nitrogen atmosphere, and then quenched by adding water (50 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 50 mL), and the combined organic layers were washed with water (2 × 10 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 50% to 60% over 13 minutes, detector: UV 220 nm) to obtain tert-butyl 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrazine-1(2H)-yl)butanoate (compound 10-OtBu) (46.0 mg, yield 33%). LCMS: (ES, m / z): RT = 0.94 min, m / z = 418.2 [M + H] + .
[0523] Step 4: A solution of compound 10-OtBu (40.0 mg, 0.08 mmol, 1 equivalent) and trifluoroacetic acid (TFA) (0.5 mL) in dichloromethane (DCM) (0.5 mL) was stirred at room temperature for 1 hour. The reaction was monitored by LC-MS. The resulting mixture was concentrated under vacuum. The crude product (35 mg) was purified by preparative HPLC (30*150 mm, 5 μm Xselect CSH C18 OBD column, mobile phase A: water (0.1% FA), mobile phase B: acetonitrile, flow rate: 25 mL / min, gradient: 38% B to 48% B over 10 minutes, wavelength: 254 / 220 nm, RT (min): 12) to obtain 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrazine-1(2H)-yl)butanoic acid (compound 10) (18.1 mg).
[0524] Compound 10: LCMS: (ES, m / z): RT=0.66 min, m / z=418.1[M+H] + . 1 H NMR(400MHz,DMSO-d6)δ12.17(s,1H),7.91(d,J=4.2Hz,1H),7.40(d,J=4.2Hz,1H),6.81(d,J=11.8Hz,1H),4.11-3.77(m,1H) ),2.25(t,J=7.4Hz,2H),2.02(d,J=4.4Hz,1H),1.89(d,J=7.4Hz,2H),1.49(s,6H),0.96(d,J=8.2Hz,2H),0.79-0.63(m,2H).
[0525] Example 9.4-(5-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-6-oxopyridazine-1(6H)-yl)butanoic acid (compound 11) and 4-(5-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-6-oxopyridazine-1(6H)-yl)butanoic acid tert-butyl (compound 11-OtBu) [ka] Step 1: A solution of 4-chloro-2H-pyridazin-3-one (1 g, 7.66 mmol, 1 equivalent), tert-butyl 4-bromobutanoate (3.41 g, 15.4 mmol, 2 equivalents), and K2CO3 (3.17 g, 223.0 mmol, 3 equivalents) in N,N-dimethylformamide (DMF) (10 mL) was stirred at 100 °C for 1 hour, and then quenched by adding water (300 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (SiO) (3 × 300 mL), and the combined organic layers were washed with water (2 × 100 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 40% to 50% over 10 minutes, detector: UV 220 nm) to obtain tert-butyl 4-(5-chloro-6-oxopyridazine-1-yl)butanoate (950 mg, yield 46%). LCMS: (ES, m / z): RT=0.79 min, m / z=372.1 [M+H] + .
[0526] Step 2: A solution of tert-butyl 4-(5-chloro-6-oxopyridazine-1-yl)butanoate (517.3 mg, 1.89 mmol, 3 equivalents), 5-cyclopropyl-4,7-difluoro-3,3-dimethylindorin-2-one (intermediate 3) (150.0 mg, 0.63 mmol, 1 equivalent), and K3PO4 (402.6 mg, 1.89 mmol, 3 equivalents) in N,N-dimethylformamide (DMF) (1.5 mL) was stirred overnight at 120 °C, and the reaction was then quenched by adding water (100 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (SiO) (3 × 100 mL), and the combined organic layers were washed with water (2 × 30 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 50% to 60% over 15 minutes, detector: UV 220 nm) to obtain tert-butyl 4-(5-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-6-oxopyridazine-1(6H)-yl)butanoate (compound 11-OtBu) (25.0 mg, yield 8%). LCMS: (ES, m / z): RT=1.00 min, m / z=481.3 [M+H] + .
[0527] Step 3: A solution of compound 11-OtBu (20.0 mg, 0.04 mmol, 1 equivalent) and trifluoroacetic acid (TFA) (0.5 mL) in dichloromethane (DCM) (0.5 mL) is stirred at room temperature for 1 hour. The resulting mixture is then concentrated under vacuum to obtain a residue, which is purified by reverse-phase flash chromatography (C18 silica gel, mobile phase is acetonitrile in water, gradient from 40% to 50% over 12 minutes, detector: UV 220 nm) to obtain a crude product (15 mg), which is then subjected to preparative HPLC (19*250 mm, 5 μm XSelect CSH). Further purification was performed using an F-phenyl OBD column, mobile phase A: water (0.05% TFA), mobile phase B: acetonitrile, flow rate: 25 mL / min, gradient: 28% B to 38% B over 10 minutes, wavelength: 254 / 220 nm, RT (min): 15, to obtain 4-(5-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-6-oxopyridazine-1(6H)-yl)butanoic acid (compound 11) (5.2 mg).
[0528] Compound 11: LCMS: (ES, m / z): RT=0.68 min, m / z=418.1[M+H] + . 1 H NMR(400MHz,DMSO-d6)δ12.13(s,1H),8.12(d,J=4.2Hz,1H),7.68(d,J=4.2Hz,1H),6.81(d,J=11.8Hz,1H),4.23(d,J=13.6Hz,1 H),4.08-3.97(m,1H),2.35-2.19(m,2H),2.04-1.80(m,3H),1.52(s,3H),1.46(s,3H),1.00-0.93(m,2H),0.73(d,J=5.6Hz,2H).
[0529] Example 10. 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoic acid (compound 16, rac-16), 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoic acid tert-butyl (compound 16-OtBu), (S)-4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoic acid tert-butyl (compound 16B) (R)-4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoate tert-butyl (compound 16A-OtBu), (S)-4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoate (compound 16B), and (R)-4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoate (compound 16A) Scheme 10A. [ka] Scheme 10B. [ka] Scheme 10C. [ka] Step 1: A solution of 5-cyclopropyl-4,7-difluoro-3,3-dimethylindorin-2-one (intermediate 3) (100.0 mg, 0.42 mmol, 1 equivalent), 3-bromopyrrolidine-2-one (76.0 mg, 0.46 mmol, 1.10 equivalents), and K2CO3 (174.8 mg, 1.26 mmol, 3 equivalents) in N,N-dimethylformamide (DMF) (1 mL) was stirred at 80°C for 1 hour under a nitrogen atmosphere, and then quenched by adding water (5 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (SiO) (3 × 20 mL), and the combined organic layers were washed with water (1 × 5 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 30% to 40% over 10 minutes, detector: UV220 / 254nm) to obtain 5-cyclopropyl-4,7-difluoro-3,3-dimethyl-1-(2-oxopyrrolidine-3-yl)indole-2-one (80 mg, yield 49%). LCMS: (ES, m / z): RT=0.714 min, m / z=321.1 [M+H] + .
[0530] Step 2: A solution of 5-cyclopropyl-4,7-difluoro-3,3-dimethyl-1-(2-oxopyrrolidine-3-yl)indole-2-one (50.0 mg, 0.15 mmol, 1 equivalent), tert-butyl 4-bromobutanoate (41.8 mg, 0.18 mmol, 1.20 equivalents), and KOH (26.3 mg, 0.46 mmol, 3 equivalents) in toluene (1.5 mL) was stirred at 100 °C for 2 hours, and then quenched by adding water (5 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 20 mL), and the combined organic layers were washed with water (1 × 5 mL) and dried over anhydrous sodium 2 SO4. After filtration, the filtrate was concentrated under reduced pressure to provide the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 40% to 50% over 10 minutes, detector: UV220nm) to obtain the crude product (45 mg), which was then preparatively HPLC (30*150 mm, 5 μm XBridge Prep OBD). Further purification by C18 column, mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile, flow rate: 60 mL / min, gradient: 68%B to 83%B over 10 minutes, wavelength: 254 / 220 nm, RT (min): 6.89) yielded tert-butyl 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoate (compound 16-OtBu) (30 mg, yield 41%), which was obtained as a mixture of stereoisomers. LCMS: (ES, m / z): RT = 0.941 min, m / z = 463.2 [M + H] + .
[0531] Step 3: The compound 16-OtBu mixture product (30 mg) is purified by preparative chiral-HPLC (2*25 cm, 5 μm CHIRALPAK IC, mobile phase A: hexane (0.5% 2 M NH3-MeOH), mobile phase B: MeOH:DCM = 1:1, flow rate: 20 mL / min, gradient: 20% B to 20% B over 11 minutes, wavelength: 220 / 254 nm), and (R)-4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl) as the first elution peak. 10.1 mg of tert-butyl butanoate (compound 16A-OtBu) was obtained (33% yield, RT(min): 8.19), and (S)-4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl) tert-butyl butanoate (compound 16B-OtBu) (9.4 mg, 31% yield, RT(min): 9.87) was obtained as the second elution peak. Compound 16B-OtBu:LCMS:(ES,m / z):RT=0.943 min, m / z=463.2[M+H]+. Compound 16A-OtBu:LCMS:(ES,m / z):RT=0.940 min, m / z=463.2[M+H]+. The absolute stereochemistry of 16A-OtBu and 16B-OtBu is known based on the X-ray crystallographic confirmation of the absolute stereochemistry of compound 16A.
[0532] Step 4: A solution of compound 16A-OtBu (10.1 mg, 0.02 mmol, 1 equivalent) and trifluoroacetic acid (TFA) (0.2 mL) in dichloromethane (DCM) (0.3 mL) was stirred at room temperature for 1 hour, and the resulting mixture was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase acetonitrile in water, gradient from 30% to 40% over 10 minutes, detector UV220 / 254 nm) to obtain (R)-4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoic acid (compound 16A) (6.3 mg, yield 70%). The absolute stereochemistry of compound 16A was confirmed by X-ray crystallography.
[0533] Step 5: A solution of compound 16B-OtBu (9.40 mg, 0.02 mmol, 1 equivalent) and trifluoroacetic acid (TFA) (0.2 mL) in dichloromethane (DCM) (0.3 mL) was stirred at room temperature for 1 hour, and the resulting mixture was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase acetonitrile in water, gradient from 30% to 40% over 10 minutes, detector UV220 / 254 nm) to obtain (S)-4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoic acid (compound 16B) (5.9 mg, yield 71%). The absolute stereochemistry of compound 16B is known based on the X-ray crystallographic confirmation of the absolute stereochemistry of compound 16A.
[0534] Compound 16A:LCMS:(ES,m / z):RT=1.414 min, m / z=405.1[M+H] + . 1 H NMR(400MHz,DMSO-d6)δ12.66-11.44(m,1H),6.98-6.67(m,1H),6.83-6.78(m,1H),5.27-5.22(m,1H),3.54-3.38(m,2H),3.26-3.14( m,2H),2.34(s,1H),2.25-2.21(m,2H),2.10-1.95(m,2H),1.82-1.63(m,2H),1.44-1.32(m,6H),0.99-0.88(m,2H),0.72-0.70(m,2H).
[0535] Compound 16B: LCMS: (ES, m / z): RT=1.414 min, m / z=405.1[M+H]+. 1H NMR(400MHz,DMSO-d6)δ12.66-11.44(bar,1H),6.96-6.69(m,1H),5.27-5.22(m,1H),3.49-3.31(m,2H),3.20-3.18(m,2H),2. 34(s,1H),2.20-2.10(m,2H),2.008-1.95(m,2H),1.82-1.63(m,2H),1.44-1.32(m,6H),0.95-0.93(m,2H),0.71-0.70(m,2H).
[0536] Example 11.2-(2-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrazine-1(2H)-yl)cyclopentyl)acetic acid (compound 20, rac-20), 2-((1S,2S)-2-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrazine-1(2H)-yl)cyclopentyl)acetic acid (compound 20A*), 2-((1R,2R)-2-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrazine-1(2H)-yl)cyclo Lopentyl)acetic acid (compound 20B*), 2-((1R,2S)-2-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrazine-1(2H)-yl)cyclopentyl)acetic acid (compound 20C*), and 2-((1S,2R)-2-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrazine-1(2H)-yl)cyclopentyl)acetic acid (compound 20D*), and compounds 20A*-OEt, 20B*-OEt, 20A*-OtBu, 20B*-OtBu, 20C*-OtBu, and 20D*-OtBu Scheme 11A. [ka] Scheme 11B. [ka] Scheme 11C. [ka] Scheme 11D. [ka] Step 1: Ethyl-2-(2-oxocyclopentyl)acetate (20.0 g, 118 mmol, 1 equivalent) and ethanol (EtOH) (200 mL) were added to a 500 mL round-bottom flask. NaBH4 (8.89 g, 235 mmol, 2 equivalents) was added at 0°C. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 1 hour. The reaction was monitored by GC-MS. The mixture was adjusted to pH 3 with HCl (2 M). The resulting mixture was extracted with ethyl acetate (SiO) (3 × 500 mL). The combined organic layers were washed with brine (2 × 500 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by silica gel column chromatography eluting with petroleum ether / ethyl acetate (1:1) to obtain ethyl-2-(2-hydroxycyclopentyl)acetate (8 g, yield 40%). LCMS:(ES,m / z):RT=0.518 min, m / z=173.1[M+H] + .
[0537] Step 2: Ethyl-2-(2-hydroxycyclopentyl)acetate (8 g, 46.5 mmol, 1 equivalent), triethylamine (14.1 g, 139 mmol, 3 equivalents), dichloromethane (DCM) (200 mL), and methanesulfonyl methanesulfonate (16.2 g, 92.9 mmol, 2 equivalents) were added to a 500 mL round-bottom flask at room temperature. The resulting mixture was stirred under a nitrogen atmosphere at room temperature for 1 hour, then quenched by adding water (200 mL) at room temperature, and the resulting mixture was extracted with CH2Cl2 (3 × 500 mL). The combined organic layers were washed with brine (2 × 500 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain ethyl-2-[2-(methanesulfonyloxy)cyclopentyl]acetate (5 g, yield 43%).
[0538] Step 3: Ethyl-2-[(1R,2S)-2-(methanesulfonyloxy)cyclopentyl]acetate (5 g, 20.0 mmol, 1 equivalent), 3-chloro-1H-pyrazine-2-one (1.56 g, 12.0 mmol, 0.6 equivalents), K2CO3 (8.28 g, 59.9 mmol, 3 equivalents), and dimethylformamide (DMF) (50 mL) were added to a 250 mL round-bottom flask at room temperature. The resulting mixture was stirred at 80°C for 16 hours under a nitrogen atmosphere, and then quenched by adding water (100 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (SiO) (3 × 100 mL), and the combined organic layers were washed with brine (2 × 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV 254nm / 220nm) to obtain ethyl-2-[(1R,2R)-2-(3-chloro-2-oxopyrazine-1-yl)cyclopentyl]acetate (240 mg, yield 4%). LCMS: (ES, m / z): RT=0.620 min, m / z=285.1 [M+H] + .
[0539] Step 4: 2-(2-(3-chloro-2-oxopyrazine-1(2H)-yl)cyclopentyl)ethyl acetate (240 mg, 0.840 mmol, 1 equivalent), 5-cyclopropyl-4,7-difluoro-3,3-dimethylindorin-2-one (intermediate 3) (100 mg, 0.42 mmol, 0.5 equivalents), (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (24.0 mg, 0.16 mmol, 0.20 equivalents), CuI (16.1 mg, 0.08 mmol, 0.10 equivalents), acetonitrile (3 mL), and K2CO3 (350 mg, 2.52 mmol, 3 equivalents) were added to a 20 mL vial at room temperature. The resulting mixture was stirred at 80°C for 16 hours under a nitrogen atmosphere, and then quenched by adding water (10 mL) at room temperature. The resulting mixture was extracted with CH2Cl2 (3 × 20 mL), and the combined organic layers were washed with water (2 × 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV 254 nm / 220 nm). Compound 20*'-OEt (180 mg, yield 43.9%) was obtained as a mixture of two cis stereoisomers as the first elution peak, and compound 20*''-OEt (0.3 mg) was obtained as a mixture of two trans stereoisomers as the second elution peak. *Cis and trans stereochemistry were arbitrarily assigned.Compound 20*'-OEt (cis, presumably) was purified again by (i) preparative HPLC (19*250mm, 5μm XSelect CSH Prep C18 OBD column, mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: acetonitrile, flow rate: 20 mL / min, gradient: 55%B to 65%B over 10 minutes, wavelength: 254 nm / 220 nm, RT(min): 15.7), and then (ii) preparative chiral HPLC (2*25cm, 5μm CHIRALPAK Further purification by IG (mobile phase A: hexane (0.5% 2M NH3-MeOH), mobile phase B: EtOH:DCM = 1:1, flow rate: 20 mL / min, gradient: 20%B to 20%B over 12 minutes, wavelength: 220 nm / 254 nm, RT (min): 7.33) yielded compound 20*'-OEt (60 mg, yield 14.7%) as a mixture of two cis stereoisomers.
[0540] Step 5: The mixture of compound 20*'-OEt from Step 4 (60.0 mg) was separated by preparative chiral HPLC (2 x 25 cm, 5 μm CHIRALPAK IC, mobile phase A: hexane (0.1% TFA), mobile phase B: EtOH:DCM = 1:1, flow rate: 20 mL / min, gradient: 50% B to 50% B over 10 minutes, wavelength: 220 nm / 254 nm) to obtain compound 20B*-OEt (20.0 mg, yield 33.3%, RT(min): 5.97) as the first elution peak and compound 20A*-OEt (25.0 mg, yield 41.7%, RT(min): 8.03) as the second elution peak. *Stereochemistry was arbitrarily assigned.
[0541] Compound 20A*-OEt:LCMS:(ES,m / z):RT=1.619 min, m / z=486.1[M+H]+. 1H NMR(400MHz,メタノール-d4)δ7.68(d,J=5.6Hz,1H),7.44(d,J=4.8Hz,1H),6.72-6.63(m,1H),5.25-5.15(m,1H),4.05(s,2H),2.84(d ,J=8.4Hz,1H),2.37-1.98(m,7H),1.84-1.74(m,1H),1.64-1.56(m,7H),1.23-1.12(m,3H),1.05-0.97(m,2H),0.74-0.66(m,2H).
[0542] Compound 20B*-OEt:LCMS:(ES,m / z):RT=1.617 min, m / z=486.1 [M+H] + . 1 H NMR(400 MHz,メタノール-d4)δ7.68(d,J=5.6Hz,1H),7.44(d,J=4.8Hz,1H),6.72-6.64(m,1H),5.25-5.15(m,1H),4.05(s,2H),2.84(d, J=8.4Hz,1H),2.34-1.97(m,7H),1.82(s,1H),1.68-1.39(m,7H),1.23-1.12(m,3H),1.06-0.97(m,2H),0.74-0.66(m,2H).
[0543] Step 6: Compound 20B*-OEt (20 mg, 0.04 mmol, 1 equivalent), trimethylstannanol (74.5 mg, 0.40 mmol, 10 equivalents), and tetrahydrofuran (THF) (1.0 mL) were added to an 8 mL vial at room temperature. The resulting mixture was stirred at 80°C for 16 hours under a nitrogen atmosphere, and then quenched by adding water (5.00 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (3 × 5 mL), and the combined organic layers were washed with water (2 × 5 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV 254nm / 220nm). Further purification was performed by preparative HPLC (19*250mm, 5μm XBridge Prep Phenyl OBD column, mobile phase A: water (0.05% TFA), mobile phase B: acetonitrile, flow rate: 25 mL / min, gradient: 40%B to 50%B over 10 minutes, wavelength: 254nm / 220nm, RT(min): 12.3) to obtain compound 20B* (6.8 mg, yield 36%). *Stereochemistry was arbitrarily assigned.
[0544] Step 7: Compound 20A*-OEt (25.0 mg, 0.05 mmol, 1 equivalent), tetrahydrofuran (THF) (1 mL), and trimethylstannano (93.10 mg, 0.50 mmol, 10 equivalents) were added to an 8 mL vial at room temperature. The resulting mixture was stirred at 80°C for 16 hours under a nitrogen atmosphere, and then quenched by adding water (5 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (3 × 5 mL), and the combined organic layers were washed with water (2 × 5 mL) and dried over anhydrous sodium 2 SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV 254nm / 220nm). Further purification was performed by preparative HPLC (30*150mm 5μm Xselect CSH C18 OBD column, mobile phase A: water (0.05% TFA), mobile phase B: acetonitrile, flow rate: 60 mL / min, gradient: 5%B to 5%B over 2 minutes, 32%B to 52%B over 15 minutes, wavelength: 254nm / 220nm, RT(min): 13.5) to obtain compound 20A* (9.8 mg, yield 40%). *Stereochemistry was arbitrarily assigned.
[0545] Compound 20A*:LCMS:(ES,m / z):RT=1.485 min, m / z=458.1[M+H] + . 1 H NMR (400MHz, methanol-d4) δ7.69(d,J=4.4Hz,1H),7.45(d,J=4.8Hz,1H),6.73-6.64(m,1H ),5.28-5.14(m,1H),2.82(d,J=7.2Hz,1H),2.34-1.96(m,7H),1.86-1.73(m,1H),1.70- 1.56(m,7H),1.05-0.94(m,2H),0.75-0.64(m,2H).
[0546] Compound 20B*: LCMS: (ES, m / z): RT=1.030 min, m / z=458.1[M+H]+. 1H NMR (400MHz, methanol-d4) δ7.70(d,J=4.4Hz,1H),7.45(d,J=4.8Hz,1H),6.73-6.64(m,1H),5.29-5.14(m,1H),2.82 (d,J=7.2Hz,1H),2.35-1.93(m,7H),1.81-1.77(m,1H),1.68-1.53(m,7H),1.05-0.96(m,2H),0.75-0.66(m,2H).
[0547] Step 8: (2-oxocyclopentyl)acetic acid (10.0 g, 70.3 mmol, 1 equivalent) and dichloromethane (DCM) (100 mL) were added to a 250 mL round-bottom flask at room temperature. (Z)-N,N'-diisopropyl tert-butoxymethaneimidoamide (141 g, 703 mmol, 10 equivalents) was added to the above mixture at 0 °C. The resulting mixture was stirred at room temperature for 2 hours, and then the reaction was quenched by adding water (500 mL) at room temperature. The resulting mixture was extracted with DCM (3 × 500 mL), and the combined organic layers were washed with brine (2 × 500 mL) and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by silica gel column chromatography eluted with petroleum ether / ethyl acetate (3:1) to obtain 2-(2-oxocyclopentyl)acetic acid tert-butyl (10 g, yield 72%). LCMS:(ES,m / z):RT=0.707min, m / z=199.1[M+H] + .
[0548] Step 9: In a 250 mL round-bottom flask, 10 g, 50.4 mmol, 1 equivalent of 2-(2-oxocyclopentyl) tert-butyl acetate, 15.3 g, 151 mmol, 3 equivalents of triethylamine (TEA), 50 mL of ethanol (EtOH), and 10.5 g, 151 mmol, 3 equivalents of hydroxylamine hydrochloride were added at room temperature. The resulting mixture was stirred at 20°C for 2 hours, and then quenched by adding 100 mL of water at room temperature. The resulting mixture was extracted with ethyl acetate (SiO) (3 × 200 mL), and the combined organic layers were washed with 100 mL of H₂O and dried over anhydrous Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure to obtain 7 g, 65% yield of 2-[(2Z)-2-(hydroxyimino)cyclopentyl] tert-butyl acetate. LCMS:(ES,m / z):RT=0.682 min, m / z=214.1[M+H] + .
[0549] Step 10: 2-[(2Z)-2-(hydroxyimino)cyclopentyl]tert-butyl acetate (7 g, 32.8 mmol, 1 equivalent), tetrahydrofuran (THF) (50 mL), and Raney nickel (9.63 g, 164 mmol, 5 equivalents) were added to a 250 mL round-bottom flask at room temperature. The mixture was stirred overnight at room temperature under a hydrogen atmosphere, then the resulting mixture was filtered, the filter cake was washed with THF (50 mL), and the filtrate was concentrated under reduced pressure to obtain 2-(2-aminocyclopentyl)tert-butyl acetate (3 g, 46% yield). LCMS: (ES, m / z): RT = 0.392 min, m / z = 200.2 [M + H] + .
[0550] Step 11: 2-(2-aminocyclopentyl)acetate tert-butyl (3 g, 15.1 mmol, 1 equivalent), 2-bromoacetonitrile (5.42 g, 45.2 mmol, 3 equivalents), and acetonitrile (10 mL) were added to a 100 mL vial at room temperature. The mixture was stirred at 80°C for 2 hours, then quenched by adding water (20 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (SiO) (3 × 100 mL), and the combined organic layers were washed with water (2 × 20 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by silica gel column chromatography eluted with petroleum ether / ethyl acetate (5:1) to obtain 2-{2-[(cyanomethyl)amino]cyclopentyl}acetate tert-butyl (3 g, yield 84%). LCMS:(ES,m / z):RT=0.535min, m / z=239.2[M+H] + .
[0551] Step 12: Add 2-{2-[(cyanomethyl)amino]cyclopentyl}tert-butyl acetate (1 g, 12.6 mmol, 1 equivalent), (COCl)2 (2.7 g, 62.9 mmol, 5 equivalents), and toluene (3 mL) to a 40 mL vial at room temperature. Stir the reaction mixture at 80°C for 2 hours, then quench by adding water (7 mL) at room temperature. Repeat the reaction twice, combine the batches, extract with ethyl acetate (SiO) (3 × 10 mL), wash the combined organic layer with water (10 mL), and dry over anhydrous sodium 2 SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 10% to 50% over 10 minutes, detector: UV 254 / 220 nm) to obtain 2-[2-(3,5-dichloro-2-oxopyrazine-1-yl)cyclopentyl]tert-butyl acetate (1 g, yield 23%). LCMS: (ES, m / z): RT=0.964 min, m / z=347.1 [M+H] + .
[0552] Step 13: In a 40 mL vial, 2-[2-(3,5-dichloro-2-oxopyrazine-1-yl)cyclopentyl]tert-butyl acetate (400 mg, 1.15 mmol, 1 equivalent), 5-cyclopropyl-4,7-difluoro-3,3-dimethylindorin-2-one (intermediate 3) (137 mg, 0.57 mmol, 0.50 equivalent), CuI (44 mg, 0.23 mmol, 0.20 equivalent), K2CO3 (478 mg, 3.45 mmol, 3 equivalents), acetonitrile (4 mL), and (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (33 mg, 0.23 mmol, 0.20 equivalent) were added at room temperature. The mixture was stirred at 80°C for 2 hours under a nitrogen atmosphere, and then quenched by adding water (5 mL) at room temperature. The resulting mixture was extracted with ethyl acetate (siRNA) (3 × 5 mL), and the combined organic layers were washed with water (2 × 10 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 10% to 50% over 10 minutes, detector: UV 254 nm) to obtain 2-(2-[5-chloro-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindole-1-yl)-2-oxopyrazine-1-yl]cyclopentyl acetate tert-butyl (115 mg, yield 18%). LCMS: (ES, m / z): RT = 0.833 min, m / z = 548.2 [M + H] + .
[0553] Step 14: In a 40 mL vial, add 2-(2-[5-chloro-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindole-1-yl)-2-oxopyrazine-1-yl]cyclopentyl acetate tert-butyl (115 mg, 0.21 mmol, 1 equivalent), 1,4-dioxane (3 mL), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (Xphos) (40 mg, 0.080 mmol, 0.40 equivalents), (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (XPhos Pd G3) (35 mg, 0.040 mmol, 0.20 equivalents), ammonium formate (27 mg, 0.42 mmol, 2 equivalents), and Cs2CO3 (210 mg, 0.63 mmol, 3 equivalents) were added at room temperature. The mixture was stirred at 80°C for 2 hours. The progress of the reaction was monitored by LC-MS. The reaction was quenched by adding water (5 mL) at room temperature. The resulting mixture was extracted with ethyl acetate ( Depositphotos) (3 × 10 mL). The combined organic layers were washed with water (20 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was then collected. The solution was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 10% to 50% over 10 minutes, detector: UV254 / 220nm) to obtain 2-(2-[3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindole-1-yl)-2-oxopyrazine-1-yl]cyclopentyl acetate tert-butyl (45 mg, yield 42%) as a mixture of four cis and trans stereoisomers. LCMS: (ES, m / z): RT=0.955 min, m / z=514.2 [M+H] + .
[0554] Step 15: Prepare the mixture from Step 14 (45 mg) of 2-(2-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrazine-1(2H)-yl)cyclopentyl) acetate tert-butyl by preparative chiral HPLC (2*25 cm, 5 μm). Separation was performed using ARTcellulose-SC (mobile phase A: hexane (0.1% TFA), mobile phase B: EtOH:DCM = 1:1, flow rate: 20 mL / min, gradient: 40% B to 40% B over 14 minutes, wavelength: 220 / 254 nm) to obtain a mixture of compound 20C*-OtBu and compound 20D*-OtBu as the first elution peak (20 mg, yield 44%, RT(min): 8.07), compound 20A*-OtBu as the second elution peak (5.0 mg, yield 11%, RT(min): 12.39), and compound 20B*-OtBu as the third elution peak (5.0 mg, yield 11%, RT(min): 15.28). *Stereochemistry was arbitrarily assigned.
[0555] Step 16: The mixture of compound 20C*-OtBu and compound 20D*-OtBu from Step 15 (20 mg) was separated by preparative chiral HPLC (2 x 25 cm, 5 μm CHIRALPAK ID, mobile phase A: hexane (0.5% 2 M NH3-MeOH), mobile phase B: EtOH, flow rate: 20 mL / min, gradient: 10% B to 10% B over 15 minutes, wavelength: 220 / 254 nm) to obtain compound 20D*-OtBu (10 mg, yield 50%, RT(min): 8.75) as the first elution peak and compound 20C*-OtBu (9.8 mg, yield 49%, RT(min): 11.38) as the second elution peak. Compound 20C*-OtBu: LCMS: (ES, m / z): RT = 1.497 min, m / z = 514.2 [M + H] + . Compound 20D*-OtBu:LCMS:(ES,m / z):RT=1.537 min, m / z=514.2[M+H] + .
[0556] Step 17: Compound 20D*-OtBu (10 mg, 0.02 mmol, 1 equivalent) and trifluoroacetic acid (TFA) (0.2 mL) were added to an 8 mL vial at room temperature in dichloromethane (DCM) (0.4 mL). The mixture was stirred at room temperature for 1 hour, then concentrated under reduced pressure and lyophilized to obtain compound 20D* (5.2 mg, 58% yield).
[0557] Step 18: Compound 20C*-OtBu (9.8 mg, 0.02 mmol, 1 equivalent) and trifluoroacetic acid (TFA) (0.2 mL) were added to an 8 mL vial at room temperature in dichloromethane (DCM) (0.4 mL). The mixture was stirred at room temperature for 1 hour, then concentrated under reduced pressure and lyophilized to obtain compound 20C* (5.2 mg, 65% yield).
[0558] Compound 20C*:LCMS:(ES,m / z):RT=1.598 min, m / z=458.2[M+H] + . 1 ¹H NMR (400MHz, methanol-d4) δ 7.88-7.83 (m, 1H), 7.47 (d, J=4.4Hz, 1H), 6.72-6.65 (m, 1H), 2.66 (s, 1H), 2.52-2.16 (m, 4H), 2.13-1.79 (m, 4H), 1.70-1.40 (m, 8H), 1.06-0.97 (m, 2H), 0.71 (d, J=6.0Hz, 2H).
[0559] Compound 20D*:LCMS:(ES,m / z):RT=1.577 min, m / z=458.2[M+H] + . 1 H NMR (400MHz, methanol-d4) δ7.85(d,J=4.4Hz,1H),7.47(d,J=4.4Hz,1H),6.72-6.65(m,1H),2.65(s,1H), 2.52-2.16(m,4H),2.13-1.78(m,4H),1.69-1.42(m,8H),1.01(d,J=8.8Hz,2H),0.71(d,J=5.2Hz,2H).
[0560] Example 12.4-(3-(4,7-difluoro-3,3-dimethyl-2-oxo-5-(trifluoromethyl)indoline-1-yl)-2-oxopyrrolidine-1-yl)butanoic acid (compound 19, rac-19), (R)-4-(3-(4,7-difluoro-3,3-dimethyl-2-oxo-5-(trifluoromethyl)indoline-1-yl)-2-oxopyrrolidine-1-yl)butanoic acid tert-butyl (compound 19A*-OtBu), (S)-4-(3-(4,7-difluoro-3,3-dimethyl-2-oxo-5-(trifluoromethyl)indoline-1-yl) (Oromethyl)indoline-1-yl)-2-oxopyrrolidine-1-yl)butanoate tert-butyl (compound 19B*-OtBu), (R)-4-(3-(4,7-difluoro-3,3-dimethyl-2-oxo-5-(trifluoromethyl)indoline-1-yl)-2-oxopyrrolidine-1-yl)butanoate (compound 19A*), and (S)-4-(3-(4,7-difluoro-3,3-dimethyl-2-oxo-5-(trifluoromethyl)indoline-1-yl)-2-oxopyrrolidine-1-yl)butanoate (compound 19B*) Scheme 12A. [ka] Scheme 12B. [ka] Scheme 12C. [ka] Step 1: 4,7-difluoro-3,3-dimethyl-5-(trifluoromethyl)indorin-2-one (intermediate 9) (300 mg, 1.13 mmol, 1 equivalent), tert-butyl 3-bromo-2-oxopyrrolidine-1-carboxylate (448 mg, 1.70 mmol, 1.50 equivalents), K2CO3 (469 mg, 3.39 mmol, 3 equivalents), and dimethylformamide (DMF) (2.5 mL) were added to an 8 mL vial. The resulting mixture was stirred overnight at 80°C and then diluted with water (30 mL). The aqueous layer was extracted with ethyl acetate (siRNA) (3 × 30 mL), concentrated under reduced pressure, and the residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 45% to 55% over 10 minutes, detector: UV 254 nm) to obtain tert-butyl 3-[4,7-difluoro-3,3-dimethyl-2-oxo-5-(trifluoromethyl)indole-1-yl]-2-oxopyrrolidine-1-carboxylate (430 mg, yield 85%). LCMS: (ES, m / z): RT = 1.09 min, m / z = 449.1 [M + H] + .
[0561] Step 2: 3-[4,7-difluoro-3,3-dimethyl-2-oxo-5-(trifluoromethyl)indole-1-yl]-2-oxopyrrolidine-1-carboxylate tert-butyl (410 mg, 0.910 mmol, 1 equivalent) and HCl (gas) in dioxane (4.0 M in 1,4-dioxane) (5.0 mL) were added to a 20 mL vial. The resulting mixture was stirred overnight at room temperature and then concentrated under reduced pressure to obtain 4,7-difluoro-3,3-dimethyl-1-(2-oxopyrrolidine-3-yl)-5-(trifluoromethyl)indole-2-one (300 mg, 94% yield). LCMS: (ES, m / z): RT = 0.71 min, m / z = 349.1 [M + H] + .
[0562] Step 3: 4,7-difluoro-3,3-dimethyl-1-(2-oxopyrrolidine-3-yl)-5-(trifluoromethyl)indole-2-one (140 mg, 0.4 mmol, 1 equivalent), tert-butyl 4-bromobutanoate (448 mg, 2.01 mmol, 5 equivalents), Cs2CO3 (1310 mg, 4.02 mmol, 10 equivalents), and dimethylformamide (DMF) (2.5 mL) were added to a 20 mL vial. The resulting mixture was stirred at 100°C for 3 hours, then diluted with water (30 mL). The aqueous layer was extracted with siRNA (4 × 30 mL), concentrated under reduced pressure, and the residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 60% to 70% over 10 minutes, detector: UV 254 nm) to obtain compound 19-OtBu (120 mg, yield 61%) as a mixture of two stereoisomers. LCMS: (ES, m / z): RT = 0.92 min, m / z = 491.1 [M + H] + .
[0563] Step 4: The mixture of compound 19-OtBu (120 mg) was separated by preparative chiral HPLC (2 x 25 cm, 5 μm CHIRALPAK IF, mobile phase A: hexane (0.5% 2 M NH3-MeOH), mobile phase B: EtOH:DCM=1:1 HPLC, flow rate: 20 mL / min, gradient: 20% B to 20% B over 10 minutes, wavelength: 220 / 254 nm) to obtain compound 19A*-OtBu (40 mg, yield 20%, RT(min): 5.92) as the first elution peak and compound 19B*-OtBu (40 mg, yield 20%, RT(min): 6.96) as the second elution peak. The stereochemistry of *(R) was reasonably assigned to compounds 19A* and 19A*-OtBu based on (i) the NLRP3 inhibitory activity of the more active isomer compound 19A* (compared to the (S)-isomer 19B*) in hWB and (ii) the known absolute (R) stereochemistry of the more active isomer compound 16A (compared to the (S)-isomer 16B).
[0564] Compound 19A*-OtBu:LCMS:(ES,m / z):RT=1.54 min, m / z=491.1[M+H]+ , 1 H NMR(400MHz,DMSO-d6)δ7.86-7.52(m,1H),5.37-4.93(m,1H),3.54-3.37(m,2H), 3.30-3.14(m,2H),2.44-2.02(m,4H),1.78-1.65(m,2H),1.43(d,J=17.2Hz,15H).
[0565] Compound 19B*-OtBu:LCMS:(ES,m / z):RT=1.54 min, m / z=491.1[M+H] + , 1 H NMR(400MHz,DMSO-d6)δ7.83-7.70(m,1H),5.36-4.94(m,1H),3.54-3.38(m,2H), 3.30-3.15(m,2H),2.45-2.00(m,4H),1.78-1.65(m,2H),1.43(d,J=17.2Hz,15H).
[0566] Step 5: Compound 19A*-OtBu (35 mg, 0.070 mmol, 1 equivalent), trifluoroacetic acid (TFA) (0.40 mL), and dichloromethane (DCM) (2.0 mL) were added to an 8 mL vial. The resulting mixture was stirred at room temperature for 2 hours, then diluted with water (15 mL), and dried by lyophilization to obtain compound 19A* (21.2 mg, 68% yield).
[0567] Step 6: Compound 19B*-OtBu (35 mg, 0.070 mmol, 1 equivalent), trifluoroacetic acid (TFA) (0.40 mL), and dichloromethane (DCM) (2.0 mL) were added to an 8 mL vial. The resulting mixture was stirred overnight at room temperature, then diluted with water (15 mL), and dried by lyophilization to obtain compound 19B* (25.6 mg, 83% yield).
[0568] Compound 19A*:LCMS:(ES,m / z):RT=1.27min, m / z=435.2[M+H] + , 1H NMR (400MHz, methanol-d4) δ7.56-7.47(m,1H),5.53-5.12(m,1H),3.68-3.53(m,2H),3.53-3. 36(m,2H),2.63-2.17(m,4H),1.99-1.84(m,J=6.8Hz,2H),1.59(s,2H),1.56-1.48(m,4H).
[0569] Compound 19B*:LCMS:(ES,m / z):RT=1.27min, m / z=435.2[M+H] + , 1 H NMR (400MHz, methanol-d4) δ7.56-7.47(m,1H),5.52-5.12(m,1H),3.68-3.53(m,2H),3.53-3. 36(m,2H),2.64-2.16(m,4H),1.99-1.85(m,J=6.8Hz,2H),1.59(s,2H),1.56-1.48(m,4H).
[0570] Example 13. 4-(3-(5-cyclopropyl-7-fluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoic acid (compound 22, rac-22), 4-(3-(5-cyclopropyl-7-fluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoic acid tert-butyl (compound 22- OtBu), (R)-4-(3-(5-cyclopropyl-7-fluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoic acid (compound 22A*), and (S)-4-(3-(5-cyclopropyl-7-fluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoic acid (compound 22B*) [ka] Step 1: A solution of 5-cyclopropyl-7-fluoro-3,3-dimethylindorin-2-one (intermediate 2) (160 mg, 0.73 mmol, 1 equivalent), 3-bromo-2-oxopyrrolidine-1-carboxylate tert-butyl (385 mg, 1.46 mmol, 2 equivalents), and K2CO3 (302 mg, 2.19 mmol, 3 equivalents) in dimethylformamide (DMF) (2 mL) was stirred overnight at 80 °C, and then quenched by adding water (3 mL) at room temperature. The resulting mixture was concentrated under reduced pressure, and the resulting residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 35% to 45% over 10 minutes, detector: UV 220 nm) to obtain tert-butyl 3-(5-cyclopropyl-7-fluoro-3,3-dimethyl-2-oxoindole-1-yl)-2-oxopyrrolidine-1-carboxylate (160 mg, yield 54%). LCMS: (ES, m / z): RT = 0.87 min, m / z = 303.1 [M + H] + .
[0571] Step 2: A solution of tert-butyl 3-(5-cyclopropyl-7-fluoro-3,3-dimethyl-2-oxoindole-1-yl)-2-oxopyrrolidine-1-carboxylate (150 mg, 0.37 mmol, 1 equivalent) and HCl (gas) (2 mL, 4 M) in 1,4-dioxane was stirred at room temperature for 1 hour. The resulting mixture was then concentrated under reduced pressure to obtain 5-cyclopropyl-7-fluoro-3,3-dimethyl-1-(2-oxopyrrolidine-3-yl)indole-2-one (120 mg, 96% yield), which was used directly in the next step. LCMS: (ES, m / z): RT = 0.65 min, m / z = 303.1 [M + H] + .
[0572] Step 3: A solution of 5-cyclopropyl-7-fluoro-3,3-dimethyl-1-(2-oxopyrrolidine-3-yl)indole-2-one (90.0 mg, 0.29 mmol, 1 equivalent), tert-butyl 4-bromobutanoate (133 mg, 0.59 mmol, 2 equivalents), and Cs2CO3 (970 mg, 2.98 mmol, 10 equivalents) in dimethylformamide (DMF) (1 mL) was stirred at 100°C for 1 hour, then diluted with water (5 mL), and the resulting mixture was concentrated under vacuum. The obtained residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 40% to 50% over 10 minutes, detector: UV 220 nm) to obtain tert-butyl 4-(3-(5-cyclopropyl-7-fluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoate (compound 22-OtBu), (80 mg, yield 60%) as a mixture of two stereoisomers. LCMS: (ES, m / z): RT=0.89 min, m / z=445.2 [M+H] + .
[0573] Step 4: The solution of compound 22-OtBu (70 mg, 0.15 mmol, 1 equivalent) and trifluoroacetic acid (TFA) (1 mL) in dichloromethane (DCM) (1 mL) is stirred at room temperature for 1 hour, then concentrated under reduced pressure to obtain a crude residue (50 mg), which is then subjected to preparative HPLC (19*250 mm, 5 μm XSelect CSH Prep C18). The compound was purified by OBD column, mobile phase A: water (0.05% TFA), mobile phase B: acetonitrile, flow rate: 25 mL / min, gradient: 28%B to 38%B over 20 minutes, wavelength: 254 / 220 nm, RT (min): 18) to obtain 4-(3-(5-cyclopropyl-7-fluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)butanoic acid (compound 22, rac-22) (35 mg, yield 57%) as a mixture of two stereoisomers. LCMS: (ES, m / z): RT = 1.08 min, m / z = 389.1 [M + H] + .
[0574] Step 5: A mixture of compound 22 (35 mg) was separated by preparative chiral HPLC (2 x 25 cm, 5 μm CHIRALPAK IF, mobile phase A: hexane (0.1% TFA), mobile phase B: isopropyl alcohol: DCM = 1:1, flow rate: 20 mL / min, gradient: 30% B to 30% B over 23 minutes, wavelength: 220 / 254 nm) to obtain compound 22-A* as the first elution peak (10.5 mg, yield 30%, RT(min): 14.53) and compound 22-B* as the second elution peak (11.8 mg, yield 34%, RT(min): 18.81). The stereochemistry of *(R) was reasonably assigned to compound 22A* based on (i) the NLRP3 inhibitory activity of the more active isomer compound 22A* (compared to the (S)-isomer 22B*) in hWB and (ii) the known absolute (R) stereochemistry of the more active isomer compound 16A (compared to the (S)-isomer 16B).
[0575] Compound 22A*:LCMS:(ES,m / z):RT=1.403 min, m / z=389.2[M+H] +。1 H NMR(400MHz,DMSO-d6)δ12.06(s,1H),7.07-6.98(m,1H),6.89-6.75(m,1H),5.25(d,J=10.2Hz,1H),3.44(d,J=16.2Hz,2H),3.31-3.17(m,J= 6.7Hz,2H),2.33-2.21(m,4H),1.92(d,J=13.4Hz,1H),1.82-1.64(m,J=6.9Hz,2H),1.28-1.14(m,6H),0.97-0.82(m,2H),0.75-0.63(m,2H).
[0576] Compound 22B*:LCMS:(ES,m / z):RT=1.395 min, m / z=389.2[M+H] + . 1H NMR(400MHz,DMSO-d6)δ12.07(s,1H),7.07-6.98(m,1H),6.89-6.76(m,1H),5.25(d,J=10.2Hz,1H),3.43(d,J=18.8Hz,2H),3.23(d,J=7.2Hz,2H) ,2.25(d,J=7.3Hz,3H),2.12-1.99(m,1H),1.92(d,J=13.4Hz,1H),1.81- 1.64(m,2H),1.28-1.14(m,6H),0.93(d,J=8.4Hz,2H),0.76-0.63(m,2H).
[0577] Example 14. 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)pentanoic acid (compound 24, rac-24), 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)pentanoate ethyl (compound 24-OEt), (S)-4-((R)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)pentanoic acid (compound 24A*), ( R)-4-((S)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)pentanoic acid (compound 24B*), (S)-4-((S)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)pentanoic acid (compound 24C*), and (R)-4-((R)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)pentanoic acid (compound 24D*) Scheme 14A. [ka] Scheme 14B. [ka] Scheme 14C. [ka] Step 1: 5-Cyclopropyl-4,7-Difluoro-3,3-dimethylindorin-2-one (intermediate 3) (500 mg, 2.10 mmol, 1 equivalent), dimethylformamide (DMF) (5 mL), 3-bromopyrrolidine-2-one (415 mg, 2.52 mmol, 1.20 equivalents), and K2CO3 (874 mg, 6.32 mmol, 3 equivalents) were added to a 20 mL vial at room temperature. The resulting mixture was stirred overnight at 80°C and then quenched by adding water (20 mL) at room temperature. The resulting mixture was extracted with CH2Cl2 (3 × 20 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV 254nm / 220nm) to obtain 5-cyclopropyl-4,7-difluoro-3,3-dimethyl-1-(2-oxopyrrolidine-3-yl)indole-2-one (400 mg, yield 53%). LCMS: (ES, m / z): RT = 0.705 min, m / z = 321.2 [M + H] + .
[0578] Step 2: 5-Cyclopropyl-4,7-Difluoro-3,3-dimethyl-1-(2-oxopyrrolidine-3-yl)indole-2-one (20 mg, 0.062 mmol, 1 equivalent) and dimethylformamide (DMF) (0.5 mL) were added to an 8 mL vial at room temperature. Then NaH (60% in mineral oil, 5.0 mg, 0.12 mmol, 2 equivalents) was added at 0°C. The resulting mixture was stirred at room temperature for 30 minutes. Then ethyl 4-bromopentanoate (39 mg, 0.19 mmol, 3 equivalents) was added at room temperature, and the resulting mixture was stirred at 100°C under a nitrogen atmosphere for 2 hours. The reaction was repeated 20 times, and then the mixtures were combined as follows: The reaction was quenched with water (20 mL) at room temperature, the mixture was extracted with CH2Cl2 (3 × 20 mL), and the combined organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain a residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 100% over 30 minutes, detector: UV254 / 220nm) to obtain ethyl 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)pentanoate (compound 24-OEt) (80 mg, yield 11%) as a mixture of two stereoisomers. LCMS: (ES, m / z): RT=0.884 min, m / z=449.2 [M+H] + .
[0579] Step 3: Compound 24-OEt (80.00 mg, 0.17 mmol, 1 equivalent), tetrahydrofuran (THF) (2 mL), and (CH3)3SnOH (322.53 mg, 1.78 mmol, 10 equivalents) were added to an 8 mL vial at room temperature. The resulting mixture was stirred at 80 °C for 16 hours, and then quenched with water (10 mL) at room temperature. The resulting mixture was extracted with CH2Cl2 (3 × 10 mL), and the combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain a residue, which was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 0% to 30% over 30 minutes, detector: UV254 / 220nm) to obtain 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)pentanoic acid (compound 24, rac-24) (70 mg, yield 70%) as a mixture of four stereoisomers. LCMS: (ES, m / z): RT=0.721 min, m / z=421.2 [M+H] + .
[0580] Step 4: The mixture of compound 24 from Step 3 (70 mg) was separated by preparative HPLC (19*250 mm, 5 μm XSelect CSH Prep C18 OBD column, mobile phase A: water (0.05% TFA), mobile phase B: acetonitrile, flow rate: 25 mL / min, gradient: 38% B to 48% B over 15 minutes, wavelength: 254 / 220 nm) to obtain compound 24'* (13 mg, yield 25%, RT(min): 12.1) as a mixture of two stereoisomers as the first elution peak, and compound 24''* (8 mg, yield 15%, RT(min): 13.6) as a mixture of two stereoisomers as the second elution peak. *Stereochemistry was arbitrarily assigned.
[0581] Compound 24'*:LCMS:(ES,m / z):RT=0.711 min, m / z=421.2[M+H] + . 1H NMR (400MHz, methanol-d4) δ6.74-6.69(m,1H),5.41-5.36(m,1H),4.25-4.11(m,1H),3.58-3.44(m,2H),2.42(s,1H),2 .33-2.12(m,3H),2.06-1.77(m,3H),1.58-1.40(m,6H),1.22(d,J=6.8Hz,3H),1.05-0.92(m,2H),0.73-0.63(m,2H).
[0582] Compound 24''*:LCMS:(ES,m / z):RT=0.731 min, m / z=421.2[M+H] + . 1 H NMR (400MHz, methanol-d4) δ6.71-6.67(m,1H),5.48(t,J=10.4Hz,1H),4.20(q,J=6.8Hz,1H),3.57-3.41(m,2H),2.46(s,1H),2.19(t, J=7.6Hz,3H),2.08-1.99(m,1H),1.83(q,J=7.6Hz,2H),1.58-1.42(m,6H),1.29-1.23(m,3H),1.04-0.96(m,2H),0.73-0.64(m,2H).
[0583] Step 5: Separate compound 24'* (13 mg) by chiral HPLC (2*25 cm, 5 μm CHIRALPAK IC, mobile phase A: hexane (0.1% TFA), mobile phase B: isopropyl alcohol (IPA): DCM=1:1, flow rate: 20 mL / min, gradient: 40% B to 40% B over 12 minutes, wavelength: 220 / 254 nm) and identify the first elution peak as (S)-4-((S)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-o Xopyrrolidine-1-yl)pentanoic acid (compound 24C*) (5.8 mg, yield 45%, RT(min): 6.64), and (R)-4-((R)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)pentanoic acid (compound 24D*) (4.7 mg, yield 36%, RT(min): 9.93) were obtained as the second elution peak. *Stereochemistry was arbitrarily assigned.
[0584] Compound 24C*:LCMS:(ES,m / z):RT=0.820 min, m / z=421.1 [M+H] + . 1 H NMR(400MHz,メタノール-d4)δ6.81-6.69(m,1H),5.45-5.06(m,1H),4.2 7-4.09(m,1H),3.52-3.39(m,2H),2.56-2.31(m,3H),2.26-2.10(m, 1H),2.11-2.02(m,1H),1.90(m,2H),1.55(s,2H),1.47(d,J=12.8Hz,4H),1.23-1.17(m,3H),1.04-0.94(m,2H),0.69(t,J=5.6Hz,2H).
[0585] Compound 24D*:LCMS:(ES,m / z):RT=0.818 min, m / z=421.1 [M+H] + . 1 H NMR(400MHz,メタノール-d4)δ6.74-6.69(m,1H),5.46-5.06(m,1H),4.27 -4.07(m,1H),3.55-3.41(m,2H),2.55-2.30(m,3H),2.27-2.12(m,1H ),2.07-2.01(m,1H),1.99-1.82(m,2H),1.55(s,2H),1.46(d,J=12.8Hz,4H),1.23-1.16(m,3H),1.04-0.94(m,2H),0.69(t,J=5.6Hz,2H).
[0586] Step 6: Separate compound 24''* (8 mg) by chiral HPLC (2*25 cm, 5 μm CHIRALPAK IG, mobile phase A: hexane (0.1% TFA), mobile phase B: isopropyl alcohol (IPA): DCM=1:1, flow rate: 20 mL / min, gradient: 40% B to 40% B over 10 minutes, wavelength: 220 / 254 nm) and identify the first elution peak as (S)-4-((R)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-o Xopyrrolidine-1-yl)pentanoic acid (compound 24A*) (2.9 mg, yield 36%, RT(min): 5.53) was obtained as the second elution peak, and (R)-4-((S)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)pentanoic acid (compound 24B*) (2.8 mg, yield 35%, RT(min): 7.18) was obtained as the second elution peak. *Stereochemistry was arbitrarily assigned.
[0587] Compound 24A*:LCMS:(ES,m / z):RT=1.615 min, m / z=421.2[M+H] + . 1 H NMR (400MHz, methanol-d4) δ6.75-6.67(m,1H),5.51-5.02(m,1H),4.28-4.13(m,1H),3.60-3.40(m,2H),2.50-2.42(m,1H),2.32(t,J=7.2Hz, 2H),2.21-2.13(m,1H),2.07-2.01(m,1H),1.94-1.79(m,2H),1.61-1 .43(m,6H),1.33-1.21(m,3H),1.03-0.95(m,2H),0.70-0.67(m,2H).
[0588] Compound 24B*:LCMS:(ES,m / z):RT=1.605 min, m / z=421.1[M+H] + . 1H NMR (400MHz, methanol-d4) δ6.75-6.68(m,1H),5.51-5.05(m,1H),4.20(d,J=9.2Hz,1H),3.59-3.41(m,2H),2.46(d,J=9.6Hz,1H),2.32(t,J=7.2 Hz,2H),2.22-2.13(m,1H),2.08-2.02(m,1H),1.95-1.80(m,2H),1.58 -1.41(m,6H),1.33-1.25(m,3H),1.04-0.95(m,2H),0.70-0.67(m,2H).
[0589] Example 15. 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)-3-methylbutanoic acid (compound 26, rac-26), (S)-4-((R)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)-3-methylbutanoic acid (compound 26A*), (S)-4-((S)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)-3-methylbutanoic acid (compound 26B*) , (R)-4-((R)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)-3-methylbutanoic acid (compound 26C*), and (R)-4-((S)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)-3-methylbutanoic acid (compound 26D*), and 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)-3-methylbutanoic acid ethyl (compound 26-OEt) Scheme 15A. [ka] Scheme 15B. [ka] Step 1: In a 250 mL three-necked round-bottom flask, ethyl 4-hydroxy-3-methylbutanoate (6.00 g, 41.004 mmol, 1 equivalent), PPh3 (32.3 g, 123 mmol, 3 equivalents), CBr4 (40.8 g, 123 mmol, 3 equivalents), and tetrahydrofuran (THF) (60 mL) were added, and the resulting mixture was stirred at room temperature under a nitrogen atmosphere for 3 hours. The reaction product was then poured into saturated NaHCO3 (aqueous solution) at 0°C, extracted with RINKAN (3 × 100 mL), and the combined organic layers were washed with brine (100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by silica gel column chromatography eluted with CH2Cl2 / petroleum ether (5:1) to obtain ethyl 4-bromo-3-methylbutanoate (3.3 g, yield 38%). LCMS:(ES,m / z):RT=0.71 min, m / z=209.1[M+H] + .
[0590] Step 2: 5-Cyclopropyl-4,7-Difluoro-3,3-dimethylindorin-2-one (intermediate 3) (500 mg, 2.10 mmol, 1 equivalent), 3-bromo-2-oxopyrrolidine-1-carboxylate tert-butyl (1.11 g, 4.20 mmol, 2 equivalents), K2CO3 (874 mg, 6.32 mmol, 3 equivalents), and dimethylformamide (DMF) (5 mL) were added to a 20 mL vial. The resulting mixture was stirred at 80°C for 1 hour, and then the reaction was quenched with water (20 mL) at room temperature. The resulting mixture was extracted with ELISA (3 × 30 mL), and the combined organic layers were washed with brine (1 × 30 mL) and dried over anhydrous sodium 2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain the residue, which was purified by silica gel column chromatography eluting with CH2Cl2 / petroleum ether (6:1) to obtain tert-butyl 3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindole-1-yl)-2-oxopyrrolidine-1-carboxylate (700 mg, yield 79%). LCMS: (ES, m / z): RT=0.91 min, m / z=421.1 [M+H]+ .
[0591] Step 3: 3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindole-1-yl)-2-oxopyrrolidine-1-carboxylate tert-butyl (700 mg, 1.66 mmol, 1 equivalent) and HCl (gas) in 1,4-dioxane (4.0 M, 7 mL) were added to a 40 mL vial. The resulting mixture was stirred at room temperature for 1 hour, then concentrated under reduced pressure to obtain 5-cyclopropyl-4,7-difluoro-3,3-dimethyl-1-(2-oxopyrrolidine-3-yl)indole-2-one hydrochloride (510 mg, 96% yield), which was used directly in the next step. LCMS: (ES, m / z): RT = 0.45 min, m / z = 321.1 [M + H] + .
[0592] Step 4: 5-Cyclopropyl-4,7-Difluoro-3,3-dimethyl-1-(2-oxopyrrolidine-3-yl)indole-2-one hydrochloride (500 mg, 1.56 mmol, 1 equivalent), ethyl 4-bromo-3-methylbutanoate (from Step 1 of this example) (3.26 g, 15.6 mmol, 10 equivalents), Cs2CO3 (1.53 g, 4.68 mmol, 3 equivalents), and dimethylformamide (DMF) (5.0 mL) were added to a 40 mL vial. The resulting mixture was stirred at 80°C for 2 hours, then filtered. The filtered cake was washed with MeOH (3 × 30 mL), and the filtrate was concentrated under reduced pressure to obtain a residue. This residue was purified by reverse-phase flash chromatography (C18 silica gel, mobile phase: acetonitrile (0.1% TFA) in water, gradient from 60% to 80% over 30 minutes, detector: UV220 / 254 nm) to obtain 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)-3-methylbutanoate ethyl (compound 26-OEt) (120 mg, yield 18%) as a mixture of four stereoisomers. LCMS: (ES, m / z): RT = 0.88 min, m / z = 449.1 [M + H] + .
[0593] Step 5: Compound 26-OEt (120 mg, 0.15 mmol, 1 equivalent), NaOH (18.7 mg, 0.450 mmol, 3 equivalents), MeOH (1 mL), and H2O (0.2 mL) were added to an 8 mL vial. The resulting mixture was stirred at room temperature for 2 hours, and then the pH of the mixture was adjusted to 3 with 1 M HCl (aqueous solution). The resulting mixture was extracted with siRNA (3 × 30 mL), the combined organic layers were washed with brine (30 mL), dried over anhydrous sodium 2SO4, filtered, and the filtrate was concentrated under reduced pressure to obtain the residue. This residue was purified by reverse-phase chromatography (C18 silica gel, mobile phase: acetonitrile in water, gradient from 20% to 50% over 30 minutes, detector: UV220 / 254 nm, RT (min): 12) to obtain 4-(3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)-3-methylbutanoic acid (compound 26) (70 mg, yield 58%) as a mixture of four stereoisomers. LCMS: (ES, m / z): RT = 0.69 min, m / z = 421.1 [M + H] + .
[0594] Step 6: A mixture of compound 26 (70 mg) is purified by preparative chiral HPLC (2*25 cm, 5 μm CHIRALPAK IA, mobile phase A: hexane (0.1% TFA), mobile phase B: isopropyl alcohol (IPA): DCM=1:1, flow rate: 20 mL / min, gradient: 20% B to 20% B over 12 minutes, wavelength: 220 / 254 nm) and the first elution peak is (S)-4-((R)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)-3-methylbutanoic acid (compound 26A*)(5 0.6 mg, yield 8%, RT(min): 5.83) was obtained, and compound 26'* (19 mg, yield 27%, RT(min): 7.56) was obtained as a mixture of two stereoisomers as the second elution peak, and (R)-4-((S)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)-3-methylbutanoic acid (compound 26D*) (4.9 mg, yield 7%, RT(min): 9.61) was obtained as the third elution peak. *Stereochemistry was arbitrarily assigned.
[0595] Compound 26A*:LCMS:(ES,m / z):RT=1.39 min, m / z=421.2[M+H] + . 1 H NMR (400MHz, methanol-d4) δ6.71(m,1H),5.45(dd,J=11.2,9.4Hz,1H),3.68-3.50(m,2H),3.28-3.08(m,2H),2.62-2.29 (m,4H),2.19-2.10(m,1H),2.08-1.98(m,1H),1.55(s,2H),1.53-1.42(m,4H),1.04-0.90(m,5H),0.74-0.65(m,2H).
[0596] Compound 26'*:LCMS:(ES,m / z):RT=1.32 min, m / z=421.2[M+H] + . 1H NMR (400MHz, methanol-d4) δ6.78-6.64(m,1H),5.47-5.04(m,1H),3.73-3.46(m,2H),3.31-3.12(m,2H),2.59-2.31(m ,3H),2.29-2.11(m,2H),2.09-1.98(m,1H),1.55(s,2H),1.52-1.41(m,4H),1.10-0.94(m,5H),0.74-0.65(m,2H).
[0597] Compound 26D*:LCMS:(ES,m / z):RT=1.25 min, m / z=421.2[M+H] + . 1 H NMR (400MHz, methanol-d4) δ6.77-6.64(m,1H),5.45(dd,J=11.0,9.4Hz,1H),3.68-3.48(m,2H),3.27-3.10(m,2H),2.64-2 .24(m,4H),2.18-2.10(m,1H),2.08-2.00(m,1H),1.55(s,2H),1.52-1.32(m,4H),1.08-0.87(m,5H),0.74-0.63(m,2H).
[0598] Step 7: The mixture product (19 mg) of compound 26'* from Step 6 is separated by preparative chiral HPLC (2 x 25 cm, 5 μm CHIRALPAK IH, mobile phase A: hexane (0.1% TFA), mobile phase B: isopropyl alcohol (IPA): DCM = 1:1, flow rate: 20 mL / min, gradient: 20% B to 20% B over 18 minutes, wavelength: 220 / 254 nm), and (S)-4-((S)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrroly The second elution peak yielded (R)-4-((R)-3-(5-cyclopropyl-4,7-difluoro-3,3-dimethyl-2-oxoindolin-1-yl)-2-oxopyrrolidine-1-yl)-3-methylbutanoic acid (compound 26C*) (6.6 mg, yield 35%, RT(min): 13.84). *Stereochemistry was arbitrarily assigned.
[0599] Compound 26B*:LCMS:(ES,m / z):RT=0.68 min, m / z=421.1[M+H] + . 1 H NMR (400MHz, methanol-d4) δ6.80-6.62(m,1H),5.43(dd,J=11.2,9.4Hz,1H),3.70-3.59(m,1H),3.59-3.47(m,1H),3.29-3.13(m,2H),2.6 2-2.25(m,4H),2.17(dd,J=17.4,9.6Hz,1H),2.08-1.97(m,1H),1.55(s,2H),1.52-1.32(m,4H),1.10-0.86(m,5H),0.76-0.61(m,2H).
[0600] Compound 26C*:LCMS:(ES,m / z):RT=1.32 min, m / z=421.2[M+H] + . 1 H NMR (400MHz, methanol-d4) δ6.78-6.63(m,1H),5.43(t,J=10.3Hz,1H),3.69-3.50(m,2H),3.30-3.12(m,2H),2 .59-2.11(m,5H),2.09-1.99(m,1H),1.55(s,2H),1.52-1.31(m,4H),1.14-0.87(m,5H),0.75-0.61(m,2H).
[0601] The additional compounds provided in Table B below were prepared according to General Method Scheme A, as described in the Preparation Methods section, in the Examples and / or the procedures provided in the Table below. NMR and LCMS data are provided for each synthesized compound. A dashed line (--) indicates that no data is available. An asterisk (*) indicates an arbitrary or reasonable stereochemical assignment. [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6] [Table 5-7] [Table 5-8]
[0602] Assay method Human whole blood (hWB) NLRP3 assay The objective of this assay is to demonstrate whether the test compound can inhibit human NLRP3 function in a whole blood system.
[0603] Human whole blood is collected from healthy volunteers after obtaining written informed consent. Heparinized lithium-coated tubing is used to collect blood from volunteers. Blood samples are distributed onto 96-well plates using 90 μl per well.
[0604] Priming procedure: Priming was performed by adding 5 μl of LPS (O26:B6, Sigma L-2654) to a final concentration of 1 μg / ml for 4.5 hours in a humidified incubator at 37°C and 5% CO2. Thirty minutes before NLRP3 activation, 5 μl of a 20x compound solution or vehicle (2% dimethyl sulfoxide (DMSO)) was added to each well, and the plate was incubated on a shaker (450 rpm) in a humidified incubator at 37°C and 5% CO2.
[0605] Alternative priming procedure: Thirty minutes before LPS priming, 5 μl of a 20-fold compound solution or vehicle (2% dimethyl sulfoxide (DMSO)) was added to each well, and the plate was incubated on a shaker (450 rpm) in a humidified incubator at 37°C and 5% CO2. Priming was performed by adding 5 μl of LPS (O26:B6, Sigma L-2654) at a final concentration of 1 μg / ml over 5 hours in a humidified incubator at 37°C and 5% CO2.
[0606] Next, activation was performed by adding 3.3 μl of 31x ATP solution per well. At the end of the 30-minute stimulation period, the plate was centrifuged (800 g, 10 minutes, room temperature), and the plasma from each well was frozen at -80°C. IL-1β levels in the supernatant were analyzed using a mesoscale discovery assay (MSD K151TUK) according to the manufacturer's instructions.
[0607] Assay IC using the priming procedure compared to alternative priming procedures 50 There is no detectable difference in the results.
[0608] The data is provided in Table C below. hWB IL-1β assay: A showed <0.3 μM IC50 50 The values represent ICs with ≥0.3μM and <0.5μM. 50 The values represent ICs with ≥0.5μM and <1.0μM. 50 The value represents the IC for ≥1.0μM and <10μM. 50 The value represents the IC with a minimum impedance of ≥10 μM. 50 Represents a value. A dashed line (--) indicates that no data is available. [Table 6]
[0609] As specified herein, R 2 and R 7Compounds of formula (I) that combine to form a heterocyclic or heteroaryl lactam ring contain features that help achieve inhibitory activity against NLRP3, and non-hydrogen R 1 Group (e.g., cyclopropyl or -CF3), R 5 / R 5 Disubstituted at the 11th position (e.g., dimethyl), and -R 4 -Z part (for example, R 4 Includes (where is a substituted or unsubstituted -C3 alkylene- and Z is -CO2H).
[0610] R 2 and R 7 When R is bonded to form a saturated heterocyclic lactam ring, 2 The stereochemistry at the carbon atom to which the compound is bonded can be an important feature. For example, as shown in Table D below, compound 18A*, which is reasonably assigned to have R stereochemistry, is >147 times more active than compound 18B*, which is reasonably assigned to have S stereochemistry. [Table 7]
[0611] R 2 and R 7 When these atoms bond to form a heteroaryllactam ring, the inclusion of an additional ring N atom can also be an important feature. For example, as shown in Table E below, including an additional ortho (compound 11), meta (compound 8), or para (compound 10) N ring atom in the lactam ring N atom results in a 3-5 times improvement in activity compared to a compound (compound 3) that has the lactam ring N as the sole N ring atom. [Table 8]
[0612] Other embodiments Any claim or specification containing "or" between one or more members of a base is deemed satisfied unless otherwise indicated to the contrary, or unless otherwise evident from the context, if one, more or all members of that base are present in, used in, or otherwise associated with a given product or process. This disclosure includes embodiments in which strictly one member of that base is present in, used in, or otherwise associated with a given product or process. This disclosure also includes embodiments in which more or all members of that base are present in, used in, or otherwise associated with a given product or process.
[0613] Furthermore, this disclosure encompasses all variations, combinations, and rearrangements in which one or more limitations, elements, clauses, and descriptive terms from one or more of the enumerated claims or embodiments are introduced into another claim or embodiment. For example, any claim dependent on another claim may be modified to include one or more limitations found in any other claim dependent on the same dependent claim. Where this disclosure enumerates elements presented as lists, for example in Markush group form, each subgroup of these elements is also disclosed, and any element may be removed from a group. Where any variable (e.g., R-base) is presented more than once (e.g., twice) in a given Markush structure, that variable may be selected from a given list of two or more elements unless otherwise stated or understood in the context of this disclosure, and it should be further understood that the variable (e.g., R-base) in each repeated occurrence (e.g., twice) is independent of each other and selected independently of its given list.
[0614] In general, where the Disclosure or aspects thereof refer to including certain elements and / or features, it should also be understood that certain embodiments or aspects thereof of the Disclosure also consist of, or essentially consist of, such elements and / or features. For the sake of simplicity, these embodiments are not specifically described herein in these terms. Furthermore, note that the terms “comprising” and “containing” are intended to be open to allow for the inclusion of additional elements or steps. Where a range is given, both endpoints are understood to be included. In addition, unless otherwise suggested or evident from the context and the understanding of those skilled in the art, any value expressed as a range may, unless the context otherwise explicitly indicates, assume any specific value or lower range within the range described in different embodiments of the Disclosure, up to one-tenth of the lower limit of the range.
[0615] This application refers to various issued patents, published patent applications, academic papers, and other publications, all of which are incorporated herein by reference. In the event of any conflict between any of the incorporated references and this disclosure, this disclosure shall prevail. Furthermore, any particular embodiment of this disclosure contained in the prior art may be expressly excluded from one or more of the claims. Such embodiments are considered to be known to those skilled in the art and may be excluded even if such exclusion is not expressly stated herein. Any particular embodiment of this disclosure may be excluded from any claim for any reason, whether or not it relates to the existence of the prior art.
[0616] The foregoing has described non-limiting embodiments of the present disclosure. Those skilled in the art will understand that various modifications and alterations to this specification can be made without departing from the spirit or scope of the present disclosure, as set forth in the following claims.
Claims
1. Compounds of the following formula (I): 【Chemistry 1】 or a pharmaceutically acceptable salt thereof, in the formula, R 1 Hello, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, or C 3 -C 6 It is a cycloalkyl, R 7 and R 2 are joined to form a 5- to 10-membered monocyclic or bicyclic heterocyclyl or a 5- to 10-membered monocyclic or bicyclic heteroaryl, wherein said heterocyclyl or heteroaryl is optionally substituted with one or more R 7a , and each R 7a is independently halo, -CN, -OH, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 6 aryl, 5- to 6-membered heteroaryl, C 3 -C 5 cycloalkyl, or 4- to 5-membered heterocyclyl, wherein said alkyl, haloalkyl, alkoxy, haloalkoxy, aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 7b , and R 7b is halo, -CN, -OH, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, or C 1 -C 6 haloalkoxy, R 3 It does not exist, or H, C 1 -C 6 Alkyl, or C 1 -C 6 It is a haloalkyl, R 4 is one or more R 4a It may be replaced with -C 1 -C 6 It is alkylene-, and each R 4a These are independently: halo, -CN, -OH, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, C 3-4 It is either a cycloalkyl or a 4-5 membered heterocycline, or two R 4a are combined into C 3 -C 5 It forms a cycloalkyl or 4-6 membered heterocyclyl ring, and the alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, and heterocyclyl are one or more R 4b It may also be replaced with R 4b is halo, -CN, -OH, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkoxy, or C 1 -C 6 It is a haloalkoxy, Z is -CO 2 H or -CO 2 PG is C 1 -C 6 Alkyl, C 6 Aryl, or (C 6 Ariel) (C 1 -C 6 Alkyl) and furthermore, alkyl and aryl are one or more halo, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, or C 1 -C 6 It may also be substituted with a haloalkoxy. Each R 5 They are independent, Hello, C 1 -C 6 Alkyl, or C 1 -C 6 It is a haloalkyl, each R 6 , R 6’ , or R 6’’ is independently H, halo, -OH, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl, or a pharmaceutically acceptable salt thereof.
2. R 1 is halo, C 1 -C 6 haloalkyl, or C 3 -C 4 cycloalkyl, R 7 and R 2 These combine to form a 5-10 member monocyclic or bicyclic heteroaryl, and the heteroaryl is composed of one or more R 7a It may also be replaced with each R 7a C is independent 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 6 Aryl, or C 3 -C 5 It is a cycloalkyl, R 3 It does not exist, R 4 is, -C 1 -C 6 It is alkylene-, Z is -CO 2 It is H, Each R 5 Independently, C 1 -C 6 It is alkyl, Each R 6 , R 6’ , or R 6’’ The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein is independently H, halo, or -OH.
3. R 1 , Br, Cl, -CF 3 A compound according to any one of claims 1 to 2, or a cyclicpropyl compound or a pharmaceutically acceptable salt thereof.
4. R 3 The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, which does not exist.
5. R 5 Each entity is the same group, the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof.
6. Each R 5 The compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein is methyl.
7. R 6 The compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, wherein is H.
8. R 6’ The compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, wherein is F or -OH.
9. R 6’’ A compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof, wherein is H or F.
10. R 7 and R 2 These combine to form one or more R 7a A compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, which forms a six-membered monocyclic heteroaryl that may be substituted with a compound.
11. R 7 and R 2 A compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, wherein the compounds bond to form a 10-membered bicyclic heteroaryl.
12. R 7a methyl, -CF 3 , C 6 A compound according to any one of claims 1 to 11, which is aryl or cyclopropyl, or a pharmaceutically acceptable salt thereof.
13. R 4 is, -C 3 A compound according to any one of claims 1 to 12, wherein the compound is alkylene- or a pharmaceutically acceptable salt thereof.
14. Z is CO 2 A compound according to any one of claims 1 to 13, wherein H is present, or a pharmaceutically acceptable salt thereof.
15. The aforementioned compound is a compound of the following formula (I-A): 【Chemistry 2】 The compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof.
16. The aforementioned compound is a compound of the following formula (I-A-a): 【Transformation 3】 The compound according to claim 15, or a pharmaceutically acceptable salt thereof.
17. The aforementioned compounds are those of the following formulas: (I-B'), (I-C'), (I-D'), (I-E'), (I-F'), or (I-G'): 【Chemistry 4】 The compound according to claim 16, or a pharmaceutically acceptable salt thereof.
18. The aforementioned compound is a compound of the following formula (I-J'): 【Transformation 5】 The compound according to claim 16, or a pharmaceutically acceptable salt thereof.
19. The aforementioned compound is a compound of the following formula (I-J'-a): 【Transformation 6】 The compound according to claim 18, or a pharmaceutically acceptable salt thereof.
20. The aforementioned compound is a compound of the following formula (I-J'-a-R): 【Transformation 7】 The compound according to claim 19, or a pharmaceutically acceptable salt thereof.
21. R 4a The compound or a pharmaceutically acceptable salt thereof according to any one of claims 16 to 20 does not exist.
22. R 7a The compound according to any one of claims 16 to 21 or a pharmaceutically acceptable salt thereof does not exist.
23. R 1 Ha-CF 3 A compound according to any one of claims 16 to 22, or a cyclicpropyl compound or a pharmaceutically acceptable salt thereof.
24. R 6’ It is a halo, R 6’’ is H or R 6’ and R 6’’ Each of the compounds or pharmaceutically acceptable salts thereof according to any one of claims 16 to 23 is independently a halo.
25. The compound according to any one of claims 1 to 24, wherein the compound is selected from the compounds listed in Table 1 or Tables 2A to 2B, or pharmaceutically acceptable salts thereof.
26. A pharmaceutical composition comprising a compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
27. A method for treating or preventing a disease or disorder, comprising administering a compound according to any one of claims 1 to 25, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 26 to a subject.
28. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, the method comprising coupling the following substituted indolinone (i) or a salt thereof with a lactam of formula (ii) or a salt thereof, 【Transformation 8】 In the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 6’ , and R 6’’ The compound is as defined in claim 1, where X is a leaving group and Z is -CO 2 It is PG, and PG is as defined in claim 1, and by coupling, Z is -CO 2 A compound of formula (I) or a salt thereof, which is PG, is obtained and optionally subsequently deprotected, such that Z is -CO 2 A method comprising obtaining a compound of formula (I) or a salt thereof, wherein H is present.
